A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Reference |
|---|
| "Melanoma is exceedingly rarely environmental." | ( Dowd, PM; Everall, JD, 1978) |
| "Malignant melanoma is rather uncommon in India." | ( Reddy, CR; Satyanarayana, BV; Sundareshwar, B; Yellama, A, 1976) |
| "Neurotropic melanoma is a rare tumor with a biphasic growth pattern associated with a change in morphology from melanocytic features toward Schwann cell features." | ( Gomez, EC; Mack, EE, 1992) |
| "Human melanomas are known to contain vimentin intermediate filaments but there has been some dispute about their expression of cytokeratins." | ( Ghose, T; Om, A; Rowden, G, 1991) |
| "Choroidal melanoma is the most common intraocular tumor and is uniquely suited for evaluation by magnetic resonance imaging (MRI) because of the paramagnetic effect of the melanin molecule." | ( Bond, JB; Gupta, KL; Haik, BG; Mihara, F, 1991) |
| "Malignant melanoma is one of the most malignant froms of cancer, for which the prognosis is still very grave." | ( Ikegawa, S; Ishihara, K, 1985) |
| "This variant of melanoma is a rare disorder with unremarkable, non-specific clinical manifestations in the oral cavity, which makes the diagnosis of this disease more difficult." | ( Chao, LS; Chen, JH; Meng, CL; Shyu, KW; Tu, CN, 1989) |
| "Subungual melanoma is rare and represents only 1% to 3% of all diagnosed melanomas in Western countries." | ( Baas, PC; Hoekstra, HJ; Oldhoff, J; Oosterhuis, JW; Schraffordt Koops, H, 1989) |
| "If melanoma is to be cured now by any systemic therapy, particularly biomodulation, new regional strategies must be devised to overcome the blood-brain barrier." | ( Mitchell, MS, 1989) |
| "Malignant melanoma is generally considered as a hormone-independent tumour." | ( Mouridsen, HT; Pedersen, L; Rose, C, 1985) |
| "Such melanomas are situated on the upper limb below the brachial insertion of the deltoid muscle, and on the lower limb below the upper third portion of the thigh." | ( Bartier, JC; Grosshans, E; Kretz, JG; Laplanche, G; Truchetet, F, 1988) |
| "Ear and scalp melanomas are high-risk lesions whose poor prognosis is not readily explained by any of the microstage factors reviewed." | ( Cooper, PH; Harpole, DH; Kaiser, DL; Wanebo, HJ; Young, DV, 1988) |
| "Malignant melanoma is common among the whites of South Africa." | ( Isaacson, C; Spector, I, 1987) |
| "Disseminated melanoma is a fertile field for application of new drugs and phase II studies." | ( Allegra, JC; Richman, SP; Seeger, J, 1986) |
| "melanoma are best treated with fractionation regimes with few fractions and high doses per fraction, whether misonidazole is present or not." | ( Brustad, T; Rofstad, EK, 1981) |
| "Pigmented nevi and melanoma are perhaps two of the most interesting problems in dermatology, oncology and pathology." | ( Lea, PJ; Pawlowski, A, 1983) |
| "Ocular melanoma is the most common malignant tumor of the eye and accounts for 70 to 80 percent of all extracutaneous melanomas." | ( Barber, NA; Didolkar, MS; Elias, EG; Moore, RH, 1980) |
| "Human melanomas are naturally resistant to methotrexate (MTX)." | ( Abelson, HT; Kufe, DW; Wick, MM, 1980) |
| "Acral lentiginous melanoma is a newly recognized subtype of malignant melanoma that occurs on volar and subungual skin." | ( Feibleman, CE; Maize, JC; Stoll, H, 1980) |
| "Subungual melanoma is rare and experience in treating this condition with isolated limb perfusion is limited." | ( Aitchison, T; Lingam, MK; Mackie, RM; McKay, AJ, 1995) |
| "Human melanomas are infiltrated by tumor-reactive T lymphocytes." | ( Diez, E; Gervois, N; Guilloux, Y; Jotereau, F; Le Dréan, E; Pandolfino, MC; Viret, C, 1994) |
| "Malignant melanoma is appropriate for this investigative and diagnostic technique because of its superficial localization." | ( Dobiás, J; Dobrota, D; Kasparová, S; Liptaj, T; Péc, J; Péc, M; Prónayová, N; Salon, F, 1995) |
| "Malignant melanoma is among the malignant tumors which still have the poorest prognosis." | ( Asano, K; Ishihara, K; Yamazaki, N, 1993) |
| "Scalp melanoma is a specific anatomical subsite associated with a high incidence of regional disease and has a poor prognosis." | ( Hudson, DA; Krige, JE, 1995) |
| "Nonocular malignant melanoma is a rare but lethal disease increasing in incidence and mortality in western countries with improved survival if diagnosed and treated early." | ( Gujarathi, M; Joshi, S; Jussawalla, DJ; Krishnamurthy, S; Yeole, B, 1994) |
| "Metastatic melanoma is notable for its resistance to chemotherapy, and methods for determining resistance in cultures would be advantageous." | ( Baguley, BC; Finlay, GJ; Holdaway, KM; Marshall, ES; Matthews, JH; Shaw, JH, 1993) |
| "Melanoma is a disease that need not be deadly." | ( Greene, MH, 1993) |
| "Intraocular melanoma is the most common primary ocular malignancy in Whites." | ( Boaziz, C; Breau, JL; Israël, L; Mazeron, JJ; Morere, JF, 1993) |
| "Metastatic melanoma is difficult to treat because of low response rates to most chemotherapy regimens and short remission durations." | ( Crowell, EB; Higa, GM, 1993) |
| "H & N melanoma is found in males more than in females and diagnosed when already locally advanced." | ( Chaitchik, S; Feldman, I; Fishman, P; Merimsky, O; Rapaport, Y; Shafir, R; Sheonfeld, Y, 1996) |
| "Malignant melanoma is a relatively uncommon cancer of increasing incidence." | ( Alonso, O; Bazzano, C; Delgado, L; Espasandin, J; Lago, G; Martinez, M; Mut, F; Saadoun, A; Touya, E, 1996) |
| "Metastatic melanoma is commonly treated with chemotherapy and/or biological agents used separately." | ( Bedikian, A; Buzaid, AC; Eton, O; Legha, SS; Papadopoulos, N; Plager, C; Ring, S, 1996) |
| "A case of malignant melanoma is presented, in which I-123 IMP scintigraphy was useful to visualize the bone metastases." | ( Fukunaga, M; Morita, K; Otsuka, N; Sone, T, 1996) |
| "Melanoma is rare in Singapore with an age-standardised rate (ASR) of 0." | ( Ang, PT; Tan, EH, 1996) |
| "Human malignant melanoma is notoriously resistant to pharmacological modulation." | ( Artuc, M; Fichtner, I; Henz, BM; Jurgovsky, K; Kern, MA; Kolde, G; Makki, A; Nürnberg, W; Pahl, HL; Rosenbach, T; Schadendorf, D; Stüting, S; von Stebut, E; Worm, M, 1996) |
| "Because malignant melanoma is a highly malignant neoplasm, correct diagnosis and appropriate treatment are essential to improve the prognosis." | ( Saida, T, 1997) |
| "Human malignant melanoma is characterised by unresponsiveness to conventional chemotherapy." | ( Berger, W; Elbling, L; Hauptmann, E; Kokoschka, EM; Micksche, M; Vetterlein, M, 1997) |
| "Melanoma is heterogeneous for its biological properties and melanoma-associated antigens (MAAs)." | ( Chi, DD; Conrad, AJ; Garrison, DA; Hoon, DS; Morton, DL; Sarantou, T; Schmid, P, 1997) |
| "While early melanoma is highly curable by surgical means, the prognosis of patients with more advanced lesions and/or metastatic disease remains poor." | ( Bezwoda, WR, 1997) |
| "Thicker melanomas are associated with a > 50% rate of regional or systemic failure." | ( Cosimi, AB; Gadd, MA; Haluska, FG; Malt, RA; Mihm, MC; Sober, AJ; Souba, WW; Tanabe, KK; Tseng, JF, 1997) |
| "Ocular melanoma is characterized by a high rate of liver metastases and is associated with a median survival time less than 5 months." | ( Bauer, J; Dorval, T; Gillet, M; Lejeune, F; Leyvraz, S; Meuli, R; Pampallona, S; Salmon, R; Spataro, V; Zografos, L, 1997) |
| "Melanomas are highly clonogenic." | ( Amicarelli, F; Brisdelli, F; D'Alessandro, E; Ligas, C; Miranda, M; Poma, A; Zarivi, O, 1997) |
| "Melanotic melanomas are hyperintense on T1-weighted images because of paramagnetic metal scavenging." | ( Bogdanova, A; Enochs, WS; Mohr, U; Petherick, P; Weissleder, R, 1997) |
| "Metastatic uveal melanoma is strongly resistant to chemotherapy, and multidrug resistance (MDR) may be involved." | ( Blom, DJ; de Waard-Siebinga, I; Flens, MJ; Jager, MJ; Koornneef, L; Luyten, GP; Scheper, RJ; van der Pol, JP, 1997) |
| "Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy." | ( Brown, BD; Bryan, RN; Eichler, HG; Jansen, B; Müller, M; Pehamberger, H; Schlagbauer-Wadl, H; van Elsas, A; Wolff, K, 1998) |
| "Metastatic melanomas are often resistant to chemotherapy." | ( Ho, V; Li, G; Tang, L; Tron, V; Zhou, X, 1998) |
| "Melanoma is a highly immunogenic malignancy, and in our previous studies the treatment of metastatic melanoma with TP5 showed encouraging results." | ( Belli, F; Cascinelli, N; Clemente, C; Lenisa, L; Mascheroni, L, 1998) |
| "Each melanoma is drained by one or, occasionally, several individual lymph nodes within the nearest lymph node region (sentinel lymph node)." | ( Bachter, D; Balda, BR; Büchels, H; Vogt, H, 1998) |
| "Acral melanomas are frequently misdiagnosed due to their less common locations and because plantar and subungual melanomas often do not fit the 'changing mole' pattern." | ( Ellwanger, U; Fierlbeck, G; Metzger, S; Rassner, G; Schiebel, U; Stroebel, W, 1998) |
| "Primary vaginal melanoma is a very rare gynecological malignant tumor (less than 150 reported cases to-date)." | ( Casella, G; di Bonito, M; Fortuna, G; Iodice, F; Stellato, G; Tramontana, R; Tramontana, S, 1998) |
| "Myxoid melanoma is problematic--introducing carcinomas and soft tissue sarcomas into the differential diagnosis." | ( Hitchcock, MG; White, WL, 1998) |
| "Since melanomas are known to contain hypoxic cells which may reduce their radiosensitivity, these in vitro results have demonstrated the potential of tirapazamine to overcome the radioresistance of hypoxia and give encouragement for further studies." | ( Stevens, G; Zhang, M, 1998) |
| "Malignant melanoma is well known for its primary unresponsiveness to chemotherapy." | ( Christmann, M; Dietel, M; Kaina, B; Kern, MA; Lage, H; Pick, M; Schadendorf, D, 1999) |
| "Melanoma is a highly malignant and increasingly common tumour." | ( Allen, TM; Chiesa, V; Kirchmeier, M; Montaldo, PG; Pagnan, G; Pastorino, F; Ponzoni, M; Raffaghello, L, 1999) |
| "Melanoma is a highly malignant and increasingly common neoplasm." | ( Allen, TM; Kirchmeier, M; Montaldo, PG; Pagnan, G; Pastorino, F; Ponzoni, M; Raffaghello, L, 1999) |
| "Metastatic melanoma is a disease associated with a poor prognosis, and dacarbazine is still the reference agent." | ( Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM, 1999) |
| "Genital melanomas are uncommon; the primary site is the vulva." | ( Fuller, PN, 1999) |
| "Melanoma is an uncommon disease in Japan." | ( Ishikawa, M; Wada, T; Yamamoto, A; Yamazaki, N, 1999) |
| "Cutaneous malignant melanoma is a life-threatening cancer with poor prognosis due to a high metastasis potential." | ( Bush, JA; Ho, VC; Li, G, 2000) |
| "Malignant uveal melanoma is the commonest primary intraocular tumour in adults." | ( Anagnostopoulos, I; Anastassiou, G; Bornfeld, N; Coupland, SE; Schilling, H; Stang, A; Stein, H, 2000) |
| "The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common." | ( Everett, JR; Gadd, MA; Greenberg, DB; Haluska, FG; Jonasch, E; Mihm, MA; Ott, M; Ryan, BF; Sober, AJ; Tanabe, KK, 2000) |
| "Uveal melanoma is the most common malignancy of the eye, but little is known about its underlying genetic defects." | ( Brantley, MA; Harbour, JW, 2000) |
| "Although malignant melanomas are often associated with cytotoxic lymphocyte infiltration, these cells are largely ineffective in inducing tumour cell kill, indicating that the melanoma cells have protective mechanisms." | ( Barral, AM; Källström, R; Rosén, A; Sander, B, 2000) |
| "The invasion of melanoma is complex and multi-staged and involves changes in both cell/extracellular matrix (ECM) and cell/cell interactions." | ( Eves, P; Ghanem, G; Layton, C; Lorigan, P; Molife, R; Morandini, R; Neil, SM; Richardson, B; Wagner, M, 2000) |
| "Uveal melanoma is the most common primary eye cancer, yet its molecular pathogenesis is poorly understood." | ( Brantley, MA; Harbour, JW, 2000) |
| "Uveal melanoma is the most common primary ocular cancer among adults and patients with distant metastases seldom survive longer than a year." | ( Bartz-Schmidt, K; Esser, P; Grisanti, S, 2001) |
| "Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level." | ( Capodieci, P; Cordón-Cardó, C; Esteller, M; Gerald, WL; Herman, JG; Lazebnik, YA; Lowe, SW; McCombie, R; Mora, J; Opitz-Araya, X; Polsky, D; Soengas, MS, 2001) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | ( Hwu, WJ, 2000) |
| "While primary uveal melanoma is usually treated by ophthalmologic oncologists, metastatic diseases is often managed by dermatologic oncologists." | ( Bock, M; Deichmann, M; Jäckel, A; Näher, H; Waldmann, V, 2001) |
| "Malignant melanoma is resected with curative intent in 80-85% of the patients." | ( Franke, W; Neumann, NJ; Ruzicka, T; Schulte, KW, 2001) |
| "Malignant melanoma is increasing in frequency at a rapid rate in the United States." | ( Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP, 2001) |
| "Uveal melanoma is characterized by a high frequency of hepatic metastases." | ( Egerer, G; Ho, AD; Keilholz, U; Lehnert, T; Max, R; Naeher, H, 2001) |
| "Non-ocular melanoma is considered to be a rare neoplasm in cats; however, more than 150 cases have been reported in the literature since 1961." | ( Graham, JC; Henry, CJ; Higginbotham, ML; Luna, LD; Moore, AS; Turnquist, SE, 2000) |
| "Malignant melanoma is a cancer whose incidence is rising rapidly, but the mechanism by which normal melanocytes become malignant in vivo is still little understood." | ( Geissinger, E; Schartl, M; Troppmair, J; Weisser, C; Wellbrock, C, 2002) |
| "Sinonasal melanomas are rare neoplasms whose diagnosis may require confirmatory immunohistochemical stains." | ( Paulino, AF; Snyder, ML, 2002) |
| "Malignant melanoma is a skin tumour, which carries a very unfavourable prognosis." | ( Arndt, R; Hartleb, J, 2001) |
| "The incidence of melanoma is estimated to be growing at the second fastest rate among all cancers in the United States." | ( Bratescu, L; Das Gupta, TK; Graves, JM; Green, A; Mehta, RG; Mehta, RR; Shilkaitis, A, 2002) |
| "Malignant melanoma is heterogeneous in terms of its biological, immunological and metastatic properties, and melanoma cells exhibit a polymorphous expression of tumour markers." | ( Enk, CD; Gimon, Z; Hochberg, M; Lotem, M; Shiloni, E, 2002) |
| "Malignant melanoma is a tumor that responds poorly to a variety of apoptosis-inducing treatment modalities, such as chemotherapy." | ( Heere-Ress, E; Jansen, B; Lucas, T; Monia, BP; Pehamberger, H; Schlagbauer-Wadl, H; Thallinger, C; Wacheck, V; Wolff, K, 2002) |
| "Malignant melanoma is a rare malignant tumor arising within the melanocytes of the skin." | ( Jang Kim, S; Ju Kim, I; Ki Kim, Y; Won Seok, J, 2002) |
| "Malignant melanoma is rapidly increasing in the United States." | ( Chapman, RA; Doolittle, GC; Flaherty, LE; Hammond, N; Klein, CE; Kraut, EH; Mills, GM; Sondak, VK; Unger, JM; Whitehead, RP, 2002) |
| "Malignant melanoma is one of the tumors which may metastasize to the thyroid gland." | ( Aigner, RM; Nicoletti, R; Schwarz, T; Wolf, G, 2002) |
| "Uveal melanoma is considered the most common primary intraocular cancer in adults, resulting in the death of approximately 50% of patients affected." | ( Folberg, R; Hendrix, MJ; Kirschmann, DA; Maniotis, AJ; Meltzer, PS; Pe'er, J; Seftor, EA; Trent, JM, 2002) |
| "Malignant melanoma is one of those malignancies with worldwide increasing incidence." | ( Aigner, RM; Richtig, E; Schwarz, T, 2002) |
| "Malignant melanoma is a tumor known for its uncontrollable growth and aggressive metastatic behavior." | ( Limonta, P; Montagnani Marelli, M; Moretti, RM; Van Groeninghen, JC, 2002) |
| "Anorectal malignant melanoma is an uncommon tumour." | ( Fierlbeck, G; Metzger, S; Ulmer, A, 2002) |
| "Malignant melanoma is the most common tumor metastatic to the GI tract." | ( Horvath, W; Khosrowshahi, E, 2002) |
| "Choroidal melanoma is the most common primary ocular cancer among the adult population." | ( Abbas, A; Braun, RD; Bukhari, SO; Wilson, W, 2002) |
| "Melanoma is highly resistant to conventional chemotherapy." | ( Buckmeier, JA; Cen, D; Gonzalez, RI; Kahlon, RS; Meyskens, FL; Tohidian, NB, 2002) |
| "Melanoma is the most common cause of death from cutaneous malignancy, and is the cancer that is most rapidly rising in incidence." | ( Arbiser, JL; Cerimele, F; Cohen, C; Cotsonis, G; Govindarajan, B; Macaron, N; Sequeira, JH; Sexton, DG; Shoji, M; Zavala-Pompa, A, 2002) |
| "Anorectal malignant melanoma is relatively rare and its prognosis is very poor because of distant metastasis via the blood or lymphatic vessels." | ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Souma, I; Yoshida, T, 2002) |
| "Cutaneous melanoma is the most aggressive form of skin carcinoma in humans, frequently with a rapid progression of disease." | ( Blaheta, HJ; Ellwanger, U; Garbe, C; Leiter, U; Meier, F; Rassner, G; Schittek, B, 2003) |
| "Malignant melanoma is one of the most rapidly increasing cancer types, and patients with metastatic disease have a very poor prognosis." | ( Bitisik, O; Camlica, H; Dalay, N; Duranyildiz, D; Kurul, S; Tas, F, 2003) |
| "Predisposition to melanoma is genetically heterogeneous." | ( Hayward, NK, 2003) |
| "Uveal melanoma is associated with a high tumor-related mortality due to the propensity to develop metastases." | ( Frants, RR; Gruis, NA; Hurks, MHMH; Jager, MJ; Krijgsman, E; Ksander, BR; Pavey, S; Tensen, CP; van der Velden, PA; Willemze, R; Zuidervaart, W, 2003) |
| "Melanoma is one of the diseases that has been primarily targeted by vaccine approaches." | ( Sondak, VK; Sosman, JA, 2003) |
| "Iris melanomas are less likely to metastasize than posterior compartment melanomas." | ( Cantón, I; Eves, PC; Haycock, JW; MacNeil, S; Rennie, IG; Sisley, K; Szabo, M; Vidal-Vanaclocha, F, 2003) |
| "Malignant melanoma is rare before puberty." | ( NEWMAN, BA, 1957) |
| "Malignant melanoma is rare before puberty." | ( NEWMAN, BA, 1957) |
| "Malignant melanoma is rare before puberty." | ( NEWMAN, BA, 1957) |
| "Malignant melanoma is rare before puberty." | ( NEWMAN, BA, 1957) |
| "Melanoma is a deadly cancer due to its propensity to metastasize." | ( Collisson, EA; De, A; Gambhir, SS; Kleer, C; Kolodney, MS; Merajver, SD; Wu, M, 2003) |
| "Malignant melanoma is one of the most worrisome tumors in terms of epidemiology, and incidence is increasing." | ( Khayat, D; Meric, JB; Rixe, O, 2003) |
| "Metastatic melanoma is usually associated with a dismal prognosis." | ( Coit, DG; Wong, SL, 2004) |
| "Melanoma is the third most common metastatic brain tumor in the United States and is a major cause of morbidity and mortality." | ( Agarwala, SS; Tarhini, AA, 2004) |
| "Uveal melanoma is the most common primary intraocular tumour in adults." | ( Hartgrink, HH; Keunen, JE; Kuppen, PJ; Noter, SL; Pijl, ME; Rothbarth, J; Tijl, FG; Tollenaar, RA; van de Velde, CJ, 2004) |
| "Uveal melanomas are rare in the Asian Indians compared to those in the West." | ( Biswas, J; Kabra, S; Krishnakumar, S; Shanmugam, MP, 2004) |
| "Melanoma is now the fifth most common type of cancer in North America." | ( Chang, TM; Yu, B, 2004) |
| "Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
| "Melanoma is an increasingly common fatal skin cancer." | ( Swi Chang, TM; Yu, B, 2004) |
| "Cutaneous melanoma is one of the highly malignant human tumours, due to its tendency to generate early metastases and its resistance to classical chemotherapy." | ( Forsea, AM; Geilen, CC; Müller, C; Orfanos, CE; Riebeling, C, 2004) |
| "Human melanoma is the most aggressive form of human skin cancer, and is notoriously resistant to any current modalities of cancer therapy." | ( Ando, K; Miyato, Y, 2004) |
| "Mucosal malignant melanomas are rare lesions, and they have different characteristics from their cutaneous counterparts." | ( Cansiz, H; Güzel, MZ; Karakullukçu, B; Ozek, H; Oztürk, O, 2005) |
| "Cutaneous melanoma is the seventh most common newly diagnosed cancer among Americans." | ( Friedman, KP; Wahl, RL, 2004) |
| "Disseminated melanoma is an incurable disease whose prognosis has remained unchanged over the past 20 years." | ( Négrier, S; Neidhardt-Bérard, EM, 2004) |
| "Uveal melanoma is the most frequent primary malignant neoplasm of the eye and has a poor prognosis in metastatic stage." | ( Keilholz, U; Schmidt-Hieber, M; Schmittel, A; Thiel, E, 2004) |
| "Melanoma is the leading cause of death from skin tumors worldwide, with an annual increase in incidence over the past decade." | ( Bar-Meir, E; Friedman, E; Orenstein, A; Regev, E; Stahl, S; Winkler, E, 2004) |
| "Osteoid malignant melanoma is a rare type of melanoma described in humans and dogs with some areas of bone differentiation." | ( Estrada, M; Fontaine, JJ; Lagadic, M; Maliver, P; Manin, S; Mialot, M, 2004) |
| "Uveal melanoma is the most frequent primary intraocular tumor in the adult population." | ( Bérubé, M; Collin, C; Germain, L; Guérin, SL; Paquet-Bouchard, C; Petitclerc, E; Talbot, M, 2005) |
| "Anorectal malignant melanoma is a rare tumor and there is no consensus on whether aggressive or local management is more appropriate." | ( Cemazar, M; Jancar, B; Rudolf, Z; Sersa, G; Snoj, M, 2005) |
| "Malignant melanoma is the seventh most common newly diagnosed cancer among Americans." | ( Alavi, A; Kumar, R, 2005) |
| "Conjunctival melanoma is an exceedingly rare tumor in black patients." | ( Colby, KA; Nagel, DS, 2005) |
| "Vaginal melanoma is a very rare but highly malignant gynecological disease, usually diagnosed in postmenopausal woman." | ( Garbi, A; Lissoni, AA; Mangioni, C; Perego, P; Signorelli, M, 2005) |
| "Melanoma is the most aggressive of skin cancers because of its high resistance to currently available therapy." | ( Järvinen, PM; Kiviharju, TM; Laiho, M; Peltonen, K; Ra, R, 2005) |
| "Melanoma is one of the neoplasias that most frequently metastasize, especially in the lung, where represents a challenge in oncology since current treatment is ineffective, and mortality is high." | ( Alcaraz Baños, M; Canteras Jordana, M; García Reverte, JM; Martínez Conesa, C; Vicente Ortega, V; Yáñez Gascón, MJ, 2005) |
| "Advanced melanoma is difficult to treat, in part because of greater resistance to therapy compared with other cancer types." | ( Braithwaite, AW; Eccles, MR; He, SJ; Stevens, G, 2005) |
| "Melanoma is the most aggressive form of skin cancer and advanced stages are invariably resistant to conventional therapeutic agents." | ( Fernández, Y; Lowe, SW; Miller, TP; Opipari, AW; Rush, JL; Soengas, MS; Steiner, P; Verhaegen, M, 2005) |
| "Uveal melanoma is the most common intraocular malignancy." | ( Baggetto, LG; Barakat, S; Bernaud, J; Dayan, G; Devouassoux-Shisheboran, M; Gambrelle, J; Gayet, L; Grange, JD; Labialle, S; Rigal, D, 2005) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults and the liver is the most common site for systemic metastases." | ( Berd, D; Mastrangelo, MJ; Patel, K; Sato, T; Shields, CL; Shields, JA; Sullivan, K, 2005) |
| "Melanoma is the aberrant proliferation of melanocytes, the cells in the skin responsible for pigment (melanin) production." | ( Chen, S; Degenhardt, K; Marín, YE; Namkoong, J; Raines, J; Shin, SS; White, E, 2005) |
| "Malignant melanoma is well known for its poor response to chemotherapy, radiotherapy and its susceptibility to immunotherapy." | ( Jović, V; Konjević, G; Radomirović, V; Spuzić, I, 2002) |
| "Melanoma is a highly metastatic cancer that accounts for the majority of skin cancer deaths." | ( Nash, KT; Welch, DR, 2006) |
| "Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans." | ( Ascierto, PA; Beneduce, G; Bomalaski, JS; Castello, G; Clark, MA; Daponte, A; De Rosa, V; Ensor, CM; Feun, LG; Holtsberg, FW; Izzo, F; Logan, TF; Melucci, MT; Ottaiano, A; Prestayko, AW; Savaraj, N; Scala, S; Simeone, E, 2005) |
| "Melanomas are heterogeneous tumours, and differentiation from other melanocytic lesions may cause problems." | ( Fröhlich, E; Garbe, C; Klessen, C; Mack, AF, 2005) |
| "Iris melanoma is a rare ocular tumour, which can be detected early in its development." | ( Hendler, K; Millodot, M; Pe'er, J, 2006) |
| "Melanoma is a glucose-avid malignancy, and preoperative PET scanning in melanoma patients has the potential to guide appropriate treatment." | ( Akhurst, T; Brady, MS; Gonen, M; Hilton, S; Larson, S; Patel, A; Spanknebel, K, 2006) |
| "Advanced melanoma is a highly drug-refractory neoplasm representing a significant unmet medical need." | ( Boldog, FL; Gallo, M; Gazit-Bornstein, G; Hackett, CS; Herrmann, J; Jeffers, M; Khramtsov, NV; Kuang, B; LaRochelle, WJ; Lichenstein, HS; MacDougall, JR; McCabe, DA; Meyer, DL; Pollack, VA; Rastelli, L; Senter, PD; Shadish, ML; Shenoy, SG; Tse, KF, 2006) |
| "Malignant melanoma is the most aggressive form of skin cancer and has proven to be highly resistant to conventional chemotherapy." | ( Niemetz, A; Pützer, BM; Racek, T; Schultz, J; Soengas, MS; Tuve, S, 2006) |
| "Malignant melanoma is the third most common skin cancer in the United States." | ( Ivry, GB; Ogle, CA; Shim, EK, 2006) |
| "The cause of melanoma is probably variable and multifactorial." | ( Ivry, GB; Ogle, CA; Shim, EK, 2006) |
| "Malignant melanomas are characterized by a high intrinsic resistance to chemotherapy." | ( Baker, B; Engel, JB; Halmos, G; Keller, G; Nagy, A; Schally, AV, 2006) |
| "The incidence of melanoma is rising, and therapeutic options for metastatic melanoma are limited." | ( Bryan, RA; Casadevall, A; Dadachova, E; Huang, X; Mints, L; Moadel, T; Nosanchuk, JD; Nosanchuk, JS; Ortiz, G; Revskaya, E; Schweitzer, AD; Zhang, T, 2006) |
| "Uveal melanoma is relatively uncommon accounting for fewer than 5% of all melanoma cases." | ( Butt, M; Eswar, CV; Gillis, P; Marshall, E; O'Neill, PA, 2006) |
| "Melanoma is the most devastating form of skin cancer." | ( Abdel-Malek, ZA; Ito, S; Kadekaro, AL; Wakamatsu, K, 2006) |
| "Human malignant melanoma is a highly aggressive form of cancer; the 5-year survival rate in patients with stage III or IV disease is <5%." | ( Ekmekcioglu, S; Fok, JY; Mehta, K, 2006) |
| "Desmoplastic melanoma is a diagnostic and therapeutic challenge." | ( Browning, J; Cebon, JS; Davis, ID; Lim, E; MacGregor, D, 2006) |
| "Iris melanomas are very rare in the prepubertal age group." | ( Axelsen, RA; Hirst, LW; Tran, TA; Welch, R, 2006) |
| "Melanomas are malignant tumors of melanocytes that, if not detected early, are highly aggressive and poorly treatable." | ( Abbe, P; Bahadoran, P; Bailet, O; Ballotti, R; Baron, V; Bertolotto, C; Gaggioli, C; Ortonne, JP; Robert, G; Spadafora, A; Tartare-Deckert, S, 2007) |
| "Metastatic melanoma is associated with high rate of patients' mortality and represents a great challenge for cancer therapies because of its notorious resistance to chemotherapeutic drugs." | ( Bar-Eli, M; Melnikova, VO, 2006) |
| "Pseudomelanoma is a pathological entity describing the histological findings in cases of recurrences of a partially excised melanocytic nevus, resembling melanoma." | ( Amichai, B; Gat, A; Grunwald, MH, 2006) |
| "Melanoma is a frequent and therapy-resistant human disease." | ( Assouti, M; Karamanos, NK; Krasagakis, K; Nikitovic, D; Sifaki, M; Tzanakakis, GN, 2006) |
| "Malignant melanoma is highly refractory to conventional radio- and chemotherapy." | ( Hei, TK; Ivanov, VN, 2006) |
| "Cutaneous melanoma is a complex disease involving genetic and environmental factors." | ( Bressac de Paillerets, B; Charles, J; Combe, MC; Leccia, MT; Leroux, D; Templier, I, 2006) |
| "Malignant melanoma is particularly resistant to conventional chemotherapy and radiotherapy." | ( Benassi, L; Bernardi, C; Bertazzoni, G; Coppi, A; Costi, MP; Gelain, A; Giannetti, A; Giudice, S; Gualdi, G; Magnoni, C; Rossi, T; Venturelli, A, 2007) |
| "Melanoma is an increasingly common and potentially lethal malignancy." | ( Chou, CC; Chung, JG; Kuo, HM; Lai, WW; Li, TM; Lin, SY; Yang, JH, 2006) |
| "Malignant melanoma is a common and frequently lethal disease." | ( Bosenberg, M; Bradbury, CM; Curley, DP; Duraisamy, S; Hobbs, C; Muthusamy, V; Nelson, B, 2006) |
| "Melanoma is a malignant skin cancer that displays a high rate of tumor cell migration and metastasis." | ( Bang, SI; Cho, D; Kim, TS; Park, H; Yang, Y, 2007) |
| "Primary mucosal melanomas are most frequently localized in the sinunasal system." | ( Hölzl, M; Lammert, I; Scherer, H; Schrom, T; Stölzel, K, 2007) |
| "Malignant melanoma is one of the most aggressive skin cancer and chemotherapeutic agents currently in use are still unsatisfactory." | ( Delogu, G; Dettori, MA; Fabbri, D; Loi, M; Mura, ME; Pagnan, G; Palmieri, G; Pisano, M; Ponzoni, M; Rozzo, C; Tilocca, MG, 2007) |
| "As melanoma is an immunogenic tumor, the effect of immunomodulating agents is consistently investigated." | ( Babović, N; Jović, V; Jurisić, V; Konjević, G; Mirjacić Martinović, K; Spuzić, I; Vuletić, A, 2007) |
| "Uveal melanoma is the most common primary malignant ocular cancer in adults." | ( Ferreira, A; Kalergis, AM; Kiessling, R; López, MN; Mendoza-Naranjo, A; Pereda, C; Poblete, R; Ramírez, M; Salazar-Onfray, F; Serrano, A, 2007) |
| "Cutaneous melanoma is the most aggressive of cutaneous neoplasms." | ( Dummer, R; Hafner, J; Hoek, KS; Mihic, D; Mnich, CD; Oberholzer, PA; Seifert, B, 2007) |
| "Myxoid melanoma is a rare variant of malignant melanoma." | ( Inoue, T; Misago, N; Narisawa, Y, 2007) |
| "Melanoma is a very aggressive and highly angiogenic tumor in which standard treatments have had only limited success." | ( Bar-Eli, M; Hu, GF; Leslie, M; Lev, D; McCarty, M; Melnikova, VO; Roiz, L; Schwartz, B; Shoseyov, O; Smirnoff, P, 2007) |
| "Melanoma is the most lethal form of skin cancer." | ( Hei, TK; Ivanov, VN; Zhou, H, 2007) |
| "Melanoma is a life-threatening disease with a high mortality rate due to rapid metastasis." | ( Dedhar, S; Li, G; Ng, P; Wong, RP, 2007) |
| "Advanced melanoma is associated with increased numbers of circulating dendritic cells and regulatory T cells." | ( Baumgartner, J; Escobar, GA; Gonzalez, R; Lewis, K; McCarter, MD; Palmer, BE; Richter, D; Robinson, W; Wilson, C, 2007) |
| "Melanoma is a hypervascular tumor and angiogenesis plays a critical role in the development/progression of metastases." | ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Ocular melanoma is the leading intraocular malignancy." | ( Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI, 2007) |
| "The melanomas are unusual tumours with a high mortality." | ( Balderrama Caballero, DH; de García Hombre, AM; Llorente Suárez, R; Martín Salvago, MD; Rodríguez Adrados, F, 2007) |
| "Metastatic uveal melanoma is resistant to conventional chemotherapy and immunotherapy." | ( Gollob, JA; Sciambi, CJ, 2007) |
| "Malignant melanoma is a highly aggressive tumor which frequently resists chemotherapy, therefore, the search for new agents for its treatment is of great importance." | ( Bergman, M; Cohen, Y; Dovrat, S; Gottlieb, H; Grossman, S; Rozenblat, S, 2008) |
| "Advanced melanoma is associated with poor prognosis warranting the development of new therapeutics, such as oncolytic adenoviruses for immunovirotherapy." | ( Bayer, W; Heim, A; Hoffmann, D; Nettelbeck, DM; Potthoff, A; Wildner, O, 2008) |
| "Malignant melanoma is a rare pathology: 1-4% of all melanomas occur before the age of 20 and 0." | ( Bouali, O; Galinier, P; Guitard, J; Lamant, L; Salazard, B, 2009) |
| "Melanoma is the most aggressive skin cancer and a serious health problem worldwide because of its increasing incidence and the lack of satisfactory chemotherapy for late stages of the disease." | ( Alvarez, E; González-Santiago, L; Martínez, T; Muñoz, A; Muñoz-Alonso, MJ; Rojas, JM; Zarich, N, 2008) |
| "Disseminated melanoma is highly therapy resistant." | ( Contractor, R; Haass, NK; Herlyn, M; Medina, CA; Nathanson, KL; Nguyen, TK; Smalley, KS; Sproesser, K, 2008) |
| "Cutaneous malignant melanoma is an aggressive type of skin cancer which causes disproportionate mortality in young and middle-aged adults." | ( Casanova, JM; Dolcet, X; Egido, R; Llobet, D; Llombart, A; Marti, RM; Matias-Guiu, X; Pérez de Santos, AM; Schoenenberger, JA; Soria, X; Sorolla, A; Vilella, R; Yeramian, A, 2008) |
| "Canine spontaneous melanoma is a highly aggressive tumor resistant to current therapies." | ( Finocchiaro, LM; Fiszman, GL; Glikin, GC; Karara, AL, 2008) |
| "Melanoma is a highly aggressive skin tumor that originates in the epidermis from melanocytes." | ( Dallaglio, K; French, LE; Hempstead, BL; Lotti, R; Marconi, A; Pincelli, C; Truzzi, F, 2008) |
| "Metastatic melanoma is largely unresponsive to DNA-damaging chemotherapy agents, although WTp53 is frequently detected." | ( Adams, LJ; Avery-Kiejda, KA; Hersey, P; Lane, DP; Scott, RJ; Vojtesek, B; Zhang, XD, 2008) |
| "Malignant melanoma is a potentially fatal skin cancer that is increasing in incidence." | ( Dutz, JP; Najar, HM, 2008) |
| "Melanoma is a highly invasive tumor with elevated mortality rates." | ( Di Serio, C; Doria, L; Landriscina, M; Marchionni, N; Masotti, G; Massi, D; Micucci, I; Pellerito, S; Prudovsky, I; Tarantini, F, 2008) |
| "Malignant melanoma is one of the most lethal cancers." | ( Chammas, R; Donatti, L; Luvizon, AC; Mercadante, AF; Nakao, LS; Naliwaiko, K; Zanata, SM, 2008) |
| "Malignant melanoma is the most deadly form of skin cancer due to its highly metastatic nature." | ( Amin, S; Desai, D; Huh, SJ; Madhunapantula, SV; Robertson, GP; Sharma, A, 2008) |
| "Melanoma is a complex genetic disease, the management of which will require an in-depth understanding of the biology underlying its initiation and progression." | ( Hassan, M; Hegemann, JH; Hengge, UR; Mirmohammadsadegh, A; Nambiar, S, 2008) |
| "Pretreated advanced melanoma is a poor prognosis scenario with few, if any, active therapeutic options." | ( Chopitea, A; Díaz-Lagares, A; Espinós, J; González, A; González-Cao, M; Martín-Algarra, S; Nieto, Y; Ponz, M; Redondo, P; Viteri, S, 2008) |
| "The diagnosis of melanoma is becoming ever more frequent." | ( Abbott, DE; Hendrix, MJ; Salomon, DS; Strizzi, L, 2008) |
| "Melanomas are in many cases immunogenic and thus have been a prime target for immunotherapy, which has resulted in objective responses in some patients." | ( Ilkovitch, D; Lopez, DM, 2008) |
| "Melanoma is a common malignancy which is poorly responsive to chemotherapy and radiation." | ( Arbiser, JL; Bhandarkar, SS; Carracedo, A; Carrillo, CO; Chen, LB; Govindarajan, B; Lefkove, B; Mechta-Grigoriou, F; Owens, MJ; Reddy, KK; Velasco, G, 2008) |
| "Melanoma is a solid tumor that is notoriously resistant to chemotherapy, and its incidence is rapidly increasing." | ( Arbiser, JL; Bhandarkar, SS; Bromberg, J; Carrillo, C; Fried, L; Govindarajan, B; Perry, BN; Reddy, K; Selvakumar, P; Sharma, RK; Sohn, A, 2008) |
| "Metastatic melanoma is a highly chemotherapy resistant tumour." | ( Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N, 2008) |
| "Metastatic melanomas are generally resistant to chemotherapy and radiation, even when wild-type for p53." | ( Andarawewa, KL; Conaway, MR; Coyner, M; Frierson, HF; Markland, F; McRoberts, K; Sanders, JM; Schwartz, MA; Swenson, S; Theodorescu, D, 2008) |
| "Melanoma is an ideal model to analyze cancer progression and differentiation since a well-characterized process of step-wise tumor progression has been defined." | ( Depass, AL; Fisher, PB; Sarkar, D; Staudt, MR, 2009) |
| "Human malignant melanoma is notoriously resistant to currently available pharmacological modulation." | ( Geng, S; Li, X; Li, Z; Liu, Y; Pan, M; Peng, Z; Ren, J; Xiao, S, 2009) |
| "Uveal melanoma is refractory to chemotherapy." | ( Aldrich, W; Dombos, C; Triozzi, PL, 2008) |
| "Melanoma is one of the most therapy-resistant cancers." | ( Dong, J; Estrada, Y; Ossowski, L, 2009) |
| "Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy." | ( Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M, 2008) |
| "Uveal melanoma is the most common primary intraocular malignant tumor in adults with 30% to 50% of patients that ultimately succumb to metastatic disease, mainly to the liver." | ( Economou, MA, 2008) |
| "Malignant melanomas are highly resistant to chemotherapy." | ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
| "Osteogenic melanoma is a rare variant of melanoma not reported in the eye before." | ( Hill, FI; Hughes, SM, 2009) |
| "Melanoma is better delineated in the samples stained in methylene blue." | ( Al-Arashi, M; Shah, S; Tannous, Z; Yaroslavsky, AN, 2009) |
| "Melanoma is the most serious, highly aggressive form of skin cancer with recent dramatic increases in incidence." | ( Cornelius, LA; Feng, Y; Gao, L; Yuan, L; Zhao, H; Zheng, H, 2009) |
| "A half of Asian melanomas are from these areas and they show completely different appearance from other lesions." | ( Celebi, M; Iyatomi, H; Oka, H; Tanaka, M, 2008) |
| "Malignant melanoma is one of the most aggressive human neoplasms and its incidence is still increasing." | ( Weinlich, G, 2009) |
| "Primary vaginal melanoma is a rare, highly malignant, and poor prognostic disease." | ( Baloglu, A; Bezircioglu, I; Cetinkaya, B; Yavuzcan, A, 2009) |
| "Malignant melanoma is a highly metastatic cutaneous cancer and typically refractory to chemotherapy." | ( Mousavi-Shafaei, P; Zangemeister-Wittke, U; Ziaee, AA, 2009) |
| "Malignant melanomas are generally drug resistant and have a very poor prognosis." | ( Andersson, Y; Fodstad, Ø; Risberg, K, 2009) |
| "Metastatic melanoma is extremely refractory to existing chemotherapeutic drugs and bioimmune adjuvant therapies, and the life span of patients with metastatic melanoma is often measured in months." | ( Bar-Eli, M; Melnikova, VO, 2009) |
| "Melanoma is highly resistant to chemotherapy." | ( Berneburg, M; Clasen, S; Eigentler, T; Forschner, A; Garbe, C; Guenova, E; Knaudt, B; Leiter, U; Meier, F; Zielinski, C, 2009) |
| "Melanoma is one of the most chemo-resistant cancers." | ( Chen, BH; Chen, CY; Chen, GS; Chen, YL; Hong, CH; Hu, WP; Lee, CH; Liao, WT; Wang, JJ; Yu, HS, 2009) |
| "Melanoma is responsive to platinum compounds and taxanes, but there is limited experience with combinations of these agents." | ( Clark, JI; Gajewski, TF; Locke, F, 2010) |
| "Metastatic melanoma is an incurable disease with an average survival of less than one year." | ( Anthony, SP; Cunningham, CC; Eager, RM; Frenette, G; Jones, B; Nemunaitis, J; O'Day, SJ; Pavlick, AC; Senzer, NN; Stephenson, J; Uprichard, M, 2009) |
| "Malignant melanoma is resistant to almost all conventional forms of chemotherapy." | ( Akbari, M; Andrew, SE; Felton, KE; Keuling, AM; Parker, AA; Tron, VA, 2009) |
| "Malignant melanomas are intrinsically resistant to many conventional treatments, such as radiation and chemotherapy, for reasons that are poorly understood." | ( Cardarelli, CO; Chen, KG; Gottesman, MM; Hearing, VJ; Lai, B; Leapman, RD; Valencia, JC; Vieira, WD; Zhang, G, 2009) |
| "Malignant melanoma is a highly aggressive and drug-resistant cancer." | ( Aurelian, L; Colunga, AG; Laing, JM, 2010) |
| "Melanoma is the most lethal human skin cancer." | ( Gil, R; Grueso, J; Hernandez-Losa, J; López-Fauqued, M; Moliné, T; Pujol, A; Recio, JA, 2010) |
| "Metastatic melanoma is associated with poor prognosis and still limited therapeutic options." | ( Borghi, M; Canese, R; De Milito, A; Della Mina, P; Fais, S; Iero, M; Iessi, E; Logozzi, M; Lozupone, F; Marino, ML; Podo, F; Rivoltini, L; Rodolfo, M; Santinami, M; Venturi, G; Villa, A, 2010) |
| "Metastasized melanoma is almost universally resistant to chemotherapy." | ( Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K, 2010) |
| "Malignant melanoma is one of the most aggressive human neoplasms which develop from the malignant transformation of normal epithelial melanocytes and share the lineage with retinal cells." | ( Bazhin, AV; Dikov, B; Eichmüller, SB; Philippov, PP; Schadendorf, D; Tambor, V, 2010) |
| "Metastatic melanoma is a highly life-threatening disease." | ( Czyz, M; Düchler, M; Koprowska, K; Lesiak, K; Nejc, D; Zalesna, I, 2010) |
| "Melanoma is the most aggressive and deadly form of skin cancer." | ( Doudican, NA; Morrison, BW; Orlow, SJ; Patel, KR, 2010) |
| "The incidence of melanoma is rising at an alarming rate and we are still awaiting an effective treatment for this malignancy." | ( Owen, LB; Sharma, B; Singh, AP; Singh, RK; Singh, S, 2010) |
| "Malignant melanoma is one of the most lethal and aggressive human malignancies." | ( Jiang, G; Liu, YQ; Mao, LJ; Pei, DS; Wei, ZP; Zheng, JN, 2010) |
| "Melanoma is an aggressive neoplasm with a propensity for metastases and resistance to therapy." | ( Nihal, M; Roelke, CT; Wood, GS, 2010) |
| "Melanoma is an aggressive form of skin cancer that is commonly fatal if not diagnosed in its early stage of development." | ( Chatterjee, SJ; McNulty, J; Pandey, S, 2011) |
| "Cutaneous melanoma is an aggressive form of human skin cancer characterized by high metastatic potential and poor prognosis." | ( Chen, J; Feilotter, HE; Garady, C; Lai, D; Paré, GC; Pemberton, JG; Tron, VA; Yang, X; Zhang, X, 2010) |
| "Uveal melanoma is the most common primary intraocular malignant tumor in adults and is defined by a poor natural outcome, as 50% of patients die from metastases." | ( Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S, 2010) |
| "Metastatic melanomas are hypervascular tumours with poor prognosis." | ( Hernberg, M; Ivaska, J; Laukka, M; Lundin, J; Pyrhönen, S; Tyynelä, K; Vihinen, PP; Vuoristo, MS, 2010) |
| "Uveal melanoma is an aggressive disease without effective adjuvant therapy for metastases." | ( Bedikian, AY; Esmaeli, B; Gombos, DS; Hwu, P; Simantov, R; Soheili, A; Williams, MD, 2010) |
| "Melanoma is an aggressive form of skin cancer with high occurrence in the United States." | ( Evans, SC; Fernandes, E; Kieliszewski, M; Soans, E; Xu, J, 2010) |
| "Melanoma is the major cause of skin cancer death worldwide." | ( Kamitani, T; Matsuo, Y, 2010) |
| "Metastatic melanoma is one of the most resistant tumors to standard chemotherapy approaches." | ( Alberola Candel, V; Gasent Blesa, JM; Grande Pulido, E; Provencio Pulla, M, 2011) |
| "While melanoma is exceptionally challenging to standard regimens, it is suited for treatment with immunotherapy based on its immunogenicity." | ( Bos, JD; Filippov, DV; Konijnenberg, D; Luiten, RM; Meeuwenoord, NJ; Melief, CJ; Picavet, DI; Tjin, EP; van den Boorn, JG; van der Veen, JP, 2010) |
| "Melanoma is the most deadly form of skin cancer without effective treatment." | ( Andreu-Pérez, P; Avila, MA; Cortés, J; Gil, R; Grueso, J; Hernandez-Losa, J; Moliné, T; Pujol, A; Recio, JA, 2010) |
| "Malignant melanoma is an aggressive skin cancer with no effective therapies currently approved for advanced disease." | ( Binder, M; Erasim, C; Harmankaya, K; Hoos, A; Ibrahim, R; Koelblinger, C; Pehamberger, H, 2011) |
| "Melanoma is a severe skin cancer that often leads to death." | ( Bathula, SR; Chen, Y; Huang, L; Yang, Q, 2010) |
| "Metastatic melanoma is an aggressive malignancy that is resistant to therapy and has a poor prognosis." | ( Chin, KV; de la Serna, IL; Keenen, B; Marathe, HG; Qi, H; Saladi, SV, 2010) |
| "Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize." | ( Katiyar, N; Katiyar, SK; Sharma, S; Singh, T; Vaid, M, 2011) |
| "Malignant melanoma is rising faster in incidence than any other malignancy." | ( Boasberg, P; Hamid, O; O'Day, S, 2010) |
| "Melanoma is the deadliest form of skin cancer, which is notoriously aggressive and chemo-resistant, and for which there is little effective treatment available if it goes undetected." | ( Chatterjee, SJ; Pandey, S, 2011) |
| "Metastatic melanoma is an aggressive cancer with very low response rate against conventional chemotherapeutic agents such as dacarbazine (DTIC)." | ( Alamanda, V; Chellappan, S; Davis, R; Lawrence, N; Pernazza, D; Pireddu, R; Sebti, S; Singh, S, 2010) |
| "Melanoma is relatively resistant to chemotherapy; improved targeting of molecules critical for cell proliferation and survival are needed." | ( Aziz, SA; Camp, RL; Conrad, P; Jilaveanu, LB; Kluger, HM; Rimm, DL; Zito, C, 2010) |
| "Melanoma is thus a model cancer to test the hypothesis that in vivo MT from cancer patients can be used as immunological probes for immunogenic tumor antigens." | ( Albertini, MR; Bostwick, BL; Macklin, MD; Newton, MA; Pei, Q; Zuleger, CL, 2011) |
| "Malignant melanoma is a highly aggressive tumor that frequently resists chemotherapy, so the search for new agents for its treatment is of great importance." | ( Castello, G; De Marino, S; Festa, C; Ialenti, A; Ianaro, A; Iorizzi, M; Napolitano, M; Panza, E; Tersigni, M; Zollo, F, 2011) |
| "Melanoma is an aggressive tumor that expresses the pigmentation enzyme tyrosinase." | ( Burd, R; Limesand, KH; Mendoza, EE; Sittadjody, S; Thangasamy, T; Vargas, AJ, 2011) |
| "Metastatic melanoma is a very aggressive cancer." | ( Dalle, S; Dumontet, C; Julia, F; Thomas, L, 2010) |
| "Today, melanomas are also classified based on molecular alterations." | ( Bauer, J; Eigentler, TK; Garbe, C; Held, L; Held, M; Meier, F; Röcken, M, 2011) |
| "Metastatic melanoma is characterized by extremely poor survival rates and hence novel therapies are urgently required." | ( Al Sabah, S; Armstrong, JL; Corazzari, M; Ellis, N; Falasca, L; Fimia, GM; Hill, DS; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP, 2011) |
| "Melanoma is a highly aggressive skin cancer with an increasing incidence." | ( Parlette, EC; Toren, KL, 2010) |
| "Melanoma is the most common tumor to metastasize to the GI tract, where it mainly involves the small bowel." | ( Fulham, M; Prakoso, E; Selby, WS; Thompson, JF, 2011) |
| "Malignant melanoma is the most malignant of skin tumor." | ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Malignant melanoma is the deadliest form of skin cancer, known for its drug resistance and high metastatic potential." | ( Amin, S; Chung, CY; Desai, D; Madhunapantula, SV; Robertson, GP, 2011) |
| "Melanoma is a tumour of transformed melanocytes, which are originally derived from the embryonic neural crest." | ( Burke, CJ; Cech, J; Chen, F; Datta, S; Granter, S; Kaufman, C; Kramer, M; Langdon, E; Lin, CY; Long, HK; Morrison, S; Mosher, J; Neuberg, D; Rahl, PB; Ratanasirintrawoot, S; Tomlinson, ML; Wheeler, GN; White, RM; Young, RA; Zon, LI, 2011) |
| "Melanoma is the deadliest form of skin cancer and its incidence has been increasing worldwide." | ( Herlyn, M; Villanueva, J; Vultur, A, 2011) |
| "Melanoma is a highly aggressive neoplastic disease attributed to transformed melanocytes." | ( Abramov, ME; Artamonov, DN; Gorbacheva, LB; Tronov, VA, 2011) |
| "The incidence of melanoma is increasing more than any other cancer, and knowledge of its genetic alterations is limited." | ( Davies, MA; Davis, S; Gartner, J; Gershenwald, JE; Lin, JC; Prickett, TD; Robinson, S; Robinson, W; Rosenberg, SA; Samuels, Y; Stemke-Hale, K; Teer, JK; Walia, V; Wei, X, 2011) |
| "Melanoma is a highly aggressive malignant tumor with an exceptional ability to develop resistance and no curative therapy is available for patients with distant metastatic disease." | ( Engebråten, O; Engesæter, BO; Flørenes, VA; Hellenes, T; Holm, R; Mælandsmo, GM; Sathermugathevan, M, 2011) |
| "Acral lentiginous melanoma is an uncommon skin malignancy that occurs with equal frequency in all races and has a worse prognosis than other types of melanoma; it presents as dark, irregular macules, papules, or nodules on the feet and, less commonly, the hands." | ( Piliang, MP, 2011) |
| "Malignant melanoma is well known for its propensity to spread to unpredictable sites." | ( Mudun, A; Ozkan, G; Sanli, Y; Turkmen, C; Yegen, G, 2011) |
| "Human malignant melanoma is highly resistant to chemotherapy and current immunotherapeutic approaches induce long term remission only in the minority of patients." | ( Busse, A; Keilholz, U, 2011) |
| "Cutaneous melanoma is an aggressive disease." | ( Bane, F; Byrne, C; deBlacam, C; Hill, AD; Hughes, E; McIlroy, M; Young, LS, 2011) |
| "Melanoma is one of the most common cancers worldwide and its incidence has been increasing over the past few decades." | ( Chen, HY; Chung, JG; Lai, TY; Lin, HY; Lin, JG; Lo, C; Ma, YS; Weng, SW; Yang, JH; Yang, JS, 2011) |
| "Scalp melanoma is aggressive and has a proclivity for regional metastasis." | ( Bradford, CR; Collar, RM; Johnson, TM; Pannucci, CJ; Rees, RS, 2012) |
| "Cutaneous malignant melanoma is an aggressive disease of poor prognosis." | ( Angel, P; Blaber, M; Blaber, SI; Hess, J; Krenzer, S; Mauch, C; Peterziel, H, 2011) |
| "Cutaneous melanoma is a tumor with rising incidence and a very poor prognosis at the disseminated stage." | ( Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S, 2011) |
| "Metastatic melanoma is a fatal disease due to the lack of successful therapies and biomarkers for early detection and its incidence has been increasing." | ( Arab, K; Claus, R; Espinosa, AV; Gast, A; Hielscher, T; Huang, JP; Kumar, R; Morrison, CD; Plass, C; Ringel, MD; Schadendorf, D; Smith, LT; Weichenhan, D, 2011) |
| "Melanoma is a heterogeneous disease where monotherapies are likely to fail due to variations in genomic signatures." | ( Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J, 2011) |
| "Melanoma is one of the most common cancers, and its incidence has continued to increase over the past few decades." | ( Azzoni, P; Benassi, L; Bertazzoni, G; Costi, MP; Giudice, S; Magnoni, C; Morini, D; Pirondi, S; Seidenari, S; Venturelli, A; Veratti, E, 2012) |
| "Malignant melanoma is an aggressive cancer of pigment-producing cells, derivates of the neural crest." | ( Heneberg, P, 2011) |
| "Cutaneous melanoma is an increasingly common and potentially lethal malignancy of melanocytes, the melanin producing cells normally located in the basal layer of the skin epidermis." | ( Chandrasekaran, S; DeLouise, LA, 2011) |
| "Most metastatic melanomas are refractory to current available therapy, underscoring the need to identify new effective treatments." | ( Doudican, NA; Orlow, SJ; Quay, E; Zhang, S, 2011) |
| "The treatment for melanoma is in rapid transition and genomic profiling is now an integral part, and hence the optimal use of karenitecin in melanoma should be re-evaluated with regard to specific mutational status." | ( Daud, AI; Munster, PN, 2011) |
| "Melanoma is the second most common cancer among young adults in the UK, where incidence rates have more than quadrupled since the 1970s." | ( Li, W; Melton, DW, 2012) |
| "Melanoma is the most serious type of skin disease and a leading cause of death from skin disease due to its highly metastatic ability." | ( Katiyar, SK; Singh, T, 2011) |
| "Melanoma is a rare but very aggressive form of cancer." | ( Dréno, B; Quéreux, G, 2011) |
| "Melanoma is easily curable by surgical excision when detected early, but it is nearly incurable when discovered in its later stages owing to resistance to treatment." | ( Amaria, R; Gonzalez, R; Lewis, K; Scheier, B, 2011) |
| "Melanoma is highly resistant to current modalities of therapy, with the extent of pigmentation playing an important role in therapeutic resistance." | ( Brozyna, AA; Janjetovic, Z; Jozwicki, W; Kim, TK; Nguyen, MN; Pfeffer, LM; Pfeffer, SR; Slominski, AT; Tuckey, RC, 2011) |
| "Malignant melanoma is known by its rapid progression and poor response to currently applied treatments." | ( Sevko, A; Umansky, V, 2012) |
| "Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin." | ( Czyż, M; Koprowska, K, 2011) |
| "Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways." | ( Allen, JD; Haass, NK; Hersey, P; Huang, DC; Lau, D; Lucas, KM; Mohana-Kumaran, N; Weninger, W; Zhang, XD, 2012) |
| "Metastatic melanoma is the second most common cancer to metastasize to the brain." | ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| "Melanoma is a lethal form of skin cancer that can metastasize rapidly." | ( Chang, FR; Du, YC; Farh, L; Hsu, CC; Tseng, WK; Wu, CC; Wu, YC, 2012) |
| "Malignant melanoma is a disease with high mortality rate caused by rapid metastasis." | ( Ciołczyk-Wierzbicka, D; Gil, D; Laidler, P, 2012) |
| "Melanoma is an increasingly common and potentially fatal malignancy of the skin and some mucous membranes." | ( Berger, A; Busch, C; Garbe, C; Ikenberg, K; Meier, F; Niessner, H; Schott, S; Sinnberg, T; Venturelli, S; Villanueva, J, 2012) |
| "Melanoma is a malignancy characterized by high invasive/metastatic potential, with no efficient therapy after metastasis." | ( Hölttä, E; Laakkonen, P; Lammi, J; Nummela, P; Saksela, O; Soikkeli, J, 2012) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults; however, current therapeutic modalities, including chemotherapy, have not been successful." | ( Cun, B; Fan, X; Ge, S; Jia, R; Song, X; Wang, H; Zhao, X, 2012) |
| "Melanoma is the fifth most common cancer in men and seventh most common in women in the USA, and prognosis for patients with advanced melanoma is poor." | ( Kim, KB; Patel, SP, 2012) |
| "Melanoma is known to be radioresistant and traditional treatments have been intractable." | ( Cui, D; Fu, S; Li, P; Luo, T; Pang, B; Ren, Q; Xu, W; Zhou, C, 2012) |
| "Melanoma is the most dangerous form of skin cancer occurring in Caucasians with rising incidence." | ( Hill, K; Oehler, B; Schaefer, M; Scholze, A, 2012) |
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| "Metastatic melanoma is a lethal skin cancer and its incidence is rising every year." | ( Aresti, U; Buqué, A; Calvo, B; Carrera, S; López-Vivanco, G; Muhialdin, JSh; Muñoz, A; Rubio, I; Sancho, A, 2012) |
| "Acral melanoma is the commonest malignant melanoma in this Sarawakian cohort." | ( Norlida, DK; Syed Alwi, SA; Zainal, AI; Zulkarnaen, M, 2012) |
| "The risk of melanoma is increased by use of biologics, and the risk of NMSC is increased by use of thiopurines." | ( Herfarth, HH; Kappelman, MD; Long, MD; Martin, CF; Pipkin, CA; Sandler, RS, 2012) |
| "Melanoma is one of the most aggressive cancers of all solid tumors." | ( Akhavan, MM; Falahtpishe, H; Ghodrati, M; Karimi, M, 2011) |
| "Melanoma is the main cause of death in skin cancers." | ( Davids, LM; Sharma, KV, 2012) |
| "Metastatic melanoma is the most aggressive skin cancer." | ( Annereau, JP; Chartrain, M; Gairin, JE; Gomes, B; Guilbaud, N; Lamant, L; Meyer, N; Riond, J; Stennevin, A; Vandenberghe, I, 2012) |
| "Melanoma is a highly metastatic cancer and there is strong evidence that the clotting initiator protein, tissue factor (TF), contributes to its aggressive pattern." | ( Andersen, JF; de Oliveira, Ada S; Francischetti, IM; Lima, LG; Machado, DE; Mariano-Oliveira, A; Monteiro, RQ; Nasciutti, LE; Petersen, LC, 2012) |
| "Cutaneous melanoma is extremely uncommon in children." | ( Kashani-Sabet, M; Leong, SP; McCalmont, TH; Miranda, SG; Zedek, D, 2011) |
| "Malignant melanoma is a deadly type of metastatic skin cancer with increased incidence over the past 30 years." | ( Arruda, DC; Farias, CF; Favero, OA; Ferreira, MJ; Figueiredo, CR; Girola, N; Lago, JH; Massaoka, MH; Matsuo, AL; Romoff, P; Scutti, JA; Travassos, LR, 2012) |
| "Melanoma is the most common oral malignancy in dogs." | ( Dank, G; Garrett, LD; Kitchell, BE; Kleiter, M; Northrup, N; Post, GS; Rassnick, KM; Segev, G; Sellon, RK; Sokolovsky, Y, 2014) |
| "Metastatic melanoma is a deadly skin cancer and is resistant to almost all existing treatment." | ( Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Bille, K; Bonet, C; Giuliano, S; Lacour, JP; Ohanna, M; Rocchi, S, 2012) |
| "Melanoma is an immunogenic tumour but, despite the wide range of immunotherapies tested, only few promising results have been reported to date." | ( Galimberti, S; Pacini, S; Petrini, I; Petrini, M; Romanini, A; Taddei, MR, 2011) |
| "Melanoma is the most aggressive form of skin cancer, responsible for the majority of skin cancer related deaths." | ( Bell, PD; Doonan, BP; God, JM; Haque, A; Hossain, A; Radwan, FF; Zhang, L, 2012) |
| "Melanoma is an aggressive and drug-resistant cancer in need of improved therapeutic strategies." | ( Aurelian, L; Hersl, J; Laing, JM; Lee, KS; Li, B; Shvartsbeyn, M; Smith, CC, 2012) |
| "Metastatic melanoma is a highly aggressive skin cancer and currently resistant to systemic therapy." | ( Bernardo, V; da Silva, DC; de Souza, CF; Jasiulionis, MG; Lopes, JD; Mai, S; Monteiro, AC; Silva, AG; Xander, P, 2012) |
| "Today, melanoma is considered as a spectrum of melanocytic malignancies that can be characterized by clinical and molecular features, including targetable mutations in several kinases." | ( Dummer, R; Eggmann, N; Goldinger, SM; Rinderknecht, J; Rozati, S, 2012) |
| "Malignant melanoma is a relatively rare but potentially aggressive tumor in children and adolescents." | ( Abasq, C; Charles-Pétillon, F; Coat, C; De Braekeleer, M; Marcorelles, P; Quintin-Roué, I; Talagas, M; Uguen, A, 2012) |
| "Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies." | ( Byron, SA; Loch, DC; Nomoto, K; Pollock, PM; Wang, J; Wellens, CL; Wortmann, A; Wu, J, 2012) |
| "Uveal melanoma is the most common intraocular neoplasm with a high tendency to metastasize predominantly to the liver." | ( Edelhauser, G; Gleiss, A; Harmankaya, K; Hoeller, C; Pehamberger, H; Schicher, N; Schindler, K, 2013) |
| "Melanoma is the most common malignant skin cancer, appears indestructible and is notoriously resistant to all current modalities of cancer treatment strategies." | ( Gude, RP; Kamran, MZ, 2012) |
| "Metastatic melanoma is an aggressive disease resistant to chemotherapy." | ( Jordan, EJ; Kelly, CM, 2012) |
| "Malignant melanoma is not a singular, homogeneous disease but rather a mixture of subtypes characterized by specific mutations." | ( Arenbergerová, M; Puzanov, I, 2012) |
| "Melanoma is a highly metastatic and deadly disease." | ( Amin, S; Desai, D; Gowda, R; Madhunapantula, SV; Robertson, GP, 2013) |
| "Malignant melanoma is difficult to treat due to its resistance to chemotherapeutic regimens." | ( Adams, E; Hailey, S; McLane, MA; Penn, R; Wong, A, 2013) |
| "Melanoma is generally refractory to current chemotherapy, thus new treatment strategies are needed." | ( Buettner, R; Horne, D; Jove, R; Liang, W; Liu, L; Ma, Y; Nam, S; Tian, Y; Yakushijin, F; Yakushijin, K; Yang, F, 2012) |
| "Most uveal melanomas are treated with radiotherapy." | ( Damato, B; Groenewald, C; Konstantinidis, L, 2013) |
| "Melanoma is the most aggressive type of malignant skin cancer derived from uncontrolled proliferation of melanocytes." | ( Alili, L; Brenneisen, P; Carroll, KS; Das, S; Giri, S; Sack, M; Seal, S; von Montfort, C; Zanger, K, 2013) |
| "Melanomas are aggressive neoplasms with limited therapeutic options." | ( Anant, S; Kaushik, G; Mammen, JM; Protti, P; Ramalingam, S; Rammamoorthy, P; Rangarajan, P; Subramaniam, D, 2012) |
| "Metastatic melanoma is an aggressive, immunogenic and molecularly heterogeneous disease for which most patients require systemic treatment." | ( Dean, E; Lorigan, P, 2012) |
| "Melanoma is an aggressive cutaneous cancer, whose incidence is growing in recent years, especially in the younger population." | ( Albano, F; Arcucci, A; De Vendittis, E; Granato, G; Montagnani, S; Romano, S; Ruocco, MR, 2013) |
| "Melanoma is one of the most chemoresistant cancers in patient care." | ( Chang, LS; Chen, CY; Chen, YK; Hsu, CC; Hu, WP; Lin, HC; Sung, PJ; Tsai, FY; Wang, JJ, 2013) |
| "Melanoma is one of the most aggressive types of skin cancer and its incidence rate is still increasing." | ( Espona-Fiedler, M; Faião-Flores, F; Maria, DA; Pérez-Tomás, R; Soto-Cerrato, V; Suarez, JA, 2013) |
| "Melanoma is one of the most aggressive skin cancers due to its high capacity to metastasize." | ( Catharino, RR; Faria, AL; Ferreira, CV; Machado, D; Oliveira, DN; Queiroz, KC; Shishido, SM; Spek, CA, 2013) |
| "Melanoma is one of the most aggressive and extremely resistant to conventional therapies neoplasms." | ( Andrieux, J; Formstecher, P; Jouy, N; Kuranda, K; Le Roy, H; Masselot, B; Mortier, L; Polakowska, R; Prochazkova, J; Quesnel, B; Ségard, P; Touil, Y; Vandomme, J; Wolowczuk, I; Zuliani, T, 2013) |
| "Invasive malignant melanoma is the most common fatal form of skin cancer." | ( Glatz, K; Itin, P; Ivanova, K; Nicolas, G; Zippelius, A, 2012) |
| "Melanoma is a lethal skin cancer that occurs predominantly among Caucasians." | ( Leow, M; Mun, KS; Pailoor, J, 2012) |
| "Malignant melanoma is one of the most lethal and aggressive human malignancies." | ( Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Tian, H; Zheng, JN, 2013) |
| "Uveal melanomas are highly metastatic and have high rate of recurrence due to the lack of effective systemic therapy." | ( Chen, F; Cun, B; Fan, X; Ge, S; Hu, D; Hu, S; Luo, Q, 2012) |
| "Malignant melanoma is a highly-aggressive type of malignancy with considerable metastatic potential and frequent resistance to cytotoxic agents." | ( Brors, B; Enk, A; Helmbold, P; Penzel, R; Schirmacher, P; Skorokhod, A, 2013) |
| "Melanoma is an aggressive skin cancer." | ( Pasonen-Seppänen, S; Poukka, M; Siiskonen, H; Sironen, R; Tyynelä-Korhonen, K, 2013) |
| "Malignant melanoma is notorious for its high resistance to chemotherapy, and new anti-melanoma drugs are urgently needed." | ( Albeck, A; Lellouche, MB; Levinger, S; Sharabi-Ronen, Y, 2014) |
| "Melanoma is the fatal form of skin cancer." | ( Guo, Y; Li, F; Li, Y; Wang, J; Zhang, J; Zhang, S, 2014) |
| "Melanoma is highly metastatic and resistant to chemotherapeutic drugs." | ( Fofaria, NM; Kudugunti, SK; Moridani, MY; Pramanik, KC; Srivastava, SK, 2013) |
| "Metastatic melanoma is characterized by a poor response to chemotherapy." | ( Berge, EO; Birkeland, E; Busch, C; Geisler, J; Jönsson, G; Knappskog, S; Lillehaug, JR; Lønning, PE, 2013) |
| "Melanoma is a very aggressive tumor that does not respond well to standard therapeutic approaches, such as radio- and chemotherapies." | ( Costa-Neto, CM; De Lucca, FL; Dillenburg-Pilla, P; Floriano, EM; Jasiulionis, MG; Maria, AG; Pereira, CD; Pesquero, JB; Ramos, SG; Reis, RI, 2013) |
| "Malignant melanoma is the most aggressive form of skin cancer." | ( Cao, Z; Guo, P; Liu, R; Pan, Y; Yang, P; Zhang, G; Zhou, Q, 2013) |
| "Melanoma is a multifactorial disease with a strong genetic component and known risk factors such as excessive ultraviolet exposure, intermittent sunburns and fair skin type." | ( De'Ambrosis, B; Sinnya, S, 2013) |
| "Canine and human melanomas are histologically disparate but show similar disease progression and response to therapies." | ( Denton, CL; Fowles, JS; Gustafson, DL, 2015) |
| "Malignant melanoma is a highly aggressive tumor with increasing incidence and high mortality." | ( Dundr, P; Dvořák, P; Dvořánková, B; Kodet, O; Krajsová, I; Krejčí, E; Lacina, L; Smetana, K; Štork, J; Szabo, P, 2013) |
| "Malignant melanomas are characterized by the ability of early metastatic dissemination to regional lymph nodes and the detection of sentinel lymph node metastases serves as an important prognostic parameter." | ( Bianchini, F; Calorini, L; Contena, C; Peppicelli, S; Tombaccini, D, 2013) |
| "Human malignant melanoma is one of the most aggressive forms of skin cancer with an exceptionally bad prognosis." | ( Lázár, V, 2013) |
| "Malignant melanoma is refractory to various chemotherapeutics including antitubulin agents such as paclitaxel." | ( Akasaka, T; Inoue, T; Kasai, S; Maesawa, C; Masuda, T; Shibazaki, M; Takahashi, K; Watanabe, A; Yasuhira, S, 2013) |
| "Human melanoma is a significant clinical problem." | ( Cabezas-Herrera, J; Fernández-Pérez, MP; Montenegro, MF; Piñero-Madrona, A; Rodríguez-López, JN; Sáez-Ayala, M; Sánchez-del-Campo, L, 2013) |
| "Mucosal melanoma is rare and associated with extremely poor prognosis." | ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "Melanoma is one of the most aggressive types of cancer, that is difficult to manage clinically." | ( Iannone, R; Montinaro, A; Morello, S; Pinto, A, 2013) |
| "Metastatic melanoma is among the most intractable cancers to treat; patients show resistance to therapy and limited survival time." | ( Ahn, NG; Litman, ES; Metzner, SI; Sousa, MC; Templeton, PD, 2013) |
| "Melanoma is resistant to most standard chemotherapeutics." | ( Bisogni, R; Calì, G; D'Angelillo, A; Di Pace, AL; Ilardi, G; Nappo, G; Romano, MF; Romano, S; Siano, M; Sorrentino, A; Staibano, S; Wang, SY, 2013) |
| "Melanoma is characterized by high resistance to chemotherapy." | ( Czyz, M; Hartman, ML; Nejc, D; Szulawska-Mroczek, A; Wozniak, M, 2013) |
| "Melanoma is one of the most aggressive cancers and its incidence is increasing worldwide." | ( Gschaider, M; Jalili, A; Kalthoff, F; Mertz, KD; Pathria, G; Romanov, J; Stingl, G; Stuetz, A; Wagner, C; Wagner, SN, 2013) |
| "Melanoma is the deadliest skin cancer, and its incidence has been increasing faster than any other cancer." | ( Atadja, P; Cheng, F; Lee, C; Lienlaf, M; Perez-Villarroel, P; Seto, E; Sotomayor, EM; Villagra, A; Wang, H; Weber, J; Woan, K; Woods, DM, 2013) |
| "Canine malignant melanomas are highly aggressive and fatal neoplasms." | ( Bonkobara, M; Hiroi, T; Ito, K; Iwata, T; Kobayashi, M; Kuroki, S; Kuroki, T; Mori, K; Nakagawa, T; Ono, K; Ozawa, Y; Sasaki, Y; Tetsuka, M; Washizu, T; Yamamoto, H, 2013) |
| "Melanoma is the most dangerous type of skin cancer." | ( Bajek, A; Czajkowski, R; Drewa, T; Schwartz, RA; Uzarska, M; Zegarska, B, 2013) |
| "Malignant melanoma is an aggressive skin cancer and it is reported to be the most treatment-resistant human cancer." | ( Aliwaini, S; Blanckenberg, A; Mapolie, S; Prince, S; Swarts, AJ, 2013) |
| "Melanoma is one of the most aggressive types of human cancers, and the mechanisms underlying melanoma invasive phenotype are not completely understood." | ( Ackroyd, J; Bagati, A; Berman, AE; Bianchi-Smiraglia, A; Bshara, W; Fedtsova, N; Gudkov, AV; Hoek, KS; Im, M; Kozlova, NI; Mannava, S; Miecznikowski, JC; Moparthy, KC; Morrison, CD; Nikiforov, MA; Omilian, AR; Shewach, DS; Wawrzyniak, JA; Zhu, Q; Zucker, SN, 2013) |
| "Uveal melanoma is the most common primary intraocular malignant tumor in adults and half of the primary tumors will develop fatal metastatic disease to the liver and the lung." | ( Ambrosini, G; Dogan, Y; Huang, R; Rajasekhar, VK; Schwartz, GK; Surriga, O, 2013) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults." | ( All-Ericsson, C; Cahlin, C; Hashimi, F; Lindnér, P; Mattsson, J; Olofsson, R; Rizell, M, 2014) |
| "Melanoma is very aggressive and major cause of mortality due to skin cancer." | ( Mittal, A; Singh, RP; Tabasum, S, 2014) |
| "Metastatic melanoma is intrinsically immunogenic, thereby facilitating the search for immune biomarkers of clinical responses to cytotoxic agents." | ( Aupérin, A; Ayyoub, M; Caignard, A; Caillat-Zucman, S; Chaba, K; Chaput, N; Dessen, P; Eggermont, A; Flament, C; Jacquelot, N; Jacques, Y; Mateus, C; Messaoudene, M; Mortier, E; Poirier-Colame, V; Porta, C; Robert, C; Romero, AI; Rusakiewicz, S; Valmori, D; Vielh, P; Zitvogel, L, 2014) |
| "Melanoma is the most aggressive form of skin cancer and, if spread outside the epidermis, has a dismal prognosis." | ( Graziani, G; Lacal, PM; Tentori, L, 2013) |
| "Melanoma is highly resistant to chemotherapy, and the mortality rate is increasing rapidly worldwide." | ( Cao, HH; Cheng, CY; Fong, WF; Kwan, HY; Su, T; Tse, AK; Yu, H; Yu, ZL, 2014) |
| "Melanoma is the third most common brain metastasis cause in the United States as it has a relatively high susceptibility to metastasize to the central nervous system." | ( Aquino, PF; Canedo, NH; Carvalho, Mda G; Carvalho, PC; Chimelli, LM; Fischer, Jde S; Franca, M; Goncalves, KM; Leprevost, FV, 2014) |
| "Cutaneous melanoma is a malignant tumor with a high metastatic potential." | ( Capovilla, M, 2013) |
| "Melanoma is the most aggressive form of skin cancer with estimated 48,000 deaths per year worldwide." | ( Backes, C; Dahmke, IN; Laschke, MW; Leidinger, P; Mahlknecht, U; Meese, E; Menger, MD; Rudzitis-Auth, J, 2013) |
| "Malignant melanoma is highly aggressive, and always resistant to conventional chemo-radiotherapy, which results in poor prognosis." | ( Cui, H; Liu, Y; Yi, L; Zhang, Y; Zhu, S, 2014) |
| "Melanoma is one of the cancers of fastest-rising incidence in the world." | ( Aguirre-Ghiso, J; Chipuk, JE; Davies, MA; Ekmekcioglu, S; Estrada, Y; Grimm, EA; Izadmehr, S; Jayaraman, P; Lopez-Rivera, E; Milton, DR; Parikh, F; Sikora, AG, 2014) |
| "Malignant melanoma is responsible for approximately 75% of skin cancer-related deaths." | ( Afaq, F; Athar, M; Ballestas, ME; Elmets, CA; Katiyar, SK; Pal, HC; Sharma, S; Strickland, LR, 2014) |
| "Melanoma is highly metastatic, but the mechanism of melanoma cell migration is still unclear." | ( Hayashi, T; Hirobe, T; Hisahara, S; Horimoto, K; Horio, Y; Jimbow, K; Kunimoto, R; Sato, M; Sugino, T; Tanimura, A; Yamashita, T, 2014) |
| "Metastatic melanoma is a fatal form of cutaneous malignancy with poor prognosis and limited therapeutic options." | ( Bishayee, A; Biswas, J; Dutta, K; Ganguly, KK; Sinha, D, 2015) |
| "Melanoma is the most aggressive form of skin cancer and until recently, it was extremely resistant to radio-, immuno-, and chemotherapy." | ( Brohem, CA; Campa, A; de Moraes Barros, SB; de Oliveira, EM; Haga, RB; Maria-Engler, SS; Paes, RD; Pennacchi, PC; Smalley, KS; Tiago, M, 2014) |
| "Metastatic melanoma is highly resistant to drug treatment, and the underlying mechanisms of this resistance remain unclear." | ( Anseth, KS; Leight, JL; Tokuda, EY, 2014) |
| "Melanoma is a deadly skin cancer with rapidly rising incidence." | ( Aires, DJ; Cai, S; Forrest, ML; Fraga, GR; Li, CZ; Yang, Q; Zhang, D, 2014) |
| "Uveal melanoma is a serious life-threatening intraocular malignancy, most often found in Caucasians (98%) and primarily involving the choroid (90%), ciliary body (7%), or iris (2%)." | ( Das, C; Ferguson, K; Manalac, J; Shields, CL; Shields, JA, 2014) |
| "Choroidal melanoma is a serious malignancy with characteristic features." | ( Das, C; Ferguson, K; Manalac, J; Shields, CL; Shields, JA, 2014) |
| "Melanoma is one of the deadliest forms of skin cancer, having a high metastatic potential and afflicting all age groups." | ( Tong, LX; Young, LC, 2014) |
| "Metastatic melanoma is the deadliest form of skin cancer." | ( Costa, VM; Diniz, C; Fresco, P; Soares, AS, 2014) |
| "Melanoma is a highly metastatic and lethal form of skin cancer." | ( Cook, M; Girotti, MR; Gore, M; Hayes, A; Larkin, J; Lorigan, P; Marais, R; Niculescu-Duvaz, D; Pedersen, M; Sanchez-Laorden, B; Saturno, G; Springer, C; Turajlic, S; Viros, A; Zambon, A, 2014) |
| "Malignant melanoma is the most aggressive and deadliest form of skin cancer due to its highly metastatic potential, which calls for new and improved therapies." | ( Berge, G; Camilio, KA; Ravuri, CS; Rekdal, O; Sveinbjørnsson, B, 2014) |
| "Melanoma is a less common type of skin cancer yet more aggressive often with a lethal ending." | ( Ilić, N; Jurišić, D; Kraljević Pavelić, S; Markova-Car, EP, 2014) |
| "Melanoma is one of the most lethal forms of skin cancer and its incidence is continuing to rise in the United States." | ( Ahmad, N; George, J; Kumar, R; Nihal, M; Sabat, G; Singh, CK, 2014) |
| "Malignant melanoma is characterized by the development of chronic inflammation in the tumor microenvironment, which leads to a strong immunosuppression associated with a rapid tumor progression." | ( Bazhin, AV; Shevchenko, I; Umansky, V; Utikal, J, 2014) |
| "Given that melanoma is identified as one of the most immunogenic solid tumors, there is continued hope that vaccine therapies will improve clinical outcomes." | ( Chandra, S; Pavlick, AC; Weiss, SA, 2014) |
| "Cutaneous melanoma is a significant cause of morbidity and mortality." | ( Damian, DL; Halliday, GM; Surjana, D; Thompson, BC, 2014) |
| "Melanomas are vascular tumors with a high incidence of BRAF mutations driving tumor proliferation." | ( Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J, 2014) |
| "Malignant melanoma is one of the most aggressive forms of cancer and its incidence is rapidly increasing." | ( Alili, L; Brenneisen, P; Das, S; Gupta, A; Karaman, E; Sack, M; Seal, S, 2014) |
| "Melanoma is the deadliest form of skin cancer and among the malignancies of highest increasing incidence over the last several decades." | ( Amaro-Ortiz, A; D'Orazio, JA; Yan, B, 2014) |
| "Malignant melanoma is the most lethal form of skin cancer, with a high propensity to metastasize to the brain." | ( Bjerkvig, R; Dale, HA; Daphu, I; Horn, S; Skaftnesmo, KO; Spriet, E; Stieber, D; Thorsen, F; Varughese, JK, 2014) |
| "Melanoma is resistant to cytotoxic therapy, and treatment options for advanced disease have been limited historically." | ( Kee, D; McArthur, G, 2014) |
| "Uveal melanoma is the most common primary intraocular tumor in adults, and up to 50% of patients will develop liver metastases." | ( Baeten, CI; Braat, AE; Frangioni, JV; Prevoo, HA; Tummers, QR; Vahrmeijer, AL; van de Velde, CJ; Verbeek, FP, 2015) |
| "Malignant melanoma is the most deadly type of skin cancer." | ( Costa, VM; Diniz, C; Fresco, P; Soares, AS, 2015) |
| "Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation." | ( Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD, 2014) |
| "Melanoma is a devastating form of skin cancer with limited therapeutic options." | ( Aplin, AE; Vu, HL, 2014) |
| "Primary anorectal melanoma is an extremely rare, aggressive malignancy with a poor prognosis." | ( Li, ZG; Qin, XJ, 2014) |
| "Metastatic melanoma is associated with a splicing switch to pro-angiogenic VEGF-A, previously shown to be regulated by SRSF1 phosphorylation by SRPK1." | ( Bates, DO; Coupland, SE; Dean, R; Gammons, MV; Lucas, R; Oltean, S, 2014) |
| "Melanoma is primarily driven by mutations in the components of mitogen-activated protein kinases (MAPK) pathway." | ( Rodríguez, CI; Setaluri, V, 2014) |
| "Melanoma is one of the most common skin neoplasms in humans and dogs." | ( Cogliati, B; Grandi, F; Miot, HA; Rocha, NS; Rocha, RM, 2014) |
| "Spreading of melanoma is associated with efficient extravasation of circulating tumor cells from the vascular system into distant target organs." | ( Desch, A; Huck, V; Magnolo, N; Poeppelmann, B; Schneider, SW; Strozyk, EA; Wegener, J, 2014) |
| "Congenital melanoma is extraordinarily rare, and 3 types have been described: transplacental metastases from the mother, de novo congenital melanoma, and melanoma occurring in association with a congenital melanocytic nevus." | ( Barnhill, RL; Li, X; Low, L; Mascarenhas, L; Su, A; Zhou, S, 2014) |
| "Melanoma is rare in Japan (1500-2000 cases/year compared with 132 000/year worldwide) and the frequency and distribution of BRAF V600 mutations are unknown." | ( Eguchi, H; Hayashi, A; Nakamura, N; Namikawa, K; Oashi, K; Ogawa, T; Omata, W; Tanaka, R; Tsuta, K; Tsutsumida, A; Yamazaki, N, 2015) |
| "Melanoma is an aggressive cancer of the melanocyte lineage." | ( Akutsu, H; Aoto, T; Miyachi, Y; Nakauchi, H; Nishimura, EK; Okamoto, N; Saida, T; Uhara, H; Umezawa, A; Yamazaki, S, 2014) |
| "Melanoma is a highly aggressive tumor due to its metastasizing potential and resistance to conventional cancer therapies." | ( Davids, LM; Kleemann, B; Lang, D; Loos, B; Scriba, TJ, 2014) |
| "Melanoma is one of the most deadly cancers because of its high propensity to metastasis, a process that requires migration and invasion of tumor cells driven by the regulated formation of adhesives structures like focal adhesions (FAs) and invasive structures like invadopodia." | ( De Mey, J; Gies, JP; Kolli-Bouhafs, K; Noulet, F; Rondé, P; Sick, E, 2014) |
| "Metastatic melanoma is considered one of the most aggressive malignant tumours, representing the deadliest form of skin cancer." | ( Costa, VM; Diniz, C; Fresco, P; Soares, AS, 2014) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults." | ( Asnaghi, L; Eberhart, CG; Enke, R; Handa, JT; Merbs, SL; Rajaii, F, 2014) |
| "Cutaneous melanoma is the most life-threatening neoplasm of the skin, accounting for most of the skin cancer deaths." | ( Chang, YL; Chiang, CP; Gao, HW; Huang, SM; Hung, HC; Ku, CF; Liu, GY; Wang, WM, 2015) |
| "Melanoma is a malignant tumor derived from epidermal melanocytes, and it is known for its aggressiveness, therapeutic resistance, and predisposition for late metastasis." | ( Anderson, CJ; Beaino, W, 2014) |
| "Melanoma is the most malignant skin cancer and is highly resistant to chemotherapy and radiotherapy." | ( Jiang, AJ; Jiang, G; Li, LT; Zheng, JN, 2015) |
| "Clear cell melanoma is a rare clear cell malignancy." | ( Andea, A; Betz, BL; Carskadon, S; Fullen, DR; Harms, PW; Palanisamy, N; Patel, RM; Pletneva, MA; Wang, M, 2014) |
| "Metastatic melanoma is a deadly form of cancer with few therapeutic options and the cause of more than 9480 deaths annually in the USA alone." | ( Agrawal, V; Frankel, AE; Frenkel, EP; Jo, C; Kleypas, K; Mauldin, JP; Meininger, CJ; Stone, EM; Woo, JH, 2014) |
| "Although melanoma is not a cancer of epithelial cells, hallmarks of EMT have been described to play a critical role in melanoma progression." | ( Christofori, G; Dummer, R; Schlegel, NC; von Planta, A; Widmer, DS, 2015) |
| "Melanoma is rare in children, but its incidence appears to be increasing." | ( Qian, Q; Yang, Y, 2014) |
| "Malignant melanoma is an aggressive form of skin cancer with limited effective therapeutic options." | ( Anant, S; Jensen, RA; Kaushik, G; Kwatra, D; Mammen, JM; Subramaniam, D, 2014) |
| "Melanoma is a very aggressive type of skin cancer." | ( Bortoluzzi, AJ; Cisilotto, J; Creczynski-Pasa, TB; Ferreira, M; Filippin-Monteiro, FB; Sa, MM, 2015) |
| "Malignant melanoma is the deadliest form of skin cancer; the treatment of advanced and recurrent forms remains a challenge." | ( Block, NL; Cai, RZ; Klukovits, A; Krishan, A; Popovics, P; Rick, FG; Schally, AV; Szalontay, L; Vidaurre, I; Zarandi, M, 2014) |
| "Melanoma is an aggressive disease with limited therapeutic options." | ( Anant, S; Jensen, RA; Kaushik, G; Mammen, JM; Ramamoorthy, P; Standing, D; Subramaniam, D; Umar, S; Venugopal, A, 2015) |
| "Malignant melanoma is the most aggressive and deadly form of skin cancer." | ( Jiang, G; Li, RH; Liu, YQ; Sun, C; Zheng, JN, 2014) |
| "Malignant melanoma is an aggressive and deadly form of skin cancer, and despite recent advances in available therapies, is still lacking in completely effective treatments." | ( Aziz, F; Fu, YS; Liu, JW; Shan, X; Wang, XQ; Yan, Q, 2014) |
| "Malignant melanoma is a form of skin cancer associated with significant mortality once it has spread beyond the skin." | ( Apalla, Z; Chan, AW; Kyrgidis, A; Mocellin, S; Pilati, P; Tzellos, T, 2014) |
| "Malignant melanoma is an aggressive tumor with poor prognosis that can have widespread metastases at presentation." | ( Bal, A; Dey, P; Jung, RS; Kapoor, R; Mittal, BR; Shukla, J, 2015) |
| "Nodular melanoma is one of the most life threatening tumors with still poor therapeutic outcome." | ( Dvořánková, B; Grim, M; Kodet, O; Kodetová, D; Kolář, M; Krejčí, E; Lacina, L; Šáchová, J; Smetana, K; Štork, J; Strnad, H; Vlček, Č, 2015) |
| "Melanoma is a lethal form of skin cancer with rising global incidence." | ( Lai, SL; Lim, TK; Lin, Q; Mustafa, MR; Wong, PF, 2015) |
| "Pure spindle-cell melanoma is a rare event, and little is known about its biological background and prognosis." | ( Bastholt, L; Bønnelykke-Behrndtz, ML; Damsgaard, TE; Danielsen, A; Georgsen, JB; Møller, HJ; Nørgaard, PH; Schmidt, H; Steiniche, T, 2015) |
| "Cutaneous melanoma is the fifth most common cancer in the United States." | ( Freedman, ND; Graubard, BI; Hollenbeck, AR; Loftfield, E; Mayne, ST; Shebl, FM; Sinha, R, 2015) |
| "Melanoma is a highly important metastasis in human cancer." | ( Chang, SJ; Chung, JG; Hsiao, YP; Hsu, SC; Huang, YP; Ji, BC; Lien, JC; Liu, HC; Tsai, CH, 2015) |
| "Malignant melanoma is a destructive and lethal form of skin cancer with poor prognosis." | ( Aziz, F; Liu, JW; Shan, X; Tian, LL; Wang, XQ; Yan, Q, 2015) |
| "Melanoma is the least common but most fatal form of skin cancer." | ( Chen, JH; Chiu, CT; Chou, FP; Hsu, CC; Hsuan, SW; Lin, HH, 2015) |
| "Malignant melanoma is a melanocytic tumor with a high potential of invasion and metastasis." | ( Li, YQ; Lv, YT; Wang, JM; Zhang, YP, 2015) |
| "Malignant melanoma is a highly aggressive form of skin cancer with a high mortality rate if not discovered in early stages." | ( Faião-Flores, F; Fruet, AC; Maria, DA; Maria-Engler, SS; Pardi, PC; Quincoces Suarez, JA, 2015) |
| "Melanoma is a life-threatening disorder and its incidence is increasing gradually." | ( Arima, H; Higashi, T; Kameyama, K; Kariya, R; Motoyama, K; Okada, S; Onodera, R; Tanaka, N, 2015) |
| "Metastatic melanoma is a highly aggressive skin cancer with a poor prognosis." | ( Gupta, K; Hardy, KM; Hendrix, MJ; Margaryan, NV; Murphy, GF; Scolyer, RA; Strizzi, L, 2015) |
| "Cutaneous melanoma is highly aggressive and its incidence is increasing worldwide." | ( Bernardes, SS; Cecchini, AL; Cecchini, R; da Silva, CF; de Souza-Neto, FP; Derossi, DR; Guarnier, FA; Melo, GP; Ramalho, LN; Simão, AN, 2015) |
| "Melanoma is a common type of skin cancer with poor survival in advanced stages." | ( Berking, C; French, LE; Heppt, MV; Kamarashev, J; Kerl, K; Reinholz, M; Tietze, JK, 2015) |
| "Melanoma is the most dangerous type of skin cancer accounting for 48,000 deaths worldwide each year and an average survival rate of about 6-10 months with conventional treatment." | ( de Martin, R; Eger, A; Holper-Schichl, YM; Hundsberger, H; Jacobi, N; Kreiseder, B; Muellauer, B; Pretsch, A; Schmid, JA; Wiesner, C, 2015) |
| "Metastatic melanoma is refractory to irradiation and chemotherapy, but amenable to immunological approaches such as immune-checkpoint-inhibiting antibodies or adoptive cell therapies." | ( Bramante, S; Cerullo, V; Heiskanen, R; Hemminki, A; Hemminki, O; Joensuu, T; Kanerva, A; Kaufmann, JK; Koski, A; Liikanen, I; Matikainen, S; Nettelbeck, DM; Oksanen, M; Pesonen, S; Vähä-Koskela, M; Vassilev, L; Veckman, V, 2015) |
| "Metastatic melanoma is a highly heterogeneous tumor; thus, methods to analyze tumor-derived cells circulating in blood should address this diversity." | ( Bowyer, S; Calapre, L; Cowell, L; Frank, MH; Gray, ES; Millward, M; Pearce, R; Reid, AL; Siew, K; Ziman, M, 2015) |
| "Uveal melanoma is highly metastatic, prognosis is poor and there are no effective treatments to extend survival." | ( Ashur-Fabian, O; Cohen, K; Davis, PJ; Ellis, M; Fabian, I; Fabian, ID; Hercbergs, A; Lin, HY; Rosner, M; Shinderman Maman, E; Vishnevskia-Dai, V; Zloto, O, 2015) |
| "Malignant melanoma is a highly aggressive cancer, and the incidence of this disease is increasing worldwide at an alarming rate." | ( Anderson, CJ; Beaino, W; Nedrow, JR, 2015) |
| "Melanoma is notorious for its propensity to metastasize, which makes treatment extremely difficult." | ( Cao, HH; Cheng, CY; Fu, XQ; Guo, H; Kwan, HY; Li, T; Su, T; Tse, AK; Yu, H; Yu, ZL, 2015) |
| "Human cutaneous melanoma is an aggressive and chemotherapy-resistant type of cancer." | ( Adinolfi, B; Breschi, MC; Carpi, S; Costa, B; Da Pozzo, E; Fogli, S; Martini, C; Nieri, P; Pellegrino, M; Podestà, A; Romanini, A, 2015) |
| "Malignant melanoma is the most dangerous type of skin cancer." | ( Arnér, ES; Brodin, B; Campbell, J; Drummond, CJ; Higgins, M; Laín, S; McCarthy, AR; Sachweh, MC; Stafford, WC, 2015) |
| "Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation." | ( Carvajal, RD; Mann, H; Nathan, PD; Schwartz, GK; Smith, I, 2015) |
| "Canine melanoma is one of the most important diseases in small animal medicine." | ( Enjoji, S; Fujiwara, N; Mizuno, T; Nakagawa, T; Ohama, T; Sato, K; Tsuji, S; Usui, T; Vitek, MP; Yabe, R, 2015) |
| "Malignant melanoma is a highly aggressive tumor which may occur in the skin, eye, and mucous membranes." | ( Agliano, F; Morabito, S; Oteri, R; Teti, D; Venza, I; Venza, M; Visalli, M, 2015) |
| "Melanoma is the most serious form of skin cancer affecting mostly people of Caucasian origin and is associated with high exposure to solar ultraviolet (UV) radiation." | ( Green, AC; Miura, K, 2015) |
| "Melanoma is the deadliest cancer." | ( Chen, CY; Chiu, CC; Wang, HM; Wu, PF, 2015) |
| "Melanoma is a skin tumor whose diffusion is rapidly increasing in the world and whose malignancy is reinforced by its high resistance to cytotoxic agents; hence the availability of new cytotoxic drugs would be very helpful to improve melanoma prognosis." | ( Aducci, P; Cattaneo, L; Cicconi, R; Ferracane, R; Giorgi, A; Graziani, G; Grosso, A; Marra, M; Mattei, M; Mignogna, G; Schininà, ME, 2015) |
| "Melanomas are malignant tumors characterized by early metastasis, rapid development, poor prognosis and high mortality." | ( Du, L; Fu, G; Jin, Y; Li, Y; Yu, X, 2015) |
| "Cutaneous melanoma is an aggressive malignancy; its incidence is increasing worldwide and its prognosis remains poor." | ( Casati, L; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM, 2015) |
| "Melanoma is a poor-prognosis cancer in both humans and dogs." | ( Haraguchi, T; Itamoto, K; Mizuno, T; Mori, T; Nakagawa, T; Noguchi, S, 2015) |
| "melanoma is 92." | ( Burns, KH; Rodić, N; Sharma, R; Taube, JM; Zampella, J, 2015) |
| "Melanoma is the most lethal form of skin cancer and successful treatment of metastatic melanoma remains challenging." | ( Baar, MP; Brenkman, AB; Burgering, BM; Campisi, J; de Keizer, PL; Hasenfuss, SC; Hoeijmakers, JH; Kruiswijk, F; Kruit, W; Naipal, KA; Putavet, D; Sivapatham, R; van den Broek, NJ; van der Spek, PJ; van Gent, DC, 2016) |
| "Melanoma is the most deadly form of cutaneous malignancy, and its incidence rates are rising worldwide." | ( Afaq, F; Agarwal, J; Athar, M; Baxter, RD; Elmets, CA; Hunt, KM; Pal, HC, 2015) |
| "Melanoma is a poor-prognosis cancer in both humans and dogs, and so the anti-tumor effects of 5-aza-2'-deoxycitidine (5-aza) on solid tumors such as melanoma have gained much attention." | ( Igase, M; Mizuno, T; Mori, T; Noguchi, S, 2015) |
| "Melanoma is one of the most aggressive and lethal cancers." | ( Deng, W; Guo, W; Huang, W; Kang, T; Li, W; Liu, T; Qin, L; Qiu, H; Shi, D; Sun, R; Tian, Y; Wang, G; Wang, J; Xu, T, 2015) |
| "Melanoma is well‑known as an aggressive and highly metastatic disease." | ( Chen, W; Feng, J; Jiang, Z; Ling, Y; Zhang, X, 2015) |
| "Conjunctival melanoma is a rare but potentially fatal ocular surface tumor." | ( Cao, Y; Zhang, Y; Zhao, M, 2015) |
| "Melanoma is one of the most malignant forms of skin cancer; with a rapidly increasing prevalence." | ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "Melanoma is a largely incurable skin malignancy owing to the underlying molecular and metabolic heterogeneity confounded by the development of resistance." | ( Bhat, MK; Chaube, B; Malvi, P; Meena, AS; Mohammad, N; Singh, SV, 2015) |
| "Patients with melanoma are supposed to develop spontaneous immune responses against specific tumor antigens." | ( Huang, G; Li, L; Li, X; Luo, Y; Ouyang, Z; Wu, H, 2016) |
| "Melanoma is the most aggressive and deadly form of cutaneous neoplasm due to its propensity to metastasize." | ( Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR, 2016) |
| "Melanoma is a malignancy of pigment-producing cells that is driven by a variety of genetic mutations and aberrations." | ( Akabane, H; Sullivan, RJ, 2016) |
| "Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans." | ( Leon-Ferre, RA; Markovic, SN, 2015) |
| "Anal melanoma is a rare malignancy with a poor prognosis." | ( Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK, 2016) |
| "Melanoma is the foremost malignant cutaneous cancer and it is extremely resistant to chemotherapy and radiotherapy." | ( Han, X; Li, Z; Ni, J; Qiao, S; Sha, Y; Song, Z; Sun, Z; Zhao, G; Zheng, S, 2016) |
| "Metastatic melanomas are highly aggressive and median survival is 6-9months for stage IV patients in the absence of treatment with anti-tumor activity." | ( Goormaghtigh, E; Le Corre, Y; Martin, L; Mathieu, V; Wald, N, 2016) |
| "Melanoma is characterized by dysregulated intracellular signalling pathways including an impairment of the cell death machinery, ultimately resulting in melanoma resistance, survival and progression." | ( Abd Elmageed, ZY; Brodell, RT; El-Khattouti, A; Haikel, Y; Hannig, M; Hassan, M; Hassan, SY; Kandil, E; Leverkus, M; Megahed, M; Selimovic, D; Taylor, EB, 2016) |
| "Melanoma is one of the most lethal skin cancers worldwide, primarily because of its propensity to metastasize." | ( Claps, G; Donn, D; Feng, Y; Freeze, HH; Fukuda, MN; Jilaveanu, L; Kluger, H; Lau, E; Perlina, A; Ronai, ZA, 2015) |
| "Digital melanoma is commonly treated with amputation or wide local excision." | ( Brodland, DG; Sharon, DJ; Terushkin, V; Zitelli, JA, 2016) |
| "Malignant melanoma is a type of skin cancer with accelerated evolution and a high metastatic potential, thus being the most aggressive type of skin tumor." | ( Blendea, A; Brănişteanu, DE; Costache, A; Georgescu, CV; Ţolea, I, 2015) |
| "Melanoma is a highly aggressive form of skin cancer with poor survival rate." | ( Katiyar, SK; Prasad, R; Singh, T; Vaid, M, 2016) |
| "Melanoma is a metastatic cancer associated with poor survival." | ( Adhikary, G; Eckert, RL; Fisher, ML; Grun, D; Kaetzel, DM, 2016) |
| "Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease." | ( Baska, F; Boros, S; Dobos, J; Garamvölgyi, R; Illyés, E; Kékesi, L; Kéri, G; Őrfi, L; Sipos, A; Szabadkai, I; Szántai-Kis, C, 2016) |
| "Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult." | ( Agopian, J; Dubreuil, P; Grim, J; Hermine, O; Kolarova, R; Kopecky, J; Lukesova, S; Mansfield, C; Moussy, A; Navratilova, B; Papik, Z; Prosvicova, J, 2015) |
| "Both PD and melanoma are likely multifactorial diseases involving genetic and environmental risk factors." | ( Disse, M; Lee, PK; Reich, H; Schram, SS, 2016) |
| "Melanoma is not only a problem for humans but also for grey horses as they have a high potential of developing melanoma lesions coupled to the mutation causing their phenotype." | ( Cavalleri, JM; Feige, K; Liebscher, G; Mueller, T; Paschke, R; Vanchangiri, K, 2016) |
| "Melanoma is the most aggressive of all skin cancers and is exceptionally resistant to therapies." | ( Bubka, M; Hoja-Łukowicz, D; Janik, M; Lityńska, A; Pocheć, E; Pokrywka, M, 2016) |
| "BRAF-mutant melanoma is characterized by aggressive metastatic potential and therapeutic resistance." | ( Bacsi, A; Fekete, T; Foldvari, Z; Garay, T; Hegedus, B; Koncz, G; Kumar, BV; Lanyi, A; Pazmandi, K; Rajnavolgyi, E; Szabo, A, 2016) |
| "Melanoma is a highly malignant neoplasm of melanocytes with considerable metastatic potential and drug resistance, explaining the need for new candidates that inhibit tumor growth and metastasis." | ( Deng, H; Gao, T; Lei, Q; Liu, L; Peng, C; Song, X; Wang, N; Wei, Y; Xia, Y; Xie, Y; Xiong, Y; Yang, F; Ye, T; Yu, L; Yu, X; Zhang, L; Zhao, L; Zhu, Y; Zuo, W, 2016) |
| "Metastatic melanoma is an aggressive cancer, often resistant to treatment." | ( Czyz, M; Gajos-Michniewicz, A, 2016) |
| "Melanoma is the more dangerous skin cancer, and metastatic melanoma still carries poor prognosis." | ( Antonicelli, F; Benguedouar, L; Bernard, P; Durlach, A; Gangloff, SC; Grange, F; Lahouel, M, 2016) |
| "Melanoma is a disease that primarily arises in the skin but is a derivative of the neural crest." | ( Carter, JH; Colligan, BM; Deddens, JA; Douglass, LE; Graff, JR; Hawkins, E; Jones, J; Lewis, TG; Lucas, D; Pemberton, JO; Spaulding, NR, 2016) |
| "Cutaneous melanoma is the most deadly cutaneous neoplasm." | ( Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R, 2016) |
| "Malignant melanoma is an aggressive, highly lethal dermatological malignancy." | ( Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M, 2016) |
| "Uveal tract melanoma is the most common primary intraocular malignancy in adults, accounting for about 5-10% of all the melanomas." | ( Beniwal, S; Beniwal, V; Kapoor, A; Kumar, HS; Mathur, H, 2016) |
| "Melanoma is an aggressive tumor with advanced disease characterized by widespread metastatic lesions and the tumor has traditionally been resistant to most forms of treatment." | ( Alkeraye, S; Arnault, JP; Chaby, G; Dadban, A; Lok, C, 2016) |
| "Acral melanoma is an uncommon type of melanoma in Caucasian patients." | ( Bekkenk, MW; Bottoni, U; Buccini, P; Calvieri, S; Cantisani, C; Carbone, A; Cigna, E; De Simone, P; Didona, D; Eibenschutz, L; Ferrari, A; Paolino, G; Richetta, AG; Scali, E; Silipo, V; Viti, G; Viti, GP, 2016) |
| "Malignant melanoma is an aggressive tumor of the skin and seems to be resistant to current therapeutic approaches." | ( Candido, S; Cavalieri, S; Libra, M; McCubrey, JA; Motta, S; Nicoletti, F; Pappalardo, F; Pennisi, M; Russo, G, 2016) |
| "Uveal melanoma is a rare but aggressive subtype of melanoma." | ( Carvajal, RD; Komatsubara, KM; Manson, DK, 2016) |
| "Melanoma is the most lethal type of skin cancer and its incidence is progressively increasing." | ( Boudewijns, S; de Haas, N; de Vries, IJ; Di Blasio, S; Figdor, CG; Gerritsen, W; Hato, SV; Koornstra, R; Tel, J; van Deutekom, V; van Erp, N; Westdorp, H, 2016) |
| "Uveal melanomas are molecularly distinct from cutaneous melanomas and lack mutations in BRAF, NRAS, KIT, and NF1." | ( Ceraudo, E; Chang, MT; Chen, Y; Chi, P; Guan, Y; Huber, T; Kazmi, MA; Moore, AR; Sakmar, TP; Sher, JJ; Shoushtari, AN; Taylor, BS; Walczak, EG; Zhang, JQ, 2016) |
| "Melanoma is a malignant tumor in which UVA (320-400 nm) radiation is considered to be an important risk factor." | ( Baban, TSA; Bauer, J; Berneburg, M; Garbe, C; Kamenisch, Y; Metzler, G; Rocken, M; Schittek, B; Schuller, W; Sinnberg, T; von Thaler, AK, 2016) |
| "Melanoma is one of the most aggressive forms of cancer with a continuously growing incidence worldwide and is usually resistant to chemotherapy agents, which is due in part to a strong resistance to apoptosis." | ( Badran, B; Fidanzi-Dugas, C; Hassan, L; Liagre, B; Limami, Y; Martin, F; Pinon, A; Seeman, J; Simon, A, 2016) |
| "Melanoma is a major public health problem." | ( Auffret, M; Bertrand, M; Darras, S; Goeminne, C; Levavasseur, M; Mortier, L, 2016) |
| "Melanoma is molecularly and structurally heterogeneous, with some tumor cells existing under hypoxic conditions." | ( Chattopadhyay, C; Cooper, ZA; Ekmekcioglu, S; Grimm, EA; Hashimoto, Y; Hwu, P; Liu, C; Qin, Y; Roszik, J; Wargo, JA, 2016) |
| "Malignant melanoma is the leading cause of death from skin cancer." | ( Beretta, G; Casati, L; Comitato, R; Festuccia, C; Gravina, GL; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM, 2016) |
| "Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin." | ( Chen, X; Han, J; Hao, W; Ma, J; Sun, S; Wang, C; Yang, M; Zheng, Q, 2016) |
| "Melanoma is the most serious type of skin cancer because it is highly frequency of drug resistance and can spread earlier and more quickly than other skin cancers." | ( Feng, Q; He, B; Xiong, Y; Yang, L; Ye, T; Yu, L; Zhang, Y; Zhao, L; Zhu, S; Zhu, Y, 2016) |
| "Intrinsic to melanoma is the expression of a continuous cycle of cytokines and oxidative stress markers." | ( Grimm, EA, 2016) |
| "Malignant melanoma is the most aggressive form of skin carcinoma, which possesses fast propagating and highly invasive characteristics." | ( Guo, G; Mei, Z; Niu, T; Tian, Y, 2016) |
| "Melanoma is one of the deadliest skin cancers and accounts for most skin-related deaths due to strong resistance to chemotherapy drugs." | ( Chen, L; Cheng, B; Gong, T; Huang, S; Ji, C; Li, D; Wang, P; Zhang, Z; Zhou, K, 2016) |
| "Metastatic melanoma is traditionally diagnosed using classic morphologic features in addition to immunohistochemical studies." | ( Kleven, DT; Powell, MR; Sheehan, DJ, 2016) |
| "Melanoma is a very malignant disease and there are still no effective treatments." | ( Chen, X; Gao, T; Jiang, M; Peng, C; Su, J; Wu, L; Zeng, W; Zhao, S, 2016) |
| "Melanoma is the deadliest form of commonly encountered skin cancer because of its rapid progression towards metastasis." | ( Granter, SR; Lee, Y; Lim, JH; Luo, C; Puigserver, P; Thomas, A; Vazquez, F; Widlund, HR, 2016) |
| "Malignant melanoma is one of the most dangerous skin cancer originating from melanocytes." | ( Kobiela, T; Lekka, M; Milner-Krawczyk, M; Sobiepanek, A, 2017) |
| "Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark." | ( Bastholt, L; Boyles, TB; Schmidt, H; Svane, IM, 2016) |
| "Melanoma is a highly lethal cutaneous tumor, killing affected patients through development of multiple poorly immunogenic metastases." | ( Pich, C; Sarrabayrouse, G; Teiti, I; Tilkin-Mariame, AF, 2017) |
| "Metastatic melanoma is the most aggressive and lethal form of skin cancer." | ( Gabr, MT; Hedlund, DK; Henning, GM; Pigge, FC; Reedy, JL; Schultz, MK, 2016) |
| "Melanoma is the deadliest form of skin cancer because of its propensity to spread beyond the primary site of disease and because it resists many forms of treatment." | ( D'Orazio, JA; Jarrett, SG, 2017) |
| "Melanoma is the most malignant type of skin cancer." | ( Han, Y; Xu, L; Zhang, D, 2016) |
| "Malignant melanoma is a fast growing form of skin cancer with increasing global incidence." | ( Finocchiaro, LME; Glikin, GC; Rossi, UA, 2017) |
| "Melanoma is a recalcitrant disease." | ( Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Unno, M, 2016) |
| "Oral mucosal melanoma is a rare disease with a relatively poor prognosis." | ( Musha, A; Nakano, T; Ohno, T; Saitoh, JI; Shirai, K; Yokoo, S, 2016) |
| "Melanoma is one of the most lethal cancers when it reaches a metastatic stage." | ( Boucher, JL; Rocchi, S; Rouaud, F; Slama-Schwok, A, 2016) |
| "Melanoma is a highly drug resistant cancer." | ( Gowda, R; Robertson, GP; Sharma, A, 2017) |
| "Metastatic melanoma is a highly aggressive skin cancer with a poor prognosis." | ( Hendrix, MJ; Kandela, I; Long, GV; Margaryan, NV; Mazar, AP; Murphy, GF; Scolyer, RA; Seftor, EA; Seftor, RE; Strizzi, L, 2017) |
| "The malignant melanoma is arising from melanocytes, cells protecting mitotically active keratinocytes against damage caused by UV light irradiation." | ( Dvořánková, B; Kodet, O; Kolář, M; Krejčí, E; Lacina, L; Naňka, O; Šedo, A; Smetana, K; Strnad, H; Szabo, P, 2017) |
| "Melanoma is a recalcitrant disease in need of transformative therapuetics." | ( Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M, 2016) |
| "Cutaneous malignant melanoma is among the deadliest human cancers, broadly resistant to most clinical therapies." | ( Merlino, G; Mishra, PJ, 2016) |
| "Melanoma is an aggressive cancer, the incidence of which is increasing worldwide." | ( Gao, XH; Griffin, N; Han, YM; Plotnikoff, NP; Qi, RQ; Shan, FP; Wang, DM; Wang, GC; Yang, J, 2016) |
| "Malignant melanoma is a highly aggressive tumor resistant to chemotherapy." | ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017) |
| "Metastatic melanoma is highly drug resistant, though the exact mechanisms of this resistance are not completely understood." | ( Anseth, KS; Jones, CE; Tokuda, EY, 2017) |
| "Melanoma is strongly tied to red hair/fair skin, a phenotype of loss-of-function polymorphisms in the MC1R (melanocortin 1 receptor) gene." | ( Cai, W; Chen, H; Chen, X; Fisher, DE; Li, H; Logan, R; Maguire, M; Robinson, K; Schwarzschild, MA; Vanderburg, CR; Wang, Y; Ya, B; Yu, Y; Zuo, F, 2017) |
| "Melanoma is the most dangerous and treatment-resistant skin cancer." | ( Albini, A; Argenziano, G; Ciarrocchi, A; Dallaglio, K; Dominici, M; Grisendi, G; Longo, C; Petrachi, T; Romagnani, A, 2017) |
| "Melanoma is mainly treated by surgery and rarely with radiation because of the high radioresistance of this tumor." | ( Kim, EH; Kim, SR, 2017) |
| "Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies." | ( Ahuja, A; Chen, L; Daud, A; Gill, J; Kamra, S, 2017) |
| "Melanoma is a highly metastatic type of cancer that is resistant to all standard anticancer therapies and thus has a poor prognosis." | ( Auclair, C; Eymard, M; Hugonin, C; Karam, M; Merzoug-Larabi, M; Spasojevic, C, 2017) |
| "Primary orbital melanoma is rare and has varied initial presentation." | ( Bains, S; Kim, U; Shanti, R, 2016) |
| "Melanoma is the most aggressive type of skin cancer." | ( Arnst, K; Li, W; Mahato, RI; Miller, DD; Mondal, G; Mundra, V; Ness, RA; Yang, R, 2017) |
| "Cutaneous melanoma is a malignant tumor of skin melanocytes that are pigment-producing cells located in the basal layer (stratum basale) of epidermis." | ( Anagnostopoulos, AK; Anastasiadou, E; Giannopoulou, AF; Konstandi, OA; Konstantakou, EG; Litou, ZI; Stravopodis, DJ; Tsangaris, GT; Velentzas, AD; Voutsinas, GE, 2017) |
| "Melanoma is the most aggressive type of skin cancer and is characterized by poor prognosis in its advanced stages because treatments are poorly effective and burdened with severe adverse effects." | ( Lelli, D; Pedone, C; Sahebkar, A, 2017) |
| "Malignant melanoma is the deadliest form of all skin cancers." | ( Li, D; Liang, G; Liu, M; Liu, W; Mei, H; Shen, Y; Wang, Q, 2017) |
| "Uveal melanoma is the most common primary intraocular malignant tumor in adults and arises from the transformation of melanocytes in the uveal tract." | ( Aplin, AE; Benovic, JL; Chua, V; Lapadula, D; Randolph, C; Wedegaertner, PB, 2017) |
| "Malignant melanoma is a highly aggressive neoplasia of melanocytic origin." | ( Hu, G; Jiang, MJ; Li, FJ; Li, LM; Long, J; Xu, C; Zhang, RH; Zhou, P, 2017) |
| "Malignant melanoma is the most invasive and fatal form of cutaneous cancer." | ( Cheng, W; Han, X; Lin, J; Ni, J; Song, Z; Zhang, Y; Zhao, G, 2017) |
| " Subungual melanoma is a rare variant of acral lentiginous melanoma that often has a poor prognosis compared with other types of melanoma." | ( Gioia Di Chiacchio, N; Haneke, E; le Voci, F; Ocampo-Garza, J; Paschoal, FM, 2017) |
| "Melanoma is the second most common non-hematopoietic malignancy after carcinomas to metastasize to the breast and often appears as a well-circumscribed, dense nodule on imaging." | ( Cimino-Mathews, A; Eisner, D; Inouye, CM; Rosenthal, DL; VandenBussche, CJ, 2017) |
| "Secondary melanomas are usually diagnosed during the early disease stage, and no case of advanced melanomas is reported in the literature, mostly due to careful surveillance in BRAFi-treated patients." | ( Montesu, MA; Onnis, G; Palmieri, G; Satta, R, 2017) |
| "Malignant melanoma is a lethal form of skin cancer and highly metastatic tumor with poor prognosis; BEL β-trefoil, a lectin, obtained by our group, possesses the ability to act specifically on malignant cells." | ( Bovi, M; Cavallini, C; Cheri, S; Dalle Carbonare, L; Innamorati, G; Mori, A; Perduca, M; Scupoli, MT; Valenti, MT, 2017) |
| "Melanoma is a dangerous form of skin cancer derived from the malignant transformation of melanocytes." | ( Botti, E; Caporali, S; Cesarini, V; Costanzo, A; Di Agostino, S; Dolci, S; Favaro, R; Guida, E; Jannini, EA; Lacal, PM; Nicolis, S; Rossi, P; Tassinari, V; Todaro, F, 2017) |
| "Melanoma is a highly aggressive tumour, and treatment efficacy depends on the stage of the tumour." | ( Chen, YN, 2017) |
| "Canine oral mucosal melanoma is an aggressive malignant neoplasm and is characterized by local infiltration and a high metastatic potential." | ( Kent, MS; Lee, BH; Neela, PH; Zehnder, AM, 2017) |
| "Melanoma is the most dangerous type of skin cancer due to the occurrence of metastases." | ( D'Oca, MGM; de Moraes, MM; Piovesan, LA; Teixeira, WKO; Treptow, TGM; Votto, APS, 2017) |
| "Melanoma is typically composed of nested and variably pigmented atypical cells." | ( Aung, PP; Curry, JL; Ivan, D; Nagarajan, P; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Valero-Torres, A, 2017) |
| "Melanoma is by far the most aggressive type of skin cancer with a poor prognosis in its advanced stages." | ( Dany, M, 2017) |
| "Melanoma is a malignant tumor with high degree of malignancy, metastasis and high mortality." | ( Chang, P; Guo, B; Hui, Q; Shi, J; Tao, K, 2017) |
| "Melanoma is responsible for most deaths among skin cancers and conventional and palliative care chemotherapy are limited due to the development of chemoresistance." | ( Bonatto, D; Chammas, R; de Freitas Saito, R; de Godoy, LMF; de Souza, GA; Greene, LJ; Otake, AH; Rosa, JC; Tortelli, TC, 2017) |
| "Anorectal malignant melanoma is often misdiagnosed as either hemorrhoids or benign anorectal conditions in inflammatory bowel disease." | ( Kim, SE; Moon, W; Park, MI; Park, SJ; Seo, KI, 2017) |
| "Stage III malignant melanoma is a heterogeneous disease where those cases deemed marginally resectable or irresecatble are frequently incurable by surgery alone." | ( Ben-Ami, E; Ben-Betzalel, G; Goitein, D; Markel, G; Nissan, A; Schachter, J; Schneebaum, S; Shapira-Frommer, R; Zippel, D, 2017) |
| "Melanoma is the most malignant form of skin cancer and is associated with a very poor prognosis." | ( Chiang, YC; Hsu, LF; Ko, HH; Lee, CW; Lee, MH; Li, SY; Tsai, MH; Yen, FL, 2017) |
| "Malignant melanoma is the most dangerous form of skin cancer, with a rapidly increasing incidence rate." | ( Carsten, B; Dyshlovoy, SA; Ermakova, SP; Gunhild, VA; Ivanchina, NV; Kicha, AA; Malyarenko, OS; Malyarenko, TV; Stonik, VA, 2017) |
| "Melanoma is the leading cause of death from skin disease due to its propensity for metastasis." | ( Chu, YL; Hsieh, SC; Sheen, LY; Wang, HC, 2017) |
| "Head and neck melanoma is a clinical challenge." | ( Bottoni, U; Calvieri, S; Cardone, M; Corsetti, P; Didona, D; Lopez, T; Losco, L; Moliterni, E; Paolino, G; Schipani, G, 2020) |
| "Tumorigenesis of melanoma is associated with trace elements." | ( Nakagawa, H; Nobeyama, Y, 2017) |
| "Malignant melanoma is one of the most common malignant diseases of the gastrointestinal tract." | ( Choi, CW; Kang, DH; Kim, HJ; Kim, HW; Kim, SJ; Lee, JS; Park, SB; Yeo, CW, 2017) |
| "Ulcerated primary melanomas are associated with an inflammatory tumor microenvironment." | ( Green, AC; Hughes, MCB; Khosrotehrani, K; Malt, M; Smith, D; Smithers, BM; van der Pols, JC; von Schuckmann, LA, 2017) |
| "Choroidal melanoma is the most common primary malignant intraocular tumor, and very few effective therapies are available to treat it." | ( Kong, F; Wang, L; Zhang, H; Zhao, X, 2017) |
| "Human melanoma is a highly aggressive incurable cancer due to intrinsic cellular resistance to apoptosis, reprogramming, proliferation and survival during tumour progression." | ( Arcidiacono, P; Bottoni, U; Calvieri, S; Crisanti, A; Kuligina, E; Pistilli, A; Ragonese, F; Rende, M; Spaccapelo, R; Stabile, A, 2018) |
| "Acral melanoma is distinct from melanoma of other cutaneous sites, yet there is considerable variation within this category." | ( Bubley, JA; Bunick, CG; Choi, J; Garfield, EM; Gerami, P; Haugh, AM; Isales, MC; Kong, BY; Kudalkar, E; Lee, CY; Merkel, EA; Quan, VL; Sosman, J; Tan, T; VandenBoom, T; Verzi, AE; Walton, K; Wenzel, AT; Zhang, B, 2018) |
| "Primary sinonasal melanoma is a rare disease." | ( Arnous, MMR; Hu, F; Lan, X; Qin, C, 2017) |
| "Melanoma is a highly invasive and metastatic cancer with high mortality rates and chemoresistance." | ( Alves-Fernandes, DK; Barros, SBM; Cardozo, LE; de Souza, N; Faião-Flores, F; Lima, DS; Maria-Engler, SS; Monteiro, G; Nakaya, HI; Oliveira, ÉA; Quincoces, JAP; Souza, GF, 2017) |
| "Melanoma is a type of skin cancers with high metastasis." | ( Huang, GX; Li, B; Lu, J; Su, J; Wang, Y; Yin, LJ; Zhou, P, 2017) |
| "Melanoma is less common among all other types of skin cancers but causes higher mortality." | ( Meeran, SM; Penta, D; Somashekar, BS, 2018) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults." | ( Liu, Y; Pan, J; Zheng, L, 2017) |
| "Metastatic melanoma is an aggressive cancer with increasing incidence and limited therapies in advanced stages." | ( Alves, AC; Araki, K; Copetti, I; Drewes, CC; Farsky, SH; Guterres, SS; Hebeda, CB; Pohlmann, AR; Sandri, S; Uchiyama, MK, 2017) |
| "Melanomas are fast growing high-mortality tumors, and specific treatments for melanomas are needed." | ( Choi, BBR; Choi, JH; Hong, JW; Kim, GC; Kim, UK; Lee, HJ; Song, KW, 2017) |
| "Malignant melanoma is the leading cause of mortality among the skin‑associated diseases because of its highly metastatic nature and lethality." | ( Li, TH; Yan, HX, 2018) |
| "Melanoma is the most lethal type of skin cancer." | ( Chammas, R; Cirilo, PDR; Corrêa, BRS; de Sousa Andrade, LN; Furuya, TK; Penalva, LOF; Qiao, M, 2017) |
| "iris melanoma) is paramount." | ( Heindl, LM; Koch, KR; Mor, JM, 2017) |
| "Melanoma is the most malignant skin cancer." | ( Guler, EM; Kocyigit, A, 2017) |
| "Melanoma is a relatively rare cancer in Colombia with mainly the acral sites, high proportion of thick and ulcerated melanomas, and relatively poor survival being distinct features, indicating the need for tailor-made primary and secondary prevention strategies." | ( de Vries, E; Reyes, E; Uribe, C, 2018) |
| "Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma." | ( Aptullahoglu, E; Esfandiari, A; Ho, YH; Lovat, P; Lunec, J; Mahdi, AK; Wang, N; Wu, CE, 2018) |
| "Cutaneous melanoma is a deadly skin cancer, resulting from malignant transformation of melanocytes." | ( Duoji, G; Grigalavicius, M; Jie, D; Juzeniene, A; Pudroma, X, 2017) |
| "Melanoma is an incurable disease for which alternative treatments to chemotherapy alone are sought." | ( Carlsen, D; Do, AV; Geary, SM; Leelakanok, N; Martin, JA; Salem, AK; Seol, D; Tobias, P, 2018) |
| "Melanoma is one of the deadliest forms of skin cancer." | ( Albertini, M; Havighurst, T; Kim, K; Kim, T; Spiegelman, VS; Xu, YG, 2018) |
| "Melanoma is a malignant proliferative disease originated from melanocyte transformations, which are characterized by a high metastatic rate and mortality." | ( Colturato-Kido, C; Ferraz, LS; Paredes-Gamero, EJ; Pelegrino, MT; Rodrigues, T; Seabra, AB; Watashi, CM; Weller, RB, 2018) |
| "Melanoma is a severe form of cancer, resistant to conventional therapies." | ( Arcidiacono, P; Bottoni, U; Calvieri, S; Crisanti, A; Pistilli, A; Ragonese, F; Rende, M; Spaccapelo, R; Stabile, AM, 2018) |
| "Malignant melanoma is highly metastatic, and melanoma patients can develop chemotherapeutic resistance against conventional melanoma therapies." | ( Choi, KC; Heo, JR; Hwang, KA; Kim, GS; Lee, GA, 2018) |
| "The incidence of melanoma is increasing, particularly in young women, and the disease remains incurable for many because of its aggressive, metastatic nature and its high rate of resistance to conventional, targeted, and immunological agents." | ( Fiore, LS; Liu, J; Plattner, R; Richards, DL; Tripathi, R; Wang, C; Yang, Y, 2018) |
| "In this scenario melanoma is one of the most aggressive ones with serious limitation in early detection and therapy." | ( Cabezas, SS; Dos Santos, SN; Helal-Neto, E; Martínez-Máñez, R; Pinto, SR; Portilho, FL; Pozzo, L; Sancenón, F; Santos-Oliveira, R, 2018) |
| "Malignant melanoma is among the most aggressive cancers and its incidence is increasing worldwide." | ( Borgognoni, L; Deng, X; Gagliardi, S; Gray, NS; Pandolfi, S; Rovida, E; Stecca, B; Tubita, A; Tusa, I; Urso, C; Wang, J, 2018) |
| "BRAFi-resistant melanomas are characterized by an increase of mitochondrial oxidative phosphorylation and are more prone to cell death induced by mitochondrial-targeting drugs." | ( Balayssac, S; Corazao-Rozas, P; Dekiouk, S; Gabert, PE; Garçon, G; Guerreschi, P; Joncquel Chevalier Curt, M; Khamari, R; Kluza, J; Maboudou, P; Malet-Martino, M; Marchetti, P; Mortier, L; Quesnel, B; Ravasi, L; Riveros-Cruz, S; Trinh, A, 2018) |
| "Melanoma is a highly aggressive malignancy and early monitoring and diagnosis are challenging at present." | ( Hu, L; Li, Z; Liang, XJ; Wang, YF; Zeng, C, 2018) |
| "Melanoma is one of the most malignant skin tumors with high mortality rate." | ( Guo, X; Hu, J; Yang, L, 2018) |
| "Acral melanoma is the most common type of melanoma in Asians, and usually results in a poor prognosis due to late diagnosis." | ( Chung, KY; Jung, J; Kim, W; Lee, SW; Oh, B; Yang, S; Yu, C, 2018) |
| "Purpose Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting." | ( Barker, P; Berking, C; Carvajal, RD; Chapman, PB; Chmielowski, B; Clemett, D; Cocquyt, V; Evans, TRJ; Frank, S; Gastaud, L; Ghiorghiu, D; Joshua, AM; Kapiteijn, E; Kilgour, E; Lai, Z; Linette, G; Lovick, S; Mariani, G; Nathan, P; Piperno-Neumann, S; Piulats, JM; Rodrigues, MJ; Schachter, J; Schwartz, GK; Shoushtari, AN; Spratt, S; Wolter, P, 2018) |
| "Malignant melanoma is a devastating skin cancer due to its severe drug resistance and prompt metastasis." | ( Gao, T; Lei, Q; Song, X; Xiong, J; Yao, Y; Zhang, L, 2018) |
| "Malignant melanoma is an important type of cancer worldwide due to its aggressiveness and poor survival rate." | ( Antony, LP; Calcagno, DQ; de Arruda Cardoso Smith, M; de Lucas Chazin, E; de Vasconcellos, MC; do Nascimento Pedrosa, T; Dos Santos Barbosa, G; Montenegro, RC; Ralph, ACL; Vasconcelos, TRA; Vasconcelos, ZS, 2018) |
| "Bilateral choroidal melanomas are rare, reported to be either simultaneous or sequential as well as treatable." | ( Finger, PT; Maheshwari, A, 2018) |
| "Malignant melanoma is the most commonly diagnosed skin cancer associated with a high rate of metastasis." | ( Kalafatis, M; Manouchehri, JM; Turner, KA, 2018) |
| "Malignant melanoma is an agressive tumour related to the overproduction of melanin, which provides colors of skin, eyes and hair." | ( Aytemir, MD; Ercan, A; Karakaya, G; Oncul, S, 2018) |
| "Melanoma is notoriously resistant to all current modalities of cancer therapies including chemotherapy." | ( Fang, Z; Li, Y; Liu, Y; Wang, S; Zhang, B; Zhang, J; Zhong, F, 2018) |
| "NRAS-mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance." | ( Amaravadi, R; Aplin, AE; Benchun, M; Boland, G; Burd, CE; Cheng, C; Echevarría-Vargas, IM; Flaherty, KT; Frederick, DT; Guterres, AN; Herlyn, M; Karakousis, G; Kossenkov, AV; Krepler, C; Liu, Q; Lu, Y; Mills, GB; Morrissette, JJ; Reyes-Uribe, PI; Schuchter, LM; Somasundaram, R; Sullivan, RJ; Villanueva, J; Weeraratna, AT; Wei, Z; Xu, W; Xu, X; Yin, X; Zhang, G, 2018) |
| "Melanoma is the most aggressive type of skin cancer." | ( Kartasasmita, RE; Kurniawan, F; Mutalib, A; Tjahjono, DH; Yoshioka, N, 2018) |
| "Malignant melanomas are amongst the most aggressive cancers." | ( Bu, CN; Dong, YL; Li, QS; Lin, MX; Ruan, BF; Shao, Q; Wang, TH; Xu, HJ; Zhang, Q; Zhou, BG, 2018) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults." | ( Pan, J; Zheng, L, 2018) |
| "Melanoma is a rare, deadly disease without effective treatment options in China." | ( Bu, L; Guo, J; Jiang, Q; Mao, L; Richie, N; Si, L; Wang, X; Xu, Z; Zhang, W; Zhang, X, 2018) |
| "Melanoma is among the most aggressive and treatment-resistant human cancers." | ( Choi, HS; Kim, G; Kim, JY; Kim, O; Lee, KY; Lim, SC, 2018) |
| "Cutaneous melanoma is the most serious type of skin cancer, so new cytotoxic weapons against novel targets in melanoma are of great interest." | ( Alcantara Barata, G; Carpi, S; Di Giuseppe, G; Fogli, S; Frontini, FP; Guella, G; Nieri, P; Poli, G; Polini, B; Romanini, A; Tuccinardi, T, 2018) |
| "Metastatic melanoma is an aggressive skin cancer with a poor prognosis." | ( Beggs, A; Bessudo, A; Cheng, P; De Santo, C; Egan, S; Mussai, F, 2018) |
| "Melanoma is the most aggressive type of skin cancer with high rates of mortality." | ( Capanema, NSV; Carvalho, IC; Carvalho, SM; Chagas, P; de Oliveira, LCA; Mansur, AAP; Mansur, HS, 2018) |
| "Melanoma is one of the most aggressive cancers which has very low response rate and survival rate." | ( Ekielski, A; Iqbal, Z; Jaggi, M; Mishra, H; Mishra, PK; Talegaonkar, S, 2018) |
| "Head and neck melanoma is associated with a high false negative (FN) sentinel lymph node biopsy (SLNB) rate." | ( Couto, RA; Gastman, B; Knackstedt, RW, 2018) |
| "Acral lentiginous melanoma is a malignant neoplasm which appears in hands and feet." | ( Barboza-Quintana, O; de la Fuente-Villarreal, D; Flores-Gutiérrez, JP; González-Ramírez, RA; Ríos-Briones, NI; Torres-López, E, 2018) |
| "Melanoma is a molecularly heterogeneous disease with many genetic mutations and altered signaling pathways." | ( Ascierto, PA; Camerlingo, R; Carriero, MV; Fratangelo, F; Gentilcore, G; Minopoli, M; Motti, ML; Palmieri, G; Pirozzi, G; Ragone, C, 2018) |
| "Metastatic melanoma is an aggressive cancer with poor prognosis and 10 year survival less than 10%." | ( Berić Jozić, G; Lukić, B; Marijanović, I; Miletić, D; Puljić Ćuk, A; Tica Sedlar, I; Tomić, K, 2018) |
| "Malignant melanoma is an aggressive form of cancer which is highly resistant to chemotherapy." | ( Gao, Y; Liang, L; Liu, J; Qin, X; Zeng, W; Zhang, Z; Zhao, P, 2018) |
| "Conjunctival melanoma is a rare, but potentially sight- and life-threatening, tumour." | ( Chaparro Tapias, TA; Coy Villamil, H; Díaz Díaz, AL; Sánchez España, JC; Secondi, R, 2018) |
| "Genotyping of melanomas is used to identify patients for treatment with BRAF and MEK inhibitors, but clinical responses are highly variable." | ( Hayward, NK; Krisp, C; Long, GV; Mann, GJ; Molloy, MP; Parker, R; Pascovici, D; Scolyer, RA; Thompson, JF; Wilmott, JS, 2018) |
| "Metastatic melanoma is an aggressive form of skin cancer that evades various anti-cancer treatments including surgery, radio-,immuno- and chemo-therapy." | ( Bittner, M; Datta, A; Hua, J; Lopes, R; Saraf, RS; Sima, C, 2018) |
| "Melanoma is a recalcitrant cancer." | ( Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Li, Y; Miyake, K; Miyake, M; Nelson, SD; Ohshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tan, Y; Unno, M; Wangsiricharoen, S; Zhang, Z; Zhao, M, 2018) |
| "As a hallmark, melanomas are highly prone to evolve into metastatic sites." | ( Araujo, CN; Chiacetti, AC; Correa, RG; Dantonio, PM; Freire, MRVB; Klein, MO, 2018) |
| "Malignant melanoma is developed from pigment-containing cells, melanocytes, and primarily found on the skin." | ( Chi, PL; Chiang, YC; Hsu, LF; Ko, HH; Ko, MI; Lee, CW; Lee, MH; Peng, KT; Tsai, CL, 2018) |
| "Malignant melanoma is a highly aggressive form of skin cancer responsible for the majority of skin cancer-related deaths." | ( Agostinis, P; Alexopoulos, LG; Antoranz, A; Guttà, C; Kulms, D; Pliaka, V; Podder, B; Rehm, M; Rožanc, J; Rufo, N; Sakellaropoulos, T; Sauter, T; Vetma, V, 2019) |
| "Malignant melanoma is an aggressive skin cancer with limited therapeutic options." | ( de Carvalho Lima, EN; Maria, DA; Piqueira, JRC, 2018) |
| "Malignant melanoma is very rare in childhood." | ( Büyükkapu Bay, S; Kebudi, R; Zülfikar, B, 2019) |
| "Cutaneous melanoma is one of the most aggressive malignancies." | ( Chen, X; Liu, N; Peng, C; Qi, M; Tao, J; Wang, KS; Zeng, GY; Zhang, JL; Zhou, JD; Zhou, YJ, 2018) |
| "Melanoma is considered as one of the most potentially fatal and aggressive malignancies." | ( Huang, F; Li, J, 2018) |
| "The melanoma is responsible for the majority of all skin cancer-related deaths worldwide." | ( Chen, J; Jiao, Z; Wang, A; Zhong, W, 2019) |
| "Malignant melanoma is a highly lethal disease, and advanced stages of melanoma have proven to be resistant to many chemotherapeutic drugs including temozolomide and paclitaxel." | ( Han, B; Sun, B; Wang, YB, 2018) |
| "Melanoma is an aggressive cutaneous malignancy, but advances over the past decade have resulted in multiple new therapeutic options, including molecularly targeted therapy, immunotherapy, and oncolytic virus therapy." | ( Aspromonte, S; Bommareddy, PK; Kaufman, HL; Rabkin, SD; Zloza, A, 2018) |
| "Melanoma is one of the most aggressive and treatment-resistant tumors that responsible for majority of skin-cancer related deaths." | ( Akasov, R; Burov, S; Emelyanova, M; Inshakov, A; Khochenkov, D; Markvicheva, E; Prokofieva, A; Ryabaya, O; Stepanova, E, 2019) |
| "Melanoma is one of the great mimickers in pathology because it has diverse morphologies and can be mistaken for carcinoma or sarcoma." | ( Alkhasawneh, A; John, I; Nassri, A, 2019) |
| "Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options." | ( Aguirre-Ghiso, J; Aplin, AE; Benovic, JL; Charpentier, TH; Farias, E; Lapadula, D; McGrath, D; Purwin, TJ; Randolph, CE; Sato, T; Tall, GG; Terai, M; Wedegaertner, PB; Wu, S; Zhang, L; Zhou, N, 2019) |
| "Melanoma is an aggressive form of skin carcinoma, highly resistant to traditional therapies." | ( García Vior, MC; Marino, J; Roguin, LP; Valli, F, 2019) |
| "Melanoma is an aggressive neoplasm with increasing incidence that is classified by the NCI as a recalcitrant cancer, i." | ( Beeharry, N; Bellacosa, A; Bhattacharjee, V; Cosentino, L; Davidson, G; Davidson, I; Devarajan, K; Dorjsuren, DG; Einarson, M; Giordano, A; Jelinek, J; Kadariya, Y; Katz, RA; Larue, L; Mancuso, P; Nicolas, E; Simeonov, A; Sobol, RW; Sun, H; Testa, JR; Tricarico, R; Yen, TJ, 2019) |
| "Melanoma is a cancer of melanocyte cells and has the highest global incidence." | ( Aydoğmuş-Öztürk, F; Beyazit, N; Choudhary, MI; Günaydın, K; Jahan, H, 2019) |
| "Iris melanoma is a rare tumour that accounts for ~3-4% of all uveal melanoma cases." | ( Al-Jamal, RT; Bosello, F; Cohen, VML, 2020) |
| "Mucosal melanoma is a rare malignant disease developed from melanocyte." | ( Barthelemy, I; Chevenet, C; Depeyre, A; Houette, A; Mansard, S; Pham Dang, N, 2019) |
| "In Norway, melanoma is the most rapidly growing type of cancer, with a 47% increase among women and 57% among men in 2000-2016." | ( Andreassen, BK; Berge, LAM; Furu, K; Green, A; Heir, T; Juzeniene, A; Larsen, IK; Robsahm, TE; Roscher, I; Stenehjem, JS; Veierød, MB, 2019) |
| "Melanoma is the most aggressive form of skin cancer, with metastatic melanoma being refractory to currently available conventional therapies." | ( Bae, J; Choi, HK; Jin, H; Kim, HY, 2019) |
| "Melanoma is rapidly evolving because of advances in noninvasive diagnosis, targeted therapies, and improved prognostic methods." | ( Prado, G; Rigel, DS; Svoboda, RM, 2019) |
| "Treatment for melanoma is a challenging clinical problem, and some new strategies are worth exploring." | ( Guo, B; Li, Z; Tang, J; Tu, C; Wang, L; Wu, H; Yang, X; Zhang, X; Zhou, Y; Zhu, X, 2019) |
| "Malignant melanoma is a highly aggressive skin cancer that is highly resistant to chemotherapy." | ( Aizawa, S; Hara, H; Harada, T; Makita, K; Nakayama, T; Ochiai, Y; Okamoto, Y; Sano, E; Ueda, T; Yoshino, A, 2019) |
| "Malignant melanoma is the deadliest form of skin cancer and highly chemoresistant." | ( Baek, SB; Jung, HJ; Lim, HN, 2019) |
| "Malignant melanoma is a highly aggressive skin cancer and metastases rapidly extend to the regional lymph nodes (stage 3) and to distal organs (stage 4)." | ( Appelqvist, R; Baldetorp, B; Berge, E; Betancourt, LH; Burestedt, E; Corthals, G; Doma, V; Eriksson, J; Gil, J; Horvath, Z; Horvatovich, P; Ingvar, C; Jönsson, G; Karpati, S; Kim, Y; Knudsen, B; Kuras, M; Kwon, HJ; Lee, B; Lindberg, H; Lundgren, L; Malm, J; Marko-Varga, G; Miliotis, T; Murillo, JR; Németh, IB; Nishimura, T; Olsson, H; Oskolas, H; Pawłowski, K; Pla, I; Rezeli, M; Sanchez, A; Sugihara, Y; Szasz, AM; Timar, J; Welinder, C; Wieslander, E, 2019) |
| "Myxoid melanoma is a rare variant of melanoma that must be recognised." | ( Capelle, C; Carpentier, O; Gerard, A; Levavasseur, M; Mortier, L; Scherman, L; Vicentini, C, 2019) |
| "Melanoma is a type of skin cancer originated by the malignant transformation of melanocytes." | ( Bagatini, MD; Cardoso, AM; da Silva Rosa Bonadiman, B; de Souza, JVG; Mânica, A; Moreno, A; Moreno, M; Morsch, VM; Paiz, A; Schetinger, MRC; Siepko, C, 2019) |
| "Melanoma is a highly invasive cancer that resists most conventional treatments." | ( Avola, R; Cardile, V; Cuellar, M; Graziano, ACE; Madrid, A; Montenegro, I; Russo, A; Villena, J, 2019) |
| "Melanoma is a high fatality skin cancer which lacks effective drugs." | ( Hambrook, JR; Lei, XP; Liang, QP; Liu, BL; Xu, TQ; Zhang, DM; Zhou, GX, 2019) |
| "Malignant melanoma is one of the most difficult cancers to treat due to its resistance to chemotherapy." | ( Arulananda, S; Behren, A; Cebon, J; Dobrovic, A; Evangelista, M; Fairlie, WD; Gunasingh, G; Haass, NK; Harris, TJ; Herold, MJ; Hobbs, C; John, T; Lee, EF; Mariadason, JM; Ramnac, C; Rohrbeck, L; Segal, D; Strasser, A; Tran, S; Zhu, H, 2019) |
| "Melanoma is one of the most malignant and aggressive cancers with high cancer-related deaths." | ( Chen, M; Deng, W; Fan, W; Hu, Z; Jin, L; Kang, T; Li, J; Li, L; Li, Y; Liu, J; Liu, T; Lu, W; Luo, M; Qiu, H; Tian, C; Yang, L; Zhang, C; Zheng, F; Zheng, Z; Zhu, Q, 2019) |
| "Advanced metastatic melanoma is a malignant tumor for which there is currently no effective treatment due to resistance development." | ( Dong, X; Ji, R; Jiang, X; Meng, L; Xin, Y; Xu, X, 2019) |
| "Cutaneous melanoma is the most aggressive skin cancer, derived from neoplastic transformation of melanocytes." | ( Cordella, M; D'Arcangelo, D; Eramo, A; Facchiano, A; Facchiano, F; Lintas, C; Mueller, S; Rossi, S; Senatore, C; Tabolacci, C; Valitutti, S, 2019) |
| "The incidence of melanoma is increasing faster than any other cancer." | ( Acharya, G; Elahy, M; Khachigian, LM; Li, Y; Xin, H, 2019) |
| "Melanoma is one of the most aggressive skin cancers and 5-year survival rate is only 4." | ( Chen, S; Dong, Z; Liu, C; Shao, W; Zhang, S; Zhang, W, 2019) |
| "Cutaneous melanoma is least common (only about 1% of skin cancers) but is the deadliest malignant tumor." | ( Otręba, M; Pajor, M; Warncke, JD, 2019) |
| "Human malignant melanoma is one of the most aggressive cancers, accompanied with poor prognosis, metastatic evolution and high mortality." | ( Fasoli, S; Gotte, G; Menegazzi, M; Prodomini, S; Raineri, A, 2019) |
| "Melanoma is one of the most malignant skin tumours with constantly increasing incidence worldwide." | ( Han, Z; Li, XJ; Li, ZF; Liu, ZJ; Xu, YY, 2019) |
| "Malignant melanoma is the leading cause of death from skin disease, due in large part to its propensity to metastasize." | ( Li, CY; Li, G; Shen, S; Wang, Q; Wang, X; Wei, X, 2019) |
| "Melanoma is responsible for the majority of deaths caused by skin cancer." | ( Bai, JZ; Fang, RH; Jia, SQ; Li, Q; Mo, Y; She, XN; Si, Y; Wang, JQ; Wu, J, 2019) |
| "Melanoma is one of the most deadly and therapy-resistant cancers." | ( Aplin, AE; Cui, YH; Deng, Y; He, C; He, YY; Hwang, S; Lu, Z; Park, G; Shah, P; Wei, J; Yang, S, 2019) |
| "Malignant melanoma is a rare disease in the pediatric population and there are no recommendations regarding its management in children, while the current standard of care in metastatic or unresectable melanoma in adult patients includes immunotherapy (anti-CTLA-4 and anti-PD-1 antibodies)." | ( Galazka, P; Marjanska, A; Marjanski, M; Styczynski, J; Wysocki, M, 2019) |
| "Melanoma is one of the most aggressive and lethal form of cancer." | ( Akasov, RA; Alova, AV; Erofeev, AS; Generalova, AN; Gorelkin, PV; Khaydukov, EV; Khochenkov, DA; Sholina, NV, 2019) |
| "Melanoma is the leading cause of skin-cancer related deaths in North America." | ( Curran, C; Liang, G; Mehaidli, A; Nguyen, C; Pandey, S; Parashar, K; Pignanelli, C; Sood, S; Vegh, C; Wang, Y; Wu, J, 2019) |
| "Melanoma is regarded as the fifth and sixth most common cancer in men and women, respectively, and it is estimated that one person dies from melanoma every hour in the USA." | ( Ashby, CR; Chauhan, H; Heenatigala Palliyage, G; Singh, S; Tiwari, AK, 2019) |
| "Melanoma is the most aggressive type of skin cancer, which readily metastasizes through lymph nodes to the lungs, liver, and brain." | ( Bariwal, J; Bhattarai, RS; Chen, H; Kumar, V; Li, W; Mahato, RI; Peng, Y, 2019) |
| "Melanoma is an aggressive malignant tumor that undergoes rapid growth and metastasis in a short time; tyrosinase (TYR) is an important biomarker for melanoma diagnosis as it is over-expressed in melanoma cells." | ( Ding, C; Fu, C; Li, S; Xiao, Y; Zhang, P; Zhang, Q, 2019) |
| "Malignant melanoma is the most aggressive and lethal form of skin cancer." | ( Chodurek, E; Pilawa, B; Zdybel, M, 2019) |
| "Melanoma is a lethal cancer." | ( Bai, J; Chen, S; Chen, Y; Chou, J; Fu, X; Li, J; Liu, Y; Wang, Y; Wu, J; Yin, C; Yu, ZL; Zheng, Z; Zhu, P, 2019) |
| "Malignant melanoma is a high aggressive malignancy in humans and causes 60-80% of deaths from skin cancer." | ( Beberok, A; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D, 2020) |
| "Melanoma is the most aggressive type of cutaneous tumors due to its metastatic potential and high mortality." | ( da Silva, DB; de Angelis, K; Fernandes, DC; Gimenez, M; Gonçalves, DA; Gonçalves, JD; Icimoto, MY; Jasiulionis, MG; Laurindo, F; Llesuy, S; Melo, FHM; Moura Soares, JP; Sant'Anna, C; Xisto, R, 2019) |
| "Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases." | ( Aasen, SN; Bjerkvig, R; Feng, Z; Hoang, T; Knappskog, S; Parajuli, H; Roy, K; Stokke, K; Thorsen, F; Wang, J, 2019) |
| "Malignant melanoma is an aggressive type of cancer and the deadliest form of skin cancer." | ( Aplak, E; Berning, L; Brenneisen, P; Reichert, AS; Scharf, L; Stahl, W; Stucki, D; von Montfort, C, 2019) |
| "Melanoma is a life-threatening group of cancers mainly affecting the skin (cutaneous melanoma, CM) and the eyes (uveal melanoma, UM)." | ( Burnier, JV; Burnier, MN; Bustamante, P; de Alba Graue, PG; Dias, AB; Goyeneche, A; Jin, E; Miyamoto, D; Tsering, T, 2019) |
| "Melanoma is the most aggressive and deadly type of skin cancer." | ( Cimino-Reale, G; Doria, F; Folini, M; Freccero, M; Recagni, M; Richter, SN; Tassinari, M; Zaffaroni, N, 2019) |
| "Malignant melanoma is one of the most leading forms of skin cancer associated with a low patient survival rate." | ( Fan, P; Fang, M; Li, Z; Zuo, C, 2020) |
| "Malignant melanoma is the most aggressive form of skin cancer; a substantial percentage of patients present with distant metastases." | ( Hong, J; Oh, E; Yun, CO, 2019) |
| "Cutaneous malignant melanoma is a neoplasm whose incidence and mortality are dramatically increasing." | ( Baldari, S; Baratto, L; Iagaru, A; Laudicella, R; Minutoli, F, 2020) |
| "Melanoma is one of the most aggressive malignancies." | ( Cao, S; Chen, X; Li, J; Li, Y; Lian, C; Peng, C; Su, J; Tao, J; Wu, L; Zeng, W; Zhao, S; Zhou, J, 2020) |
| "Melanoma is known as the most aggressive and lethal type of cutaneous cancer due to its rapid development of drug resistance to chemotherapy drugs." | ( Cheng, B; Huang, JW; Ji, C; Lin, M; Xiang, N; Yu, Y; Zhang, J, 2019) |
| "The incidence of melanoma is increasing over the years with a still poor prognosis and the lack of a cure able to guarantee an adequate survival of patients." | ( Barlev, NA; Corà, D; Corazzari, M; Cotella, D; Gagliardi, M; Piacentini, M; Santoro, C, 2019) |
| "Melanoma is a lethal tumor because of its severe metastatic potential, and serine/threonine-protein kinase B-raf inhibitors (BRAFi) are used in patients harboring BRAF-mutation." | ( Campagnari, R; Fasoli, S; Gotte, G; Menegazzi, M; Raineri, A, 2019) |
| "Melanoma is the most life-threatening and aggressive class of skin malignancies." | ( Abbaszadeh-Goudarzi, K; Asemi, Z; Goodarzi, M; Hajighadimi, S; Mirzaei, H; Moradizarmehri, S; Piccirillo, SGM; Pourhanifeh, MH; Shafiee, A, 2021) |
| "Melanoma is lethal." | ( Chen, SB; Huang, YM; Li, CY; Su, T; Wang, XN; Wang, YP; Yang, ZY; Yu, ZL; Zhu, PL, 2020) |
| "Melanoma is a malignant neoplasia that is highly resistant to chemotherapy and radiotherapy and is associated with poor prognosis in advanced stage." | ( Barceló, C; Dolcet, X; Eritja, N; Felip, I; García-Mulero, S; Macià, A; Maiques, O; Martí, RM; Matías-Guiu, X; Megino, C; Navaridas, R; Penin, RM; Piulats, JM; Sanz-Pamplona, R; Sisó, P; Soria, X; Urdanibia, I, 2020) |
| "Nodular melanoma is more likely to occur in head and neck sites including the peri-auricular area, ear and cheek." | ( Kelly, JW; Mclean, C; Pan, Y; Wee, E; Wolfe, R, 2020) |
| "Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception." | ( Fukushima, S; Hatta, N; Hida, T; Ihn, H; Minagawa, A; Okuyama, R; Omodaka, T; Takata, M; Uhara, H; Wakamatsu, K, 2020) |
| "Malignant melanoma is an aggressive skin cancer with poor survival outcomes for patients diagnosed at an advanced stage." | ( Burnett, K; Callan, B; Callan, JF; Dhillon, SK; Matin, RN; McHale, AP; McKaig, T; Nesbitt, H; Porter, SL; Rizk, N; Sheng, Y; White, B, 2020) |
| "Malignant melanoma is the most aggressive form of skin cancer, and once it becomes metastatic the prognosis is very poor." | ( Aplak, E; Brenneisen, P; Haasler, L; Reichert, AS; Stahl, W; Steckel, B; Stucki, D; von Montfort, C, 2020) |
| "Melanoma is the most aggressive form of skin cancer, with high metastasis rates and poor prognosis." | ( Bauer, R; Brvar, L; Deutsch, A; Durchschein, C; Kleinegger, F; Kretschmer, N; Liegl-Atzwanger, B; Prokesch, A; Rinner, B; Stallinger, A, 2020) |
| "Melanoma is the most aggressive type of skin cancer, highly resistant to conventional therapies." | ( García Vior, MC; Marino, J; Roguin, LP; Valli, F, 2020) |
| "Melanoma is a form of skin cancer with high mortality owing to its fast progression and metastatic capacity." | ( Bellan, DL; Biscaia, SMP; Duarte, MER; Ferreira, LG; Franco, CRC; Gonçalves, JP; Mazepa, E; Noseda, MD; Oliveira, CC; Rossi, GR; Trindade, ES, 2020) |
| "Acral and mucosal melanomas are commonly associated with copy number (CN) alterations rather than specific point mutations, with CN alterations inKIT, CDK4, and CCND1 occurring frequently." | ( Ashida, A; Kiniwa, Y; Mikoshiba, A; Okuyama, R; Sakaizawa, K, 2020) |
| "Mucosal melanoma is rare and accounts for 1." | ( Cocorocchio, E; Conforti, F; Ferrucci, PF; Pala, L, 2020) |
| "Melanoma is the most dangerous form of skin cancer with a very poor prognosis." | ( Alem, FZ; Bejaoui, M; Isoda, H; Rhourri-Frih, B; Villareal, MO, 2020) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults." | ( Albano, V; Alessio, G; Falcone, V; Guerriero, S; Lastella, P; Piscitelli, D; Resta, N; Stella, A, 2021) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults." | ( Albano, V; Alessio, G; Falcone, V; Guerriero, S; Lastella, P; Piscitelli, D; Resta, N; Stella, A, 2021) |
| "Melanoma is a life-threatening cancer with limited treatments." | ( Chen, L; Deng, S; Fan, L; Lou, F; Niu, L; Peng, D; Sun, L; Sun, Y; Wang, C; Wang, H; Wang, Z; Xu, Z; Yin, Q, 2020) |
| "Recently, melanoma is the most common skin cancer with a high mortality rate not only in United States, but also in East Asia." | ( Seo, KI; Won, YS, 2020) |
| "Melanoma is one of the most aggressive, therapy-resistant skin cancers in the world." | ( Dai, X; Qiao, Z; Xiang, L; Xiao, Q; Xu, Z; Yang, Y; Ying, J; Zhang, C, 2020) |
| "Melanoma is a malignant tumor of melanocytes that is a serious threat to human health." | ( Li, S; Yu, Y; Zhang, F; Zhang, Q, 2020) |
| "Malignant melanoma is one of the most invasive tumours." | ( Chen, X; Guo, J; Liang, L; Liu, H; Liu, J; Liu, N; Peng, C; Qi, M; Su, J; Zhang, J; Zhao, S, 2020) |
| "Skin melanoma is one of the most aggressive and difficult-to-treat human malignancies, characterized by poor survival rates, thus requiring urgent novel therapeutic approaches." | ( Antunes, F; Bincoletto, C; Buri, MV; Chammas, R; Corazzari, M; Fimia, GM; Gagliardi, M; Pereira, GJS; Piacentini, M; Saito, RF; Smaili, SS, 2020) |
| "As melanoma is one of the most common types of cancer, in many cases resistant to current treatment regimens, the aim of this study was to assess and compare anti-melanoma activity of the two benzoquinones." | ( Galanty, A; Grabowska, K; Podolak, I; Sobolewska, D; Wróbel-Biedrawa, D; Żmudzki, P, 2020) |
| "Melanoma is the most aggressive type of skin cancer, leading to metabolic rewiring and enhancement of metastatic transformation." | ( Benaki, D; Giannopoulou, AF; Gikas, E; Iliou, A; Konstantakou, EG; Kosmopoulou, M; Mikros, E; Panagiotakis, A; Papassideri, IS; Stravopodis, DJ; Velentzas, AD, 2020) |
| "Melanoma is an aggressive malignancy of melanocytes and most commonly arises in the skin." | ( Guo, W; Tian, Y, 2020) |
| "Melanoma is a model tumor in immuno-oncology." | ( Bâldea, I; Gabriela Filip, A; Hopârtean, A; Kacso, T; Kutasi, E; Lupu, M; Stretea, R; Tudor, DV, 2020) |
| "Melanoma is a deadly type of skin cancer that is particularly difficult to treat owing to its resistance to radiation therapy." | ( Im, H; Lee, J; Ryu, KY; Yi, JY, 2020) |
| "Melanoma is the most malignant form of skin cancer with high metastatic potential." | ( Chen, W; Chiang, C; Huang, S; Wang, S; Xiao, T; Zhao, Y; Zheng, D; Zou, Y, 2020) |
| "Metastatic melanoma is the most aggressive skin cancer." | ( Chai, J; He, S; Li, M; Li, Z; Liu, X; Wu, J; Xu, J, 2020) |
| "Although melanoma is considered one of the most immunogenic malignancies, spontaneous T-cell responses to melanoma antigens are ineffective due to tumor cell-intrinsic or microenvironment-driven immune evasion mechanisms." | ( Górniak, P; Juszczyński, P; Polak, A; Rutkowski, P; Szydłowski, M; Wasylecka-Juszczyńska, M; Ługowska, I, 2020) |
| "Melanoma is the most serious type of skin cancer and remains highly drug-resistant." | ( Ahn, JS; Jang, JH; Jang, JP; Jung, HJ; Lim, HN; Shin, HJ, 2020) |
| "Melanoma is a skin cancer with high invasive potential and high lethality." | ( Aranha, ESP; da Silva, EL; da Silva, FMA; de Moraes, MEA; de Sousa, LB; de Vasconcellos, MC; Koolen, HHF; Lima, ES; Mesquita, FP; Montenegro, RC; Rocha, WC, 2020) |
| "Scalp melanomas are even more troublesome, because they typically exhibit more aggressive biologic behavior and are often diagnosed at a late stage." | ( Czuwara, J; Giuffrida, R; Goldust, M; Grabbe, S; Jafferany, M; Lee, Y; Lotti, T; Rao, B; Rudnicka, L; Saaiq, M; Wollina, U; Zalaudek, I, 2020) |
| "Melanoma is characterized by high malignancy and early onset of metastasis." | ( Cheng, H; Li, Q; Li, S; Su, J; Wang, M; Wang, Y, 2020) |
| "Melanoma is a deadly form of skin cancer that accounts for a disproportionally large proportion of cancer-related deaths in younger people." | ( Abali, GK; Amarasinghe, K; Harvey, KF; Kulkarni, A; Li, J; McLean, C; Molania, R; Papenfuss, AT; Shackleton, M; Szeto, P; Vergara, IA; Yang, L; Zhang, X; Zhang, Y, 2020) |
| "Malignant melanoma is a devastating disease." | ( Alimohammadi, M; Bekeschus, S; Golpur, M; Hadavi, S; Niaki, HA; Rafiei, A; Sohbatzadeh, F; Valadan, R, 2020) |
| "Canine melanoma is a malignant tumour that exhibits aggressive behaviour, and frequently metastasizes to regional lymph nodes and distant sites." | ( Chiu, YH; Chung, TF; Hsu, CH; Huang, KC; Huang, WH; Liao, AT; Lin, CS; Liu, CC; Liu, IL, 2021) |
| "Metastatic uveal melanoma is a highly aggressive disease with no standard of care treatment option." | ( Andrews, MC; Arulananda, S; Cebon, J; Goodwin, M; Palmer, J; Parakh, S, 2019) |
| "Vulvar and vaginal melanomas are rare cancers of the female genital tract and account for 1% to 3% of all melanomas diagnosed in women." | ( Bogani, G; Brusadelli, C; Ditto, A; Guerrisi, R; Lopez, S; Raspagliesi, F, 2020) |
| "Melanoma is the most lethal form of skin cancer because it spreads easily to other tissues, thereby decreasing the efficiency of its treatment via chemo-, radio-, and surgical therapies." | ( Hwang, J; Jin, JO, 2020) |
| "Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur." | ( Boekestijn, B; Burgmans, MC; de Geus-Oei, LF; de Leede, EM; Handgraaf, HJM; Hilling, DE; Kapiteijn, E; Lutjeboer, J; Martini, CH; Meijer, TS; Speetjens, FM; Tijl, FGJ; Vahrmeijer, AL; van der Meer, RW; van Erkel, AR; Vuijk, J, 2021) |
| "Melanoma is a malignant cancer of the skin associated with a high mortality." | ( Abrahamse, H; Ghazaeian, M; Hosseinzadeh, R; Khorsandi, K; Naderi, A, 2021) |
| "Melanoma is a type of skin cancer with an elevated incidence of metastasis and chemoresistance." | ( Alves-Fernandes, DK; Amengual-Rigo, P; Branco, PC; Chapman, E; Costa-Lotufo, LV; da Silva, AB; Guallar, V; Jimenez, PC; Machado-Neto, JA; Maria-Engler, SS; Mollasalehi, N; Pessoa, ODL; Pontes, CA; Rezende-Teixeira, P, 2020) |
| "Melanoma is the deadliest type of skin cancer." | ( Braz, WR; do Nascimento, S; Fernandes, FS; Ferreira, NH; Nassar, EJ; Ribeiro, AB; Rinaldi-Neto, F; Tavares, DC, 2020) |
| "Melanoma is the most dangerous type of skin cancer because of its high invasion and metastasis ability." | ( Lei, PM; Leung, CH; Ma, DL; Wang, W; Yang, GJ, 2020) |
| "Malignant melanoma is an emerging problem worldwide due to the high degree of lethalness." | ( Brzózka, Z; Chudy, M; Lamch, Ł; Piechota, B; Tokarska, K; Wilk, KA; Żukowski, K, 2020) |
| "Malignant melanoma is a kind of highly invasive and deadly diseases." | ( Chen, Y; Li, X; Liu, X; Rao, M; Shi, B; Sun, X; Wang, Y; Yuan, Y; Zhang, M, 2020) |
| "Melanoma is one of the most aggressive malignancies and its treatment remains challenging due to its highly metastatic property and availability of limited effective drugs." | ( Ghosh, S; Juin, SK; Majumdar, S, 2020) |
| "Melanoma is responsible for nearly 9,000 deaths each year in the United States." | ( Hignett, E; Khachemoune, A; Nguyen, K, 2020) |
| "Renal melanoma is rare." | ( Huang, L; Liu, Y; Meng, F; Ran, P, 2020) |
| "Melanoma is an aggressive cancer with rapid progression, relapse, and metastasis." | ( Chu, Y; Gao, JQ; Jiang, ZH; Ning, XH; Niu, J; Peng, LH; Shao, HT; Wang, MZ; Yuan, TJ; Zhang, L, 2020) |
| "Melanoma is the most life-threatening skin cancer with increasing incidence around the world." | ( Gao, T; Guo, S; Guo, W; Li, C; Liu, Y; Ma, J; Shi, Q; Wang, H; Yi, X; Zhao, T, 2020) |
| "Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment." | ( Abu Eid, M; Bennett, B; Boyle, KA; Cheng, G; Dwinell, MB; Hardy, M; Kalyanaraman, B; Kresty, LA; McAllister, D; Weh, K; Zielonka, J; Zielonka, M, 2020) |
| "Malignant melanoma is a common form of skin cancer that contains different cell types recognized by various cell surface markers." | ( Jobani, BM; Mohebi, E; Najafzadeh, N, 2020) |
| "Malignant melanoma is the deadliest skin cancer, due to its propensity to metastasize." | ( Allegra, M; Busà, R; De Cicco, P; Ercolano, G; Formisano, C; Ianaro, A; Taglialatela-Scafati, O, 2021) |
| "Scalp melanoma is a subgroup of melanomas on the head and neck, historically associated with worst prognosis." | ( Calsavara, VF; Duprat Neto, JP; Oliveira Santos Filho, IDA; Pinto Blumetti, T; Porto, AC; Tavoloni Braga, JC, 2020) |
| "Tapioca iris melanoma is a rarer yet devastating form with wide and challenging differential diagnoses because of its amelanotic nodular appearance." | ( Calvo-Andrés, R; Cervera-Taulet, E; Mata-Moret, L; Monferrer-Adsuara, C; Montero-Hernández, J; Ortiz-Salvador, M, 2020) |
| "Tapioca iris melanomas are uncommon tumors with a presentation/surgical management that differs from other malignant tumors." | ( Calvo-Andrés, R; Cervera-Taulet, E; Mata-Moret, L; Monferrer-Adsuara, C; Montero-Hernández, J; Ortiz-Salvador, M, 2020) |
| "Melanoma is notoriously resistant to current cancer therapy." | ( Kung, ML; Tai, MH; Weng, CH; Wu, CS; Wu, JC; Wu, MH, 2020) |
| "Scalp melanomas are usually thicker and show worse prognosis than other sites and other head and neck melanomas." | ( Argenziano, G; Benati, E; Collgros, H; Dika, E; Gallo, BM; Guitera, P; Hirata, SH; Lambertini, M; Lobato Williams, A; Longo, C; Menzies, SW; Pereira, AR, 2021) |
| "Melanoma are malignant tumors derived from melanocytes being responsible for the majority of skin cancer deaths with an increasing rate of incidence." | ( Cheng, X; Hübner, R; Kail, D; Schirrmacher, R; von Kiedrowski, V; Wängler, B; Wängler, C, 2020) |
| "Melanoma is the most aggressive form of skin cancer and one of the most treatment-refractory malignancies." | ( Barbieri, G; Costantini, F; Di Sano, C, 2020) |
| "Uveal melanoma is the most common type of intraocular cancer with a low mean annual incidence of 5‑10 cases per million." | ( Álvarez-Mon, M; Buján, J; Coca, S; Fraile-Martínez, O; García-Honduvilla, N; Ortega, MA; Teus, MA, 2020) |
| "Melanoma is one of the most aggressive forms of skin tumour with poor prognosis; no effective therapy has been established for melanoma at the metastatic stage." | ( Duan, X; Huang, J; Huang, Y; Lai, Y; Long, H; Wu, W; Zhang, S; Zhang, Y, 2021) |
| "Melanoma is the most aggressive and fatal type of skin cancer due to being highly proliferative." | ( Abou-Kheir, W; Ausina, P; Branco, JR; Demaria, TM; Esteves, AM; Leandro, JGB; Mendonça, APM; Ochioni, AC; Oliveira, MF; Palhano, FL; Sola-Penna, M; Zancan, P, 2020) |
| "Cutaneous melanoma is the deadliest form of skin cancer, and gambogic acid (GA) exhibits potent anti-melanoma activity." | ( Hou, T; Pang, Y; Wang, C; Wang, Q; Wang, W; Wu, S; Zhang, D, 2021) |
| "Ocular melanoma is classified under the category of noncutaneous melanomas." | ( Jaimini, A; Jain, A; Jain, M; John, AR; Kishore, B; Pandit, AG; Sharma, A; Singh, A; Vishnoi, MG, 2020) |
| "Melanoma is one of the most aggressive forms of human cancer and its incidence has significantly increased worldwide over the last decades." | ( Almazan, F; Bermúdez-Sánchez, S; López-Nevot, MÁ; Martin, A; Montoyo-Pujol, YG; Wang, X, 2021) |
| "Cutaneous melanoma is the deadliest type of skin cancer, characterized by a high molecular and metabolic heterogeneity which contributes to therapy resistance." | ( Brito, C; Bronze, MR; Pojo, M; Serra, AT; Silva, S; Tomás, A, 2021) |
| "Melanoma is considered the most aggressive type of skin cancer, still without effective treatment." | ( Bazylińska, U; Chodaczek, G; Kulbacka, J; Rossowska, J; Saczko, J; Szewczyk, A, 2021) |
| "Melanoma is a malignant tumor of the skin with a high metastasis rate and poor prognosis." | ( Chen, J; Fan, J; Pan, C; Tang, S; Zhang, W; Zhong, X, 2021) |
| "Melanoma is considered to be one of the most aggressive human tumors." | ( Azawi, S; Liehr, T; Piaszinski, K; Rincic, M, 2021) |
| "Melanoma is an invasive and very aggressive skin cancer due to its multi-drug resistance that results in poor patient survival." | ( Alencar, LMR; Alexis, F; da Silva de Barros, AO; Dahoumane, SA; de Oliveira Siqueira, LB; do Reis, SRR; Helal-Neto, E; Pinto, SR; Portilho, FL; Ricci-Junior, E; Santos-Oliveira, R, 2021) |
| "Melanoma is a life-threatening cancer characterized with a potentially metastatic tumor of melanocytic origin." | ( Berköz, M; Keskin, S; Korkmaz, D; Krośniak, M; Özkan-Yılmaz, F; Özlüer-Hunt, A; Türkmen, Ö, 2021) |
| "Melanoma is one of the most aggressive skin cancers." | ( Bao, H; Wu, X, 2021) |
| "Melanoma is an aggressive and highly metastatic type of skin cancer where the design of new therapies is of utmost importance for the clinical management of the disease." | ( Anestopoulos, I; Cheung, W; Franco, R; Kyriakou, S; Mantso, T; Mitsiogianni, M; Panayiotidis, MI; Pappa, A; Tetard, D; Trafalis, DT; Veuger, S, 2021) |
| "Melanoma is a highly malignant skin cancer that frequently metastasizes to the lung, bone, and brain at an early phase." | ( Mukai, T; Munekane, M; Sano, K; Sasaki, H; Tanaka, T; Yamasaki, T, 2021) |
| "Melanoma is a leading cause of cancer deaths worldwide." | ( Bilska, B; Kleszczyński, K; Piotrowska, A; Pyza, E; Reiter, RJ; Schedel, F; Slominski, AT; Stefan, J; Steinbrink, K; Tulic, MK; Zmijewski, M, 2021) |
| "Malignant melanoma is the most aggressive form of skin cancer with high metastatic capacity." | ( Benedicto, A; Hernandez-Unzueta, I; Márquez, J; Sanz, E, 2021) |
| "Iris melanoma is a rare form of uveal melanoma with potential metastic spread." | ( Foerster, P; Heidorn, S; Liegl, R; Muacevic, A; Priglinger, SG; Schmelter, V, 2021) |
| "Malignant melanoma is a life-threatening form of skin cancer with a low response rate to single-agent chemotherapy." | ( Chen, S; Liu, C; Song, M; Tao, Z; Xia, W; Zhang, W; Zhu, B, 2021) |
| "Malignant melanoma is a critical and aggressive skin tumor with a steeply rising incidence and a less favorable prognosis due to the lack of efficient treatment." | ( Fang, J; Huang, X; Liang, X; Liu, J; Wang, X; Yang, Y, 2021) |
| "Melanoma is the most common type of skin cancer." | ( Cai, M; Chen, RX; Deng, B; Deng, SH; Ding, WJ; Jiang, XL; Kan, J; Liu, B; Tan, ZB; Wu, YT; Xu, YC; Zhang, EX; Zhang, JZ; Zhang, SW, 2021) |
| "Melanoma is an aggressive tumor with still poor therapy outcomes." | ( Audano, M; Beretta, G; Fontana, F; Limonta, P; Marzagalli, M; Mitro, N; Procacci, P; Raimondi, M; Sartori, P, 2021) |
| "Canine malignant melanoma is highly aggressive and generally chemoresistant." | ( Bonkobara, M; Kurita, S; Michishita, M; Miyamoto, R; Nagashima, T; Noguchi, S; Tamura, K; Tani, H; Yayoshi, N, 2021) |
| "Metastatic melanoma is an aggressive skin cancer and associated with a poor prognosis." | ( Federico, A; Granados, K; Hüser, L; Liu, K; Novak, D; Poelchen, J; Steinfass, T; Sun, Q; Umansky, V; Utikal, J; Vierthaler, M; Wu, H, 2021) |
| "Uveal melanoma is the most common primary intraocular tumour in adults." | ( Kang, H; Ling, F; Ping, L; Xin, X, 2021) |
| "Melanoma is known to aggressively metastasize and is one of the prominent causes of skin cancer mortality." | ( Chang, SN; Choi, DK; Hwang, BS; Kang, SC; Khan, I; Kim, CG; Lee, H; Park, JG; Park, SM, 2021) |
| "Melanoma is the most lethal of all skin-related cancers with incidences continuously rising." | ( Baden, C; Chan, KC; Grote, S; Handgretinger, R; Mezger, M; Schleicher, S; Ureña-Bailén, G, 2021) |
| "Melanoma is an aggressive skin cancer with increasing incidence rates globally." | ( Anestopoulos, I; Franco, R; Kyriakou, S; Mitsiogianni, M; Panayiotidis, MI; Pappa, A; Trafalis, DT, 2021) |
| "Melanoma is a cancer of melanocytes, pigmented cells that give rise to skin tone, hair, and eye color." | ( Dean, DN; Lee, JC, 2021) |
| "Malignant melanoma is one of the most devastating types of cancer with rapid relapse and low survival rate." | ( Hu, L; Li, Q; Liu, G; Mu, Z; Sun, F; Wu, X; Zhang, D; Zhang, M; Zhang, W, 2021) |
| "Metastatic melanoma is often accompanied by the development of brain metastases, at presentation or during the course of therapy." | ( Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP, 2021) |
| "Choroidal melanoma is a devastating disease that causes visual loss and a high mortality rate due to metastasis." | ( Chen, YF; Jin, Q; Lai, Y; Li, YZ; Liao, HF; Qiu, WL; Shi, ML; Wu, WQ; Yu, DL, 2021) |
| "Melanoma is a malignant cancer that affects melanocytes and is considered the most aggressive skin-type cancer." | ( Alves, RJ; Bonifacio, JHO; Corrêa, CB; de Franca, MNF; de Lucca Junior, W; Dos Santos, EWP; Isidório, RG; Ottoni, FM; Santos, JF; Scher, R, 2021) |
| "Melanoma is a kind of skin cancer that is begun by the alteration of melanocytes." | ( Adili, A; Akbari, M; Alkafaji, HA; Cid-Arregui, A; Deljavanghodrati, M; Hasanzadeh, A; Heshmati, R; Hojjatipour, T; Jalili, M; Jarahian, M; Marofi, F; Rahman, HS; Raji, A; Sandoghchian Shotorbani, S; Shomali, N; Tamjidifar, R; Tarzi, S; Zekiy, AO, 2021) |
| "Mucosal melanomas are rare and only a small portion bear BRAF mutations while cutaneous melanomas have a much higher prevalence and often harbor BRAF mutations." | ( Blokx, WAM; Jansen, AML; Kamphuis, AM; Koppes, SA; Rijken, JA; Schrader, AMR, 2022) |
| "Malignant melanoma is a well-known diagnostic pitfall, given its propensity to metastasize to different sites and mimic various entities." | ( Lajara, S; Landau, M, 2021) |
| "Conjunctival melanoma is extremely rare in children and has low rates of resolution." | ( María Moral, R; María Peiró, A; Monteagudo, C; Moreno, L; Muriel, J, 2022) |
| "Malignant melanoma is a highly aggressive skin cancer characterized by an elevated grade of tumor cell plasticity." | ( Andreucci, E; Biagioni, A; Bianchini, F; Calorini, L; Del Rosso, M; Fibbi, G; Fucci, L; Guida, M; Laurenzana, A; Margheri, F; Nediani, C; Peppicelli, S; Ruzzolini, J; Serrat, S, 2022) |
| "Mucosal melanoma is a rare condition." | ( Baa, AK; Rastogi, S; Sachani, H; Shamim, SA; Tripathy, S, 2021) |
| "Melanoma is the deadliest form of skin cancer." | ( Bosenberg, M; Talty, R, 2022) |
| "Melanoma is associated with poor prognosis in its advanced stages." | ( Akay, BN; Apalla, Z; Bhari, N; Goldust, M; Grabbe, S; Patil, A; Salerni, G; Schwaertz, RA, 2022) |
| "Malignant melanoma is considered the most aggressive skin carcinoma with invasive growth patterns." | ( Du, Y; Gu, Y; Jiang, L; Liu, J; Tang, X; Wu, X, 2021) |
| "Melanoma is a highly aggressive type of skin cancer." | ( Chen, X; Kuang, X; Liang, L; Liu, H; Liu, J; Su, J; Xiang, M; Xie, Z; Zhao, S, 2021) |
| "Ocular melanoma is a disorder that is rarely found but is deadly." | ( Aldina, R; Aprilliantina, YS; Novita, HD; Sadono, EG, 2021) |
| "Melanoma is one of the most common malignant tumors." | ( Li, X; Shi, S; Xu, J; Yin, P; Zhang, Q; Zhang, S; Zhang, T; Zhu, S, 2021) |
| "Human melanoma is a highly aggressive type of cancer, causing significant mortalities despite the advances in treatment." | ( Cai, S; Dai, S; Liu, W; Ma, Z; Xia, H; Xiong, Q; Yan, X; Zhu, Z, 2021) |
| "Cutaneous melanoma is one of the most common malignant skin cancer with high lethality." | ( Fu, J; Gao, X; Pan, X; Quan, G; Wen, T; Wen, X; Wu, C; Yang, D; Zhao, Y; Zhou, Y, 2021) |
| "Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma." | ( Abdullah, SE; Baurain, JF; Butler, MO; Carvajal, RD; Curti, B; Demidov, L; Dummer, R; Gastaud, L; Goodall, H; Hamid, O; Hassel, JC; Holland, C; Joshua, AM; Kirkwood, JM; Mauch, C; Milhem, M; Nathan, P; Ochsenreither, S; Orloff, M; Piperno-Neumann, S; Piulats, JM; Rutkowski, P; Sacco, JJ; Salama, AKS; Schlaak, M; Shoushtari, AN; Sullivan, RJ; Yushak, M, 2021) |
| "Melanoma is the most lethal form of skin cancer, which is intrinsically resistant to conventional chemotherapy." | ( Chuang, YJ; Liu, LY; Shyu, YM, 2021) |
| "Melanoma is a highly aggressive and treatment-resistant cancer, and the incidence and mortality rates are increasing worldwide." | ( Chun, KS; Joo, SH; Lee, HS; Raut, PK, 2021) |
| "Malignant melanoma is an aggressive tumor with a high potential for distant metastases." | ( Amaya, S; Minami, T; Mitsui, T; Munemoto, Y; Nakanuma, Y; Saito, K; Shimada, M; Takashima, Y; Terada, T; Yamagishi, Y, 2021) |
| "Nevoid melanoma is a subtype of melanoma that histologically resembles a melanocytic nevus." | ( Fujimoto, M; Haga, H; Ishida, Y; Kaku, Y; Ogawa, S; Shea, CR; Takeuchi, Y; Tsujimura, M; Usui, S; Yamada, Y, 2022) |
| "(1) Background: Melanoma is an aggressive neoplasm derived from melanocyte precursors with a high metastatic potential." | ( Jęśkowiak, I; Mączyński, M; Szeląg, A; Wiatrak, B, 2021) |
| "Melanoma is most common in white, older men, with an average age of diagnosis of 65." | ( Aluru, JS; Barsouk, A; Rawla, P; Saginala, K, 2021) |
| "Mucosal melanoma is rare and has distinct clinical and genetic features." | ( Cao, J; Chen, Y; Jiang, S; Jin, F; Kong, Y; Liu, X; Luo, Z; Meng, Y; Xu, Y; Yang, H; Zhang, X, 2022) |
| "Melanoma is one of the most aggressive and life-threatening skin cancers, and in this research, we aimed to explore the functional role of circular RNA VANGL1 (circVANGL1) in melanoma progression." | ( Hou, C; Leng, S; Mo, L; Wang, L; Wu, J; Xie, X; Xu, Y; Zhou, H, 2021) |
| "Melanomas are aggressive tumors with a high metastatic potential and an increasing incidence rate." | ( Aigelsreiter, A; Anders, I; Bernecker, C; Brandl, W; Garofalo, M; Hebesberger, T; Heitzer, E; Hirschmugl, B; Kashofer, K; Kretschmer, N; Richtig, E; Richtig, G; Riedl, S; Rinner, B; Schlenke, P; Schrom, S; Wadsack, C; Wallner, SA; Zweytick, D, 2021) |
| "Malignant melanoma is responsible for the majority of skin cancer-related deaths." | ( Banach, K; Beberok, A; Kowalska, J; Rok, J; Rzepka, Z; Wrześniok, D, 2021) |
| "Malignant melanoma is the most aggressive of skin cancers and the 19th most common cancer worldwide, with an estimated age-standardized incidence rate of 2." | ( Abbatepaolo, C; Arezzo, F; Bellitti, E; Cazzato, G; Cimmino, A; Colagrande, A; Cormio, G; Foti, C; Ingravallo, G; Lettini, T; Loizzi, V; Lospalluti, L; Resta, L; Romita, P; Rossi, R; Sablone, S, 2021) |
| "Melanoma is a type of skin cancer with low survival rates after it has metastasized." | ( Abrantes, JLF; Barreto Fonseca, EM; Clerici, SP; Cordeiro, HG; Ferreira-Halder, CV; Gonçalves, PR; Maria-Engler, SS; Massaro, RR; Milani, R; Rocha-Brito, KJP; Scotá Ferreira, AP, 2022) |
| "Melanoma is the most lethal form of skin cancer, and its incidence has increased considerably in the last decades." | ( Assmann, CE; Bianchin, NB; das Neves Oliveira, M; de Andrade, CM; de Oliveira, JS; Morsch, VM; Palma, TV; Pillat, MM; Schetinger, MRC; Ulrich, H, 2022) |
| "Malignant melanoma is rare in the pediatric population and management is largely extrapolated from adult guidelines." | ( Aldrink, JH; Baertschiger, RM; Fahy, AS; Helenowski, I; Lautz, TB; Wayne, JD, 2022) |
| "Malignant melanoma is regarded as the most aggressive form of skin cancer, and is responsible for most death caused by skin cancer." | ( Bing, T; Chen, H; Jin, S; Li, W; Shangguan, D; Wang, R, 2021) |
| "Malignant melanoma is the deadliest form of skin cancer and NRF2 has been proposed as a main regulator of tumor cell malignancy." | ( Depke, M; Gschwendtner, A; Hengstschläger, M; Hundsberger, H; Mikula, M; Schmidt, F; Trautinger, F; Weitzenböck, HP; Wiesner, C, 2022) |
| "Melanoma is the most dangerous type of skin cancer and is responsible for 75% of deaths from skin cancers." | ( Baciu, DD; Dumitrașcu, AM; Palade, B; Sălăgeanu, A; Vasile, V, 2022) |
| "Melanoma is the most dangerous form of skin cancer, with an abrupt growth of its incidence over the last years." | ( Almeida Paz, FA; Biazzotto, JC; Castro, KADF; Cavaleiro, JAS; da Silva, RS; Faustino, MAF; Jager, AV; Mendes, RF; Mesquita, M; Moura, NMM; Nakagaki, S; P M S Neves, MG; Ramos, L; Simões, MMQ; Tomé, AC, 2021) |
| "Melanoma is the deadliest form of skin cancer, and its incidence has alarmingly increased in the last few decades, creating a need for novel treatment approaches." | ( Bastos, V; Oliveira, H; Salvador, D, 2021) |
| "Melanoma is the most threatening form of metastatic skin cancer that develops from melanocytes and causes a large majority of deaths due to poor therapeutic prognosis." | ( An, J; Chi, SG; Jangili, P; Ji, MS; Jung, E; Kim, JS; Shim, I, 2021) |
| "Melanoma is a treatment-resistant cancer of melanocytes." | ( Athar, M; Elmets, CA; Slominski, A, 2022) |
| "Uveal melanoma is the most common primary malignancy of the eye in adults." | ( Adamski, W; Brązert, A; Marszałek, A; Rospond-Kubiak, I; Stodolska-Nowak, A; Sygut, J, 2021) |
| "Melanoma is a kind of skin cancer, also known as malignant melanoma, that developed in melanocytes cells, which produced melanin." | ( Cui, X; Idrees, BS; Khan, MN; Teng, G; Wang, Q; Wei, K; Xiangli, W, 2022) |
| "Melanoma is the most serious type of skin cancer, and surgery is an effective method to treat melanoma." | ( Chen, X; Cheng, M; He, Z; Lu, Q; Lu, Y; Song, J; Sun, J; Wang, H; Wang, K; Ye, H; Zhai, Y; Zhang, H; Zhao, J, 2022) |
| "Melanoma is the most aggressive skin cancer, and its incidence has continued to rise during the past decades." | ( Almeida, AA; Bressan, GC; Lima, ÂMA; Lima, GDA; Machado-Neves, M; Oliveira, LL; Rodrigues, MP; Santiago, SS; Teixeira, RR; Vale, JAD, 2022) |
| "Melanoma is the most lethal malignancy in skin cancer and may occur at any site and express melanocytes." | ( Li, J; Liu, K; Liu, Y; Lu, S; Su, J; Sun, J; Wang, B; Wang, F; Wang, Z; Wei, Z; Yang, Y; Zhang, H; Zhao, L, 2022) |
| "Cutaneous malignant melanoma is the fastest growing and the most aggressive form of skin cancer that is diagnosed." | ( Juszczak, AM; Končić, MZ; Tomczyk, M; Wöelfle, U, 2022) |
| "Mucosal melanoma is an aggressive melanoma subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy." | ( Bai, X; Chi, Z; Cui, C; Dai, J; Feng, H; Flaherty, KT; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Tang, X; Wang, X; Wu, X; Yan, X; Yao, S; Zhou, L, 2022) |
| "Cutaneous melanoma is the deadliest type of skin cancer, although it accounts for a minority of all skin cancers." | ( Arslanbaeva, L; Cogo, P; Pece, S; Ravazzolo, M; Santoro, MM; Simonato, M; Tosi, G; Tucci, FA, 2022) |
| "Early detection of melanoma is instrumental as the 5-year survival decreases from 93." | ( Garland-Kledzik, M; Hamilton, O; Likar, C; Thomay, A; Williams, A, 2022) |
| "Melanoma is an immunogenic tumor and a serious type of skin cancer." | ( Bae, H; Han, IH; Hwang, DS; Jeong, C; Park, SH; Yang, J, 2022) |
| "Melanoma is a fatal cancer with a significant feature of resistance to traditional chemotherapeutic drugs and radiotherapy." | ( Chen, X; Li, J; Liu, N; Long, J; Peng, C; Tang, L; Yan, B; Zhang, J, 2022) |
| "Melanoma is a type of tumor that originates from melanocytes." | ( Cestari, MM; de Lima Bellan, D; Disner, GR; Kalegari, P; Leme, DM; Martinez, GR; Mazepa, E; Meira, WV, 2022) |
| "Melanoma is a drug-resistant cancer, representing a serious challenge in cancer treatment." | ( Bastos, V; Oliveira, H; Salvador, D, 2022) |
| "Melanoma is characterized by high glucose uptake, partially mediated through elevated pyruvate dehydrogenase kinase (PDK), making PDK a potential treatment target in melanoma." | ( Bakker, BM; de Jong, S; Evers, B; Jalving, M; Tiersma, JF, 2022) |
| "Uveal melanoma is a rare form of cancer with high mortality." | ( Hagström, A; Kal Omar, R; Stålhammar, G; Williams, PA, 2022) |
| "Cutaneous melanoma is a malignant tumor, which develops from dermal melanocytes." | ( Boucenna, V; Boucenna, W; Delbarre, M; Errera, MH; Fauviaux, E; Jany, B; Promelle, V, 2022) |
| "Melanoma is characterized by oncogenic mutations in pathways regulating cell growth, proliferation, and metabolism." | ( Blackham, A; Box, J; Demberger, L; Federowicz, B; Friedland, JC; Ginn, S; Horton, M; Knoerzer, D; McIntosh, A; Nair, S; Shapiro, M; Sheikh, H; Stuhlmiller, TJ; Wolfe, Z, 2022) |
| "Primary scalp melanomas are associated with a higher rate of brain metastasis than primary cutaneous melanomas occurring at other head and neck and body sites, but the reason is unclear." | ( Ch'ng, S; Choksi, H; Li, AT; Lo, SN; London, K; Long, GV; Menzies, AM; Miin Yip, J; Pires da Silva, I; Potter, AJ; Saw, RPM; Scolyer, RA; Shannon, KF; Shivalingam, B; Thompson, JF; Varey, AHR, 2022) |
| "Melanoma is a complex and heterogenous disease, displays the deadliest form of skin cancer, and accounts for approx." | ( Bauer, R; Durchschein, C; Hufner, A; Kretschmer, N; Lohberger, B; Rinner, B, 2022) |
| "Cutaneous melanoma is one of the most aggressive human malignancies and shows increasing incidence." | ( Atmoko, H; Bahri, R; Bulfone-Paus, S; Dummer, R; Garcia-Rodriguez, KM; Kiss, O; Levesque, MP; Martínez-Gómez, JM; Prise, I; Smith, MP; Wellbrock, C, 2022) |
| "Melanoma is the most lethal skin cancer characterized by its high metastatic potential." | ( Jianping, K; Jianqiang, W; Suwei, D; Xiang, M; Yanbin, X; Yunqing, W; Zhen, L; Zhuohui, P, 2022) |
| "Malignant melanoma is an aggressive and deadly form of skin cancer and novel and improved therapeutic options are needed." | ( Albino, M; Correia, I; Côrte-Real, L; Gaspar, MM; Lopes, J; Matos, CP; Mendes, F; Pessoa, JC; Reis, CP; Tomaz, AI; Viana, AS, 2022) |
| "Malignant melanoma is a malignant tumor with a poor prognosis." | ( Di Guardo, L, 2022) |
| "Melanoma is considered one of the most aggressive skin cancers." | ( Karaś, K; Karwaciak, I; Pastwińska, J; Ratajewski, M, 2022) |
| "Melanoma is a type of skin cancer with an estimated 5-year survival rate of approximately 90%." | ( Basson, C; Bipath, P; Hlophe, Y; Joubert, AM; Nkandeu, DS; Nyakudya, T; Serem, JC, 2022) |
| "Melanoma is one of the most common skin infections, has triggered significant morbidity and mortality across the globe." | ( Aqeel, M; Awan, L; Bashir, Z; Jan, Z; Kalsoom, S; Muhammad Ali, G; Munir, A; Nadeem, T; Sadia, H; Saeed, A; Ud Din, S, 2022) |
| "Melanoma is one of the most aggressive human cancers with poor prognosis and high mortality for its high metastatic ability." | ( Lee, S; Tseng, T; Uen, W; Wu, CP, 2022) |
| "Skin melanoma is one of the most common cancer types in the United States and worldwide, and its incidence continues to grow." | ( Afrin, H; Aguilera, RJ; Borrego, EA; Deaguero, IG; Huda, MN; Islam, T; Kumar, R; Nurunnabi, M; Tanner, EEL; Varela-Ramirez, A, 2022) |
| "Malignant melanoma is an aggressive skin tumor with a rapidly increasing incidence and there is not yet a successful treatment strategy." | ( Aras, S; Cansaran-Duman, D; Eskiler, GG; Yangın, S, 2022) |
| "Melanoma is the most malignant skin tumor and is difficult to cure with the alternative treatments of chemotherapy, biotherapy, and immunotherapy." | ( Du, Y; Gu, Y; Jiang, L; Lang, Y; Li, A; Liu, J; Liu, X; Tang, X; Zhao, Y, 2022) |
| "Melanoma is an aggressive malignancy with a high heterogeneity and metastatic potential." | ( Huang, L; Huang, W; Lin, W; Liu, S; Lu, X; Tang, Y; Wang, H; Yang, H; Zhang, Y, 2022) |
| "Cutaneous malignant melanoma is fastest-growing cancer in white populations with a large majority of dermal cancer death." | ( Abdi, F; Arkan, E; Eidizadeh, M; Gamizgy, YH; Mansouri, K; Naseriyeh, T; Valipour, E, 2023) |
| "The incidence of melanoma is steadily increasing worldwide." | ( Bąk, W; Bargieł, J; Cabaj, J; Góralczyk, A; Grabarska, A; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "Melanoma is a malignant skin cancer that is prone to metastasis in the early stage and has a poor prognosis." | ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Qian, C; Ren, H; Tao, X; Wang, A; Yang, Z, 2022) |
| "Melanoma is a highly aggressive cancer that can metastasize at early stage." | ( Cao, S; Gong, M; Ma, Q; Qian, W; Wang, S; Wang, Z; Wu, S; Yue, Y; Zhang, S; Zhang, W; Zhu, Z, 2022) |
| "Melanoma is one of the deadliest malignancies." | ( Lan, S; Wu, D; Zhang, Y, 2022) |
| "Melanoma is the deadliest of skin cancers and has a high tendency to metastasize to distant organs." | ( Bogeski, I; Bonilla Del Rio, Z; Brafford, P; Cappello, S; Ellenrieder, V; Gibhardt, CS; Herlyn, M; Ickes, C; Jakobs, S; Katschinski, DM; Lange, F; Latif, MU; Lenz, C; Nanadikar, M; Rehling, P; Roesch, A; Schön, MP; Shannan, B; Shumanska, M; Stanisz, H; Stejerean-Todoran, I; Sung, HM; Urlaub, H; Vultur, A; Waters, A; Wilting, J; Wittek, A; Wölling, A; Zhang, X; Zimmermann, K, 2022) |
| "Malignant melanoma is among the tumor entities with the highest increase of incidence worldwide." | ( Benz, F; Groeber-Becker, FK; Junger, C; Leikeim, A; Monaghan, MG; Neto, NGB; Schilling, B; Schmidt, FF; Tiltmann, K; Wußmann, M, 2022) |
| "Melanoma is the most malignant form of skin cancer across the globe." | ( Bagasariya, D; Bala Singh, S; Charankumar, K; Famta, P; Fernandes, V; Kumar Khatri, D; Shah, S; Srivastava, S, 2022) |
| "Melanoma is a kind of aggressive skin neoplasms with high mortality." | ( Ji, G; Luo, B; Shen, G; Tian, T, 2022) |
| "Melanoma is a form of skin cancer that starts in melanocytes." | ( Bagasariya, D; Bala Singh, S; Charan Kumar, K; Famta, P; Fernandes, V; Kumar Khatri, D; Sabiya Samim, K; Shah, S; Srivastava, S, 2022) |
| "Melanoma is one of the most aggressive cancers, with 1." | ( Adrianzen, L; Chiu, YM; Keck, M; Lodhi, N; Nagpal, P; Parvez, Z; Sarojini, S; Suh, KS, 2023) |
| "Melanoma is an aggressive cancer with fast metastatic spread and reduced survival time." | ( Almeida, CP; da Silva, VHSR; de Araújo Campos, MR; de Carvalho, BA; de Souza Silva, FH; Del Puerto, HL; Ferreira, E; Lima, BM; Ribeiro, TS; Rocha, SA; Veloso, ES, 2022) |
| "Melanoma is one of the most severe cancerous diseases." | ( Duong, KT; Le, UM; Nguyen, T; Tran, TT; Wang, H, 2022) |
| "Melanoma is an aggressive and metastatic skin cancer caused by genetic mutations in melanocytes, and its incidence is increasing year by year." | ( Fang, X; Fu, Q; Li, S; Li, Y; Qiu, X; Wang, P; Wang, X; Wu, X, 2023) |
| "Melanoma is an aggressive cancer." | ( Jiang, XL; Li, JK; Wang, Y; Yung, KK; Zhang, Z; Zhu, PL, 2023) |
| "Melanoma is the riskiest type of skin cancer." | ( Baghbani, E; Baradaran, B; Mahboob, S; Montazami, N; Noorolyai, S; Rahmani, S; Sameti, P; Sorkhabi, A; Vazirabad, AF; Zargari, F, 2022) |
| "Melanoma is mainly caused by sunlight radiation, but other environmental risk factors are not well known." | ( Antonelli, G; Boffetta, P; Collatuzzo, G; Dika, E; Fortes, C; Mastroeni, S; Visci, G; Zunarelli, C, 2023) |
| "Melanoma is mainly caused by sunlight radiation, but other environmental risk factors are not well known." | ( Antonelli, G; Boffetta, P; Collatuzzo, G; Dika, E; Fortes, C; Mastroeni, S; Visci, G; Zunarelli, C, 2023) |
| "Melanoma is mainly caused by sunlight radiation, but other environmental risk factors are not well known." | ( Antonelli, G; Boffetta, P; Collatuzzo, G; Dika, E; Fortes, C; Mastroeni, S; Visci, G; Zunarelli, C, 2023) |
| "Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has a higher incidence in East Asians." | ( Chen, K; Li, T; Li, X; Li, Y; Liao, Z; Liu, H; Liu, X; Lu, J; Shen, H; Teng, S; Wang, D; Wang, J; Wei, J; Xiang, L; Xing, R; Yang, J; Yang, M; Yang, T; Yang, Y; Zhang, C; Zhao, G; Zhao, J, 2022) |
| "Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has a higher incidence in East Asians." | ( Chen, K; Li, T; Li, X; Li, Y; Liao, Z; Liu, H; Liu, X; Lu, J; Shen, H; Teng, S; Wang, D; Wang, J; Wei, J; Xiang, L; Xing, R; Yang, J; Yang, M; Yang, T; Yang, Y; Zhang, C; Zhao, G; Zhao, J, 2022) |
| "Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has a higher incidence in East Asians." | ( Chen, K; Li, T; Li, X; Li, Y; Liao, Z; Liu, H; Liu, X; Lu, J; Shen, H; Teng, S; Wang, D; Wang, J; Wei, J; Xiang, L; Xing, R; Yang, J; Yang, M; Yang, T; Yang, Y; Zhang, C; Zhao, G; Zhao, J, 2022) |
| "Melanoma is a highly heterogeneous malignant tumor that exhibits various forms of drug resistance." | ( Belenyuk, VD; Esimbekova, AR; Palkina, NV; Ruksha, TG; Savchenko, AA; Sergeeva, EY; Zinchenko, IS, 2023) |
| "Acral melanoma is a predominant and aggressive subtype of melanoma in non-Caucasian populations." | ( Chen, LT; Cheng, ST; Hsieh, CC; Hwang, DY; Ito, T; Jiang, KY; Kaku-Ito, Y; Li, TW; Shen, CH; Su, YC, 2023) |
| "Melanoma is an aggressive malignancy with a high mortality rate." | ( Chen, YJ; Ding, WJ; Dou, X; Fu, XQ; Li, SA; Liu, B; Liu, YX; Wang, XQ; Wu, JY; Wu, Y; Xu, BW; Yu, ZL, 2023) |
| "Malignant melanoma is a skin cancer characterized by rapid development, poor prognosis and high mortality." | ( Góralczyk, A; Grabarska, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "Melanoma is deadly, physically impairing, and has ongoing treatment deficiencies." | ( Bachari, A; Mantri, N; Nassar, N; Piva, T; Schanknecht, E, 2023) |
| "Melanoma is a malignant tumor that originates from the skin's melanocytes and has the highest death rate from skin cancer." | ( Aghazadeh, E; Qobadi, A; Shakiban, D; Tabeshpour, J; Yousefsani, BS, 2023) |
| "Melanoma is a highly aggressive cancer endowed with a unique capacity of rapidly metastasizing, which is fundamentally driven by aberrant cell motility behaviors." | ( Bayet, E; Constantin, B; Fautrel, A; Joussaume, A; Khammari, A; Le Devedec, D; Leverrier-Penna, S; Mallavialle, A; Marionneau-Lambot, S; Penna, A; Perret, R; Rambow, F; Shoji, KF; Tartare-Deckert, S; Viel, R, 2023) |
| "Melanoma is still one of the most dangerous cancers." | ( Banach, K; Kowalska, J; Rok, J; Rzepka, Z; Wrześniok, D, 2023) |
| "Melanoma is a highly aggressive neoplasm with a high degree of malignancy and rapid acquisition of resistance by cancer cells." | ( Janeczek, M; Jawień, P; Jęśkowiak-Kossakowska, I; Krzyżak, E; Mączyński, M; Szafran, R; Szeląg, A; Wiatrak, B, 2023) |
| "Cutaneous melanoma is an aggressive and deadly cancer resulting from malignant transformation of cells involved in skin pigmentation." | ( Chen, C; Zhang, X, 2023) |
| "Cutaneous melanoma is an aggressive human malignancy, leading to high mortality worldwide." | ( Chang, Y; Chen, Y; Lv, L; Ying, H; Zhou, J, 2023) |
| "Malignant melanoma is an aggressive skin cancer, accounting for the majority of skin cancer deaths." | ( Leenutaphong, P; Nararatwanchai, T; Phetchengkao, W; Poommarapan, K; Rummaneethorn, P; Srihirun, S; Srisubat, A; Suriyachan, K; Suwanpidokkul, N; Tancharoen, S, 2023) |
| "Cutaneous melanoma is the most aggressive type of skin cancer; it is difficult to treat, and has been highlighted in recent years due to increasing numbers of cases worldwide." | ( Bagatini, MD; da Silva, AP; da Silva, GB; Manica, D; Marafon, F; Moreno, M, 2023) |
| "Malignant melanoma is considered a deadly aggressive form of skin cancer that frequently metastasizes to various distal organs, which harbors mutations of the BRAF or NRAS which occur in 30 to 50% of melanoma patients." | ( Godugu, C; Nagula, S; Pooladanda, V; Thatikonda, S; Tokala, R, 2023) |
| "Melanoma is the most common form of skin cancer." | ( Chen, Y; Li, L; Li, S; Liang, Y; Luo, J; Wang, B; Wang, D; Xu, Y, 2023) |
| "Uveal melanoma is a highly malignant tumor in the eye." | ( Cao, Y; Chen, L; Hu, Y; Li, J; Ma, C; Shi, J; Wang, M; Xie, J; Yao, W; Zhao, W, 2023) |
| "Uveal melanoma is the most common primary intraocular tumor in adults." | ( Hagström, A; Kal Omar, R; Stålhammar, G, 2023) |
| "Uveal melanoma is the most common primary intraocular malignancy in adults and has a high incidence of metastatic disease." | ( Ambrosini, G; Garyantes, T; Musi, E; Natale, CA; Schwartz, GK, 2023) |
| "Melanoma is the most aggressive type of skin cancer." | ( Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F, 2023) |
| "External ear melanomas are relatively rare and usually occur in the regions of helix and ear lobes." | ( Ding, H; Fan, D; Huang, Z; Liu, Y; Wan, Z, 2023) |
| "Melanoma is a dangerous type of skin cancer sometimes treated with radiotherapy." | ( Amini, SM; Janzadeh, A; Mohamadkazem, M; Moshiri, A; Neshastehriz, A, 2023) |
| "Melanoma is the most aggressive form of skin cancer, with increasing incidence and mortality rates." | ( Amaral, JD; Francisco, AP; Gaspar, MM; Godinho-Santos, A; Matias, M; Mendes, E; Perry, MJ; Pinho, JO; Rodrigues, CMP, 2023) |
| "Melanomas are characterised by accelerated cell proliferation and metabolic reprogramming resulting from the contemporary dysregulation of the MAPK pathway, glycolysis and the tricarboxylic acid (TCA) cycle." | ( Akman, M; Ariano, C; Astanina, E; Bussolino, F; Casanova, E; Comunanza, V; Corà, D; Costanza, F; Doronzo, G; Riganti, C, 2023) |
| "Metastatic melanoma is a very aggressive skin cancer." | ( Cabral, FL; da Silva, JLG; de Andrade, CM; Doleski, PH; Ebone, RDS; Jantsch, MH; Leal, DBR; Manzoni, AG; Passos, DF; Schetinger, MRC; Soares, ABU; Viana, AR, 2023) |
| "Melanoma is responsible for more than half of the deaths related to skin cancer in the last few decades." | ( Kukk, AF; Roth, B; Wu, D, 2023) |
| "(1) Malignant melanomas are dangerous skin cancers, and the treatment of melanomas with various cytostatic drugs often causes side effects and after their prolonged use resistance to these drugs appears." | ( Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ, 2023) |
| "Melanoma is considered a lethal and treatment-resistant skin cancer with a high risk of recurrence, making it a major clinical challenge." | ( Król, O; Piotrowska, A; Zaucha, R; Żmijewski, MA, 2023) |
| "Malignant melanoma is one of the most aggressive and lethal skin cancer." | ( Ding, C; Ge, X; Jiang, J; Li, S; Li, Y; Qiao, Y; Wang, D; Wang, M; Wang, Y; Zheng, X, 2023) |
| "Melanoma is the deadliest form of skin cancer and surgery is currently the most effective treatment." | ( Geary, SM; Naguib, YW; Salem, AK; Tambunlertchai, S, 2023) |
| "Ocular melanoma is a rare kind of eye malignancy that threatens the patient's eyesight." | ( Aghamiri, SM; Hashemi, S; Jaberi, R; Kahani, M; Siavashpour, Z; Zaidi, H, 2023) |
| "Melanoma is one of the most aggressive types of malignant tumors, commonly affecting young individuals." | ( Palkina, N; Ruksha, T; Sergeeva, E, 2021) |
| "Melanoma is a notoriously radioresistant type of skin cancer." | ( Im, H; Kim, DY; Kim, EJ; Lee, HJ; Lee, J; Yi, JY, 2023) |
| "Melanoma is a highly aggressive and metastatic cancer occurring in both humans and dogs." | ( Fujiwara, N; Yamamoto, M, 2023) |
| "Malignant melanoma is challenging to treat, and metastatic cases need chemotherapy strategies." | ( Cserepes, M; Kigyós, A; Ladányi, A; Surguta, SE; Tóvári, J; Vári-Mező, D, 2023) |
| "Cutaneous melanoma is one of the most aggressive human cancers and is the deadliest form of skin cancer, essentially due to metastases." | ( Baumann, A; Bonnet, PA; Deleuze-Masquéfa, C; Patinote, C; Pellegrin, E; Raevens, S, 2023) |
| "Melanoma is a highly aggressive and life-threatening form of skin cancer that accounts for a significant proportion of cancer-related deaths worldwide." | ( Bargieł, J; Cabaj, J; Wróblewska-Łuczka, P; Łuszczki, JJ, 2023) |
| "Melanoma is the most lethal malignancy in skin cancers." | ( Bai, Q; Deng, Z; Fajardo, E; Fang, Y; Lequio, M; Mathew, AM; Mayberry, TG; Nelson, CJ; Wakefield, MR; Xiao, H, 2023) |
| "Melanoma is a skin cancer with a high mortality rate due to its invasive characteristics." | ( Fernandes E Silva, E; Lopes, AC; Nascimento, MAD; Paiva, LS; Salgado, MTSF; Votto, APS, 2023) |
| "Melanoma is a highly aggressive form of skin cancer with limited therapeutic options." | ( Chen, Z; Feng, X; Hu, X; Huang, Q; Liu, Z; Qi, Y; Song, H; Song, Y; Tao, C; Wang, L; Zeng, L, 2023) |
| "Melanoma is of great interest due to its aggressive behavior and less favorable prognosis." | ( Chen, J; Chen, Y; Li, Y; Pan, X; Pu, Y; Zhang, L, 2023) |
| "Cutaneous melanoma is an aggressive cancer, which is the most common type of melanoma." | ( Cheng, H; Li, Q; Liu, C; Tu, Y; Wang, M; Zhang, M, 2023) |
| "Cutaneous melanoma is one of the most prevalent tumors, and it is still a huge challenge in the current clinical treatment." | ( Ge, B; Guo, A; Jian, L; Lin, J; Wu, H; Xiang, S; Zeng, H; Zhang, P; Zhou, B, 2023) |
| "Melanoma is a malignancy of the skin that is resistant to conventional treatment, necessitating the development of effective and safe new therapies." | ( Cai, Y; Feng, J; Ni, H; Xu, X; Yu, S; Zhang, J, 2023) |
| "Melanoma is widely recognized to resist advanced cancer treatments, including immune checkpoint inhibitors, kinase inhibitors, and chemotherapy." | ( Bachari, A; Dekiwadia, C; Mantri, N; Nassar, N; Piva, TJ; Telukutla, S; Zomer, R, 2023) |
| "Melanoma is one of the leading causes of cancer death." | ( Zhong, H; Zhong, Z, 2023) |
| "Malignant melanoma is a dangerous skin cancer, accounting for the majority of skin cancer-related deaths." | ( Wilanowski, T; Wnuk, J, 2023) |
| "Melanoma is an aggressive malignancy, historically characterized with a poor prognosis and few treatment options." | ( Baldessari, C; Depenni, R; Dominici, M; Greco, S; Pugliese, G; Venturelli, M, 2023) |
| Excerpt | Reference |
|---|
| "Hormone-treated melanoma dice (5-240 min) were analyzed for tyrosinase activity (EC 1." | ( Abramowitz, J; Chavin, W, 1978) |
| "Hormone treated melanoma dice (5--240 min) were analyzed for tyrosinase activity, cyclic AMP (cAMP) and cyclic GMP (cGMP)." | ( Abramowitz, J; Chavin, W, 1978) |
| "The traditional treatment for melanoma recurrences on an extremity has been surgical excision or less often amputation." | ( Hansson, JA; Simert, G; Vang, J, 1977) |
| "Survival curves are presented for the treatment of B16 melanomas with a range of single doses of cyclophosphamide (CY), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), or 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl)-1-nitro-sourea (MeCCNU)." | ( Hill, RP; Stanley, JA, 1975) |
| "One of eleven "untreated" melanoma patients stimulated significantly to the melanoma antigen." | ( Golub, SH; Holmes, EC; Morton, DL; Roth, JA, 1975) |
| "The results of surgical treatment of 31 melanomas of the non-subungual region of the hand are reviewed." | ( McCarthy, WH; Quinn, MJ; Thompson, JF; Wikramanayake, R, 1992) |
| "Successful treatment of melanoma patients by interferon resulted in complete disappearance of all extracerebral lesions, but left the brain vulnerable to involvement by metastases, and was frequently a site of relapse." | ( Chaitchik, S; Merimsky, O, 1992) |
| "Sera from melanoma patients treated with whole melanoma cell vaccine were used as the source of human antibody to the glycoprotein antigen." | ( Euhus, DM; Gupta, RK; Morton, DL, 1990) |
| "The role of perfusion as primary treatment of large melanomas of the foot is confirmed and recommended." | ( Bulman, AS; Skene, AI; Thomas, JM; Westbury, G; Williams, TR, 1990) |
| "Recombinant human IFN-gamma, used for treatment of melanoma and renal carcinoma, was found to induce HLA-DR expression on human keratinocytes in vivo." | ( Radaszkiewicz, T; Steiner, A; Volc-Platzer, B; Wolff, K, 1988) |
| "Many BRMs have been used in treatment of melanoma, e." | ( Hayasaka, K; Ishihara, K; Yamazaki, N, 1989) |
| "Of the high-dose combination-treated melanoma colony-forming units, 97% did not form small growth units; most remained as arrested single cells, but the cells and small growth units could still metabolize tetrazolium stain after the experiment, suggesting that the high-dose combination arrested the growth of the melanoma colony-forming units via a non-cytotoxic mechanism." | ( Bregman, MD; Meyskens, FL, 1986) |
| "Twenty-one days after radiation treatment the melanomas showed regrowth and uptake of 125I-ITU was about equal to that in non-treated controls." | ( Bakker, CN; Franken, NA; Journée-de Korver, JG; Oosterhuis, JA; Pauwels, EK; Van Langevelde, A, 1986) |
| "The authors have treated 255 uveal melanomas with helium ion radiation." | ( Char, DH; Crawford, JB, 1987) |
| "During a combined treatment of human melanoma cells with Cisplatin and irradiation under aerobic conditions, interaction between the two treatment modalities is observed." | ( Ziegler, W, 1986) |
| "DMTU-treated melanoma cells had a decreased capacity to form tumors in syngeneic mice." | ( Aloni, D; Beery, E; Nordenberg, J; Novogrodsky, A; Stenzel, KH; Wasserman, L, 1985) |
| "Advances in the treatment of melanoma have resulted mainly from improved surgical management of the primary tumour assisted by a greater appreciation of major prognostic factors in the natural history of the disease." | ( Balch, CM; Hersey, P, 1984) |
| "Drug treated melanoma dice (5--480 min) were analyzed for tyrosinase activity and cyclic nucleotide levels (cAMP, cGMP)." | ( Abramowitz, J; Chavin, W, 1980) |
| "Subsequent treatment of melanomas with DFB 24 h after the initial treatment resulted in a further decrease in relative tumor volume to 40-50% of control tumor volume and a growth curve delay of 2." | ( Jenkins, VK; Mayer, RT; Perry, RR, 1984) |
| "Results of treatment of B16 melanoma and Lewis lung carcinoma with 3,4-dihydroxybenzohydroxamic acid are used to demonstrate this definition." | ( Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL, 1982) |
| "On the other hand, treatment of melanoma cells with tunicamycin (final concentration, 1." | ( Ferrone, S; Glassy, MC; Imai, K; Ng, AK, 1981) |
| "Regarding the local treatment of melanoma immunotherapy with DNCB is shown to be of temporary benefit in some cases." | ( Gstöttner, R; Lübbe, D, 1980) |
| "By contrast, treatment of melanoma cells that were in a more advanced stage of maturation resulted in profound alterations in cell growth, morphology, and pigmentation consistent with terminal differentiation." | ( Hudgins, WR; Liu, L; Samid, D; Shack, S; Stetler-Stevenson, WG, 1994) |
| "ICG-enhanced laser treatment of melanoma (14 eyes) was compared with treatment by laser alone (4 eyes), ICG alone (1 eye), and no treatment (2 eyes)." | ( Chong, LP; de Queiroz, JM; Liggett, PE; Ozler, SA, 1993) |
| "Here we found that treatment of 70W melanoma cells with neurotrophin NT-3 increased Matrigel invasion, whereas treatment with neurotrophins other than NGF or NT-3 did not influence invasion." | ( Carson, DD; Marchetti, D; McQuillan, DJ; Nicolson, GL; Spohn, WC, 1996) |
| "Without treatment, melanomas can progress to metastatic disease and result in death." | ( Joshi, M, 1997) |
| "Surgical treatment of melanoma can be divided into therapy of the primary lesion, treatment of the lymph nodes, treatment of distant metastases, and treatment of in-transit disease by regional administration of intravascular chemotherapeutics." | ( Fraker, DL, 1997) |
| "After treatment of melanomas with anti-GD2 monoclonal antibody (MAb) (14G2a), some patients develop sensorimotor demyelinating polyneuropathy with and without the syndrome of inappropriate antidiuretic hormone (SIADH)." | ( Handa, S; Tagawa, Y; Takahashi, H; Yamada, M; Yuki, N, 1997) |
| "Genistein treatment of the melanoma cell lines resulted in cell cycle arrest at G2/M check point and no significant apoptosis was observed." | ( Green, A; Kichina, J; Rauth, S, 1997) |
| "We further demonstrate that treatment of melanoma cells with either H-89 or PKA RI alpha antisense oligonucleotides also resulted in a decreased internalization of two other ligands of LRP, activated alpha2M and lactoferrin, indicating that PKA activity is associated with LRP." | ( Goretzki, L; Mueller, BM, 1997) |
| "In this investigation, we treated human melanoma cells with two groups of catechols." | ( Bolton, JL; Huang, Z; Iverson, SL; Krol, ES; Pezzuto, JM; Pisha, E; Shen, L; van Breemen, RB, 1997) |
| "Here we found that treatment of 70W melanoma cells with neurotrophin-3 (NT-3) increased Matrigel invasion, whereas treatment with neurotrophins other than NGF or NT-3 did not influence invasion." | ( Marchetti, D; Nicolson, GL, 1997) |
| "Both pretreatment and simultaneous treatment of melanoma cells with IFN-alpha or IFN-beta inhibited the IL-1beta and TNF-alpha up-regulation of IL-8 mRNA levels." | ( Singh, RK; Varney, ML, 1998) |
| "Tamoxifen (TAM) is widely used in the treatment of melanoma, typically in combination with chemo- and/or immunotherapy." | ( Chen, Q; Gibbs, P; Robinson, WA, 1998) |
| "IFN-gamma treatment of Mz18 melanoma cells leads to up-regulation of LMP2/7 and TAP1/2, as well as to up-regulation of HLA-B and HLA-C MHC loci alleles, but not HLA-A2 or HLA-A3." | ( Castelli, C; Gollin, SM; Karbach, J; Knuth, A; Lotze, MT; Maeurer, MJ; Martin, D; Salter, R; Storkus, WJ; Swaney, W, 1996) |
| "Our results indicate that a combined treatment of melanoma with VD and selected retinoids is promising but should be adapted to individual types of tumor." | ( Carlberg, C; Danielsson, C; Törmä, H; Vahlquist, A, 1999) |
| "Indeed, treatment of melanoma cells with TNFalpha before UVC irradiation partially suppressed UVC-induced apoptosis, further supporting the protective role of TNFalpha in UVC-treated melanoma cells." | ( Ivanov, VN; Ronai, Z, 1999) |
| "Our results indicate that treatment of M21 melanoma cells with a(v)-integrin antagonists disrupts the actin cytoskeleton, redistributes a(v)-integrin and induces molecular disassembly of focal contacts." | ( Casaroli-Marano, RP; Castel, S; García, R; Mitjans, F; Pagan, R; Piulats, J; Reina, M; Vilaró, S, 2000) |
| "Finally, comparison of control and AMG-treated melanoma cells by pathway-specific gene array analysis indicated that inhibition of NO synthesis led, before induction of apoptosis, to up-regulation of mRNA levels of genes involved in the apoptosis pathway such as Bax, caspase-1, caspase-3, caspase-6, gadd45beta, mdm2, and TRAIL." | ( Anichini, A; Bersani, I; Carsana, M; Salvucci, O; Tragni, G, 2001) |
| "With both treatments melanoma cells died through an apoptotic process, associated with detachment of cells from the monolayer." | ( Comporti, M; Del Bello, B; Maellaro, E; Valentini, MA; Zunino, F, 2001) |
| "Intraarterial fotemustine treatment of uveal melanoma metastatic to the liver is well tolerated, and in some patients is associated with prolonged survival." | ( Egerer, G; Ho, AD; Keilholz, U; Lehnert, T; Max, R; Naeher, H, 2001) |
| "Complete regression was reported in the treatment of melanoma (ca." | ( Borodkina, AG; Egorov, GN; Gorbunova, VA; Manziuk, LV; Orel, NF; Semina, OV, 2001) |
| "Importantly, in vivo treatment of human melanoma xenograft tumors in athymic nude mice with LeTx results in significant or complete tumor regression without apparent side effects, suggesting that inhibiting the MAPK signaling pathway may be a useful strategy for treating melanoma." | ( Duesbery, NS; Koo, HM; Leppla, SH; McWilliams, MJ; VanBrocklin, M; Vande Woude, GF, 2002) |
| "In peripheral blood lymphocytes from untreated melanoma patients with advanced disease, a fraction of tumor antigen (Melan-A/MART-1)-specific T cells were non-naive, thus revealing tumor-driven immune activation." | ( Batard, P; Cerottini, JC; Guillaume, P; Liénard, D; Pittet, MJ; Rimoldi, D; Romero, P; Speiser, DE, 2002) |
| "Pretreatment but not post-treatment of the melanoma cells with POH, however, markedly reduced levels of UV-induced reactive oxygen species." | ( Alberts, DS; Giaccia, A; Gregus, J; Kaper, F; Lluria-Prevatt, M; Morreale, J; Powell, MB, 2002) |
| "We have reported that treatment of melanoma patients with a vaccine consisting of autologous tumor cells modified with the hapten, dinitrophenyl (DNP) and preceded by low-dose cyclophosphamide induces delayed-type hypersensitivity (DTH) to autologous, unmodified tumor cells and that this response is a significant predictor of survival." | ( Berd, D; Mastrangelo, MJ; Sato, T, 2002) |
| "We have reported that treatment of melanoma patients with a vaccine consisting of autologous tumor cells modified with the hapten, dinitrophenyl (DNP), induced delayed-type hypersensitivity (DTH) to autologous, unmodified tumor cells." | ( Berd, D, 2003) |
| "Prolonged DEX treatment of melanoma cells resulted in constitutive increases in both STAT3 and PI-3 kinase protein levels that were correlated with increased melanoma resistance to antiproliferative hormone action." | ( Krasil'nikov, M; Shatskaya, V, 2002) |
| "Curcumin-treated B16F10 melanoma cells formed eight-fold fewer lung metastases in C57BL6 mice." | ( Chatterjee, A; Chattopadhyay, N; Mitra, A; Ray, S; Siddiqi, M, 2003) |
| "Current treatment for melanoma of the lower limb includes excision of the primary tumor with ilioinguinal lymphadenectomy in the case of lymph node metastases." | ( Picciotto, F; Siatis, D; Volpi, E; Zaccagna, A, 2003) |
| "Most importantly, 5-FU- or DTIC-treated melanoma cells also became sensitive to low-avidity CTL, which per se are less cytolytic to melanomas." | ( Haluska, FG; Yang, S, 2004) |
| "Earlier we have found that prolonged treatment of melanoma cells with dexamethasone results in formation of a cell subline which was resistant to growth inhibitory dexamethasone action." | ( Gershtein, ES; Krasil'nikov, MA; Luzai, EV; Scherbakov, AM; Shatskaya, VA; Shtil, AA, 2004) |
| "Since dacarbazine was approved for treating metastatic melanoma in the 1970s, numerous studies have evaluated whether different schedules and dacarbazine-based combinations improve clinical outcomes." | ( Eggermont, AM; Kirkwood, JM, 2004) |
| "A Phase I/II protocol for treating cutaneuos melanomas with BNCT was designed in Argentina by the Comisión Nacional de Energía Atómica and the medical center Instituto Roffo." | ( Argerich, C; Batistoni, DA; Blaumann, HR; Bonomi, MR; Calzetta Larrieu, OA; Castiglia, SG; Dagrosa, MA; Feld, DB; González, SJ; Jiménez Rebagliati, R; Liberman, SJ; Longhino, J; Menéndez, P; Roth, BM; Santa Cruz, GA, 2004) |
| "Regional perfusion treatments for melanoma, using the alkylating agent melphalan, show variable responses in magnitude and duration." | ( Abdel-Wahab, O; Abdel-Wahab, Z; Cheng, TY; Colvin, OM; Friedman, HS; Grubbs, EG; Peterson, B; Pruitt, SK; Tyler, DS, 2004) |
| "As new methods for treating melanoma emerge and become more available, confocal microscopy can play a significant role by improving sensitivity in diagnosis, by increasing rates of successful initial excision, and by serving as a noninvasive means of monitoring therapy." | ( Astner, S; Curiel-Lewandrowski, C; Frankenthaler, RA; González, S; Swindells, KJ; Tahan, SR; Williams, CM, 2004) |
| "EGCG treatment of the melanoma cell lines resulted in decreased cell proliferation (as assessed by Ki-67 and PCNA protein levels) and induction of apoptosis (as assessed cleavage of PARP, TUNEL assay and JC-1 assay)." | ( Ahmad, N; Mukhtar, H; Nihal, M; Wood, GS, 2005) |
| "We successfully treated nodular melanoma and diffuse PAM in a young black woman using a combination of excision with cryotherapy and topical mitomycin C, suggesting that these lesions are amenable to the same types of therapy previously described for white patients." | ( Colby, KA; Nagel, DS, 2005) |
| "First, we show that treatment of melanoma and fibrosarcoma cells with inhibitors used to suppress methylation (N-methyl-2-deoxyadenosine, adenosine, dl-homocysteine) had profound and rapid effects on phosphorylation of STAT1 and STAT3 but also on p38 and Erk signaling cascades which are known to cross-talk with the Jak/STAT pathway." | ( Bauer, UM; Behrmann, I; Haan, S; Heinrich, PC; Komyod, W, 2005) |
| "In untreated malignant melanomas contrast agent echography revealed the presence of a dense microcirculation inside the mass." | ( Cennamo, G; De Rosa, G; Forte, R; Staibano, S, 2005) |
| "These data suggest that treatment of melanoma cells with PAX3-AS complements cytotoxicity induced by cisplatin." | ( Braithwaite, AW; Eccles, MR; He, SJ; Stevens, G, 2005) |
| "Local treatment of uveal melanoma by radiotherapy involves the use of brachytherapy with radioactive plaques attached to the sclera, or proton irradiation." | ( Boyd, SR; Cree, IA; Errington, RD; Gittos, A; Hungerford, JL; Richter, M, 2006) |
| "To determine the size of untreated choroidal melanomas resolved by whole body positron emission tomography fused with computed tomography (PET/CT)." | ( Finger, PT; Kurli, M; Reddy, S; Tena, LB, 2005) |
| "50 consecutive patients with untreated choroidal melanomas underwent whole body PET/CT." | ( Finger, PT; Kurli, M; Reddy, S; Tena, LB, 2005) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| "Adult patients with previously treated metastatic melanoma received Apomine 100 mg orally, twice daily (total dose 200 mg per day) continuously for 28 days (defined as a cycle)." | ( Floret, S; Gonzalez, R; Legha, SS; Lewis, KD; Lutzky, J; O'Day, S; Robinson, WA; Ruvuna, F; Thompson, JA; Weber, JS, 2006) |
| "A total of 151 untreated metastatic melanoma patients were randomized, 75 on arm A (cisplatin 30 mg/m2 on days 1-3, vindesine 2." | ( Bajetta, E; Bernengo, MG; Cascinelli, N; Daponte, A; Del Vecchio, M; Formisano, B; Fusi, A; Legha, SS; Nova, P; Queirolo, P; Sertoli, MR; Taveggia, P, 2006) |
| "Adjuvant treatment of melanoma continues to challenge clinicians and patients." | ( Cunningham, C; Jackson, BJ; McFadden, DW; Ng, A; Riggs, DR; Rizvi, I, 2006) |
| "NG or HP treatment of melanoma cells produced a remarkable reduction of cell proliferation, paralleled with both the lowering of the intracellular levels of polyamine, spermidine and spermine and the enhancement of transglutaminase (TGase, EC 2." | ( Beninati, S; Forni, C; Lentini, A; Provenzano, B, 2007) |
| "In addition, combined trichostatin A/ET treatment in melanoma cells expressing high MAGE-A levels reestablishes p53 response and reverts the chemoresistance." | ( Bublik, DR; Gobessi, S; Monte, M; Peche, LY; Pierotti, MA; Rodolfo, M; Schneider, C; Simonatto, M, 2006) |
| "In contrast to the untreated melanoma-bearing control group, (177)Lu-DOTA-Re(Arg(11))CCMSH administration yielded rapid and lasting therapeutic effects in the treatment groups." | ( Miao, Y; Quinn, TP; Shelton, T, 2007) |
| "Fifty consecutively treated melanoma patients who were progressive after at least one previous chemotherapy received cisplatin 100 mg/m(2) intravenously and carboplatin 200 mg/m(2) intravenously in a 2-day regimen once every 28 days." | ( Gabriel, V; Hofmann, MA; Kiecker, F; Milling, A; Sterry, W; Trefzer, U, 2007) |
| "To enhance the efficacy of ATO in the treatment of melanoma, we sought to identify compounds that potentiate the cytotoxic effects of ATO in melanoma cells." | ( Bowling, BD; Doudican, N; Manga, P; Orlow, SJ, 2008) |
| "The combined treatment of melanoma cells with sorafenib and rapamycin led to an approximately twofold increase of cell death compared with sorafenib monotreatment (P<0." | ( Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW, 2008) |
| "Sequential treatment of melanoma cells, first with gamma-irradiation to upregulate TRAIL-R surface expression, and then with resveratrol to suppress antiapoptotic proteins cFLIP and Bcl-xL and induce TRAIL surface expression, had dramatic effects on upregulation of apoptosis in some melanoma lines, including SW1 and WM35." | ( Hei, TK; Ivanov, VN; Johnson, GE, 2008) |
| "Patients with previously treated metastatic melanoma received paclitaxel 70 mg/m(2) weekly and bevacizumab 10 mg/kg biweekly for 5 consecutive weeks every 6 weeks." | ( Chopitea, A; Díaz-Lagares, A; Espinós, J; González, A; González-Cao, M; Martín-Algarra, S; Nieto, Y; Ponz, M; Redondo, P; Viteri, S, 2008) |
| "For the treatment of melanoma DNA vaccines are a promising therapeutic approach." | ( Beijnen, JH; Haanen, JB; Nuijen, B; Quaak, SG; Schumacher, TN; Toebes, M; van den Berg, JH, 2008) |
| "TMECG treatment of melanoma cells resulted in the downregulation of antiapoptotic Bcl-2, the upregulation of proapoptotic Bax and the activation of caspase-3; however, it did not induce the expression of the apoptosis protease-activating factor-1 (Apaf-1)." | ( Rodríguez-López, JN; Sánchez-del-Campo, L, 2008) |
| "Moreover, AZT monotreatment of melanoma in a severe combined immunodeficiency-mouse xenotransplantation model resulted in significant tumor reduction." | ( Ferko, B; Humer, J; Muster, T; Pehamberger, H; Rapberger, R; Waltenberger, A, 2008) |
| "The sole curative treatment of melanoma being surgery, the most useful indications of PET-CT are preoperative staging of one (or more) nodal or distant metastases, whether histologically confirmed or not." | ( Brenot-Rossi, I; Chuto, G; Gaudy-Marqueste, C; Grob, JJ; Nicol, I; Richard, MA, 2008) |
| "A 42-year-old white woman who had been treated for plantar melanoma 10 years ago showed concomitant nodular lesions in the mandibular gingiva and facial skin." | ( Bonan, PR; Coletta, RD; Guimarães, AL; Laranjeira, AL; Martelli-Júnior, H; Vargas, PA, 2008) |
| "The first step in treatment of melanoma is the removal of the lesions, usually by surgical excision." | ( Al-Arashi, M; Shah, S; Tannous, Z; Yaroslavsky, AN, 2009) |
| "Furthermore, treatment of melanoma cells with the demethylating agent 5-aza-2'-deoxycytidine reinduces Rap1GAP expression, followed by decreased Rap1 activity, ERK phosphorylation, and cell proliferation and survival-changes that are significantly blunted in cells transfected by small interfering RNA-mediated Rap1GAP knockdown." | ( Cornelius, LA; Feng, Y; Gao, L; Yuan, L; Zhao, H; Zheng, H, 2009) |
| "Collection of specimens from SCP-treated melanoma patients in a cooperative group phase III trial comparing this regimen with the chemotherapy alone is ongoing, and confirmation of these findings is necessary." | ( Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C, 2009) |
| "After treatment of the melanoma cells with DOX-liposome-loaded microbubbles and ultrasound, DOX was mainly present in the nuclei of the cancer cells, whereas it was mainly detected in the cytoplasm of cells treated with DOX-liposomes." | ( De Smedt, SC; Demeester, J; Geers, B; Lentacker, I; Sanders, NN, 2010) |
| "The clinical potential of TRAIL in the treatment of melanoma may therefore be limited unless given with agents that increase the cell surface expression of TRAIL death receptors." | ( Croft, A; Dong, L; Hersey, P; Jiang, CC; Lavis, CJ; Liu, H; Tay, KH; Tseng, HY; Yang, F; Zhang, XD, 2009) |
| "For this purpose, we treated B16-F0 melanoma cells with alpha-Melanocyte Stimulating Hormone (alpha-MSH) and we showed a rapid induction of catalase through a cAMP/PKA-dependent, microphthalmia-associated transcription factor (MITF) independent mechanism, acting at post-transcriptional level." | ( Aspite, N; Bellei, B; Flori, E; Kovacs, D; Maresca, V; Picardo, M, 2010) |
| "Indeed, as compared with untreated melanoma cells, pretreatment with hIFN-gamma and GGTI-298 together rendered the melanoma cells more efficient at inducing the: i) activation of CD8 T lymphocytes (CD8+/CD69+); ii) proliferation of tumor-specific CD8 T cells (MelanA-MART1/TCR+); iii) secretion of hIFN-gamma; and iv) anti-melanoma specific cytotoxic cells." | ( Armand-Labit, V; Favre, G; Moriez, R; Pich, C; Rochaix, P; Sarrabayrouse, G; Tilkin-Mariamé, AF, 2010) |
| "This is an innovative proposal to treat melanoma cell lines that until now have not received the benefit of the PDT protocol for treatment." | ( Barbugli, PA; Espreafico, EM; Siqueira-Moura, MP; Tedesco, AC, 2010) |
| "Intratumoral treatment of human melanoma xenografts with AdwtRGD-PH20 resulted in degradation of hyaluronan (HA), enhanced viral distribution, and induced tumor regression in all treated tumors." | ( Alemany, R; Cascallo, M; Gros, A; Guedan, S; Mercade, E; Rojas, JJ, 2010) |
| "Novel plaques are used to treat iris melanoma at the Mayo Clinic Rochester." | ( Furutani, KM; Pulido, JS; Rogers, DW; Stafford, SL; Thomson, RM, 2010) |
| "In vitro experiments showed that MTA treatment inhibited melanoma cell proliferation and viability in a dose dependent manner, where BRAF mutant melanoma cell lines appear to be more sensitive." | ( Andreu-Pérez, P; Avila, MA; Cortés, J; Gil, R; Grueso, J; Hernandez-Losa, J; Moliné, T; Pujol, A; Recio, JA, 2010) |
| "After the treatment of melanoma cells with a DNA methyltransferase inhibitor and subsequent transcriptomic profiling, we had identified earlier a cohort of melanoma progression-associated genes regulated by methylation." | ( Dervan, PA; Esteller, M; Faller, WJ; Fraga, MF; Gallagher, WM; Gremel, G; Hegarty, S; Rafferty, M; Ryan, D, 2010) |
| "Successful treatment of melanoma is still challenging, because metastasis remain chemoresistant and radioresistant." | ( Hörnle, M; Kashkar, H; Kulms, D; Peters, N; Thayaparasingham, B; Vörsmann, H, 2011) |
| "Previously untreated, metastatic melanoma patients (n = 20) received bevacizumab (at 15 mg/kg every 3 weeks) and fotemustine (100 mg/m² by intravenous administration on days 1, 8, and 15, repeated after 4 weeks) in a multicenter, single-arm, open-label, phase II study." | ( Anichini, A; Bajetta, E; Bedognetti, D; Canova, S; Del Vecchio, M; Di Guardo, L; Morosini, P; Mortarini, R; Perrone, T; Pimpinelli, N; Queirolo, P; Sertoli, MR, 2010) |
| "There may be a role for imiquimod in treating melanoma in situ of the vulva." | ( Crawford, RI; Sadownik, LA, 2010) |
| "ILP is an attractive treatment option in melanoma patients with multiple in-transit metastases." | ( Deroose, JP; Eggermont, AM; van Geel, AN; Verhoef, C, 2011) |
| "We also observed less hypoxia in treated melanoma xenografts, despite successful anti-angiogenic blockade, but no change in hypoxia of colorectal xenografts, suggesting that decreases in tumor hypoxia reflect a complex relationship with vascular density." | ( Adamcic, U; Coomber, BL; Lacombe, K; Minhas, K; Patten, SG; Skowronski, K, 2010) |
| "In this study, we show that treatment of 451Lu melanoma cells with the dietary flavonoid fisetin (3,7,3',4'-tetrahydroxyflavone) resulted in decreased cell viability with G1-phase arrest and disruption of Wnt/β-catenin signaling." | ( Afaq, F; Ahmad, A; Johnson, JJ; Maddodi, N; Mukhtar, H; Sarfaraz, S; Setaluri, V; Syed, DN, 2011) |
| "Because of the challenges in treating melanoma and S-phase specificity of camptothecin, we performed a study to search what melanoma cell cycle phases are susceptible to this substance." | ( Cichorek, M, 2011) |
| "At present, choice of treatment for skin melanoma depends on empirical data on efficacy of medication." | ( Ievleva, AG; Imianitov, EN; Moiseenko, VM; Protsenko, SA; Zhabina, AS, 2010) |
| "Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i." | ( Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R, 2012) |
| "A 55-year-old patient with a history of treated melanoma was operated on urgently for a severe T10-11 spinal cord compression by a huge metastasis involving the peridural space and the vertebral bone." | ( DeWaele, L; Mastronardi, L, 2011) |
| "We also show that bryostatin-1 treatment of melanoma cells increases class II protein levels by upregulating the class II transactivator (CIITA) gene." | ( Amria, S; Haque, A; Hossain, A; Komlosi, P; Nagarkatti, M; Sundaram, K; Zhao, D, 2011) |
| "As an alternative approach, pretreatment of melanoma cells with statin at decreased doses (5-20 μM) dramatically enhanced TRAIL-induced apoptosis, due to suppression of the NF-κB and STAT3-transcriptional targets (including COX-2) and downregulation of cFLIP-L (a caspase-8 inhibitor) protein levels." | ( Hei, TK; Ivanov, VN, 2011) |
| "Culture supernatants from NO scavenger-treated melanoma cells promoted the migration of plasmacytoid dendritic cells, which was diminished when the cells were treated with a CXCL10-neutralizing antibody." | ( Ekmekcioglu, S; Grimm, EA; Tanese, K, 2012) |
| "Interferon-α2b (IFN-α2b) is used to treat melanoma but there is a need to improve its efficacy." | ( Chen, L; Lawrence, HR; Lawrence, NJ; Pernazza, D; Schneeberger, VE; Sebti, SM; Win-Piazza, H; Wu, J, 2012) |
| "Twenty-seven of thirty-eight patients treated had melanoma tumours assessable for ASS staining before treatment." | ( Bomalaski, J; Elgart, G; Feun, LG; Jungbluth, AA; Kuo, MT; Marini, A; Moffat, F; Rodgers, SE; Savaraj, N; Sisson, W; Walker, G; Wangpaichitr, M; Wu, CJ; You, M, 2012) |
| "Notably, treatment of melanoma growing subcutaneously in mice with jacaranone significantly extended the mean survival times in a dose-dependent manner." | ( Arruda, DC; Farias, CF; Favero, OA; Ferreira, MJ; Figueiredo, CR; Girola, N; Lago, JH; Massaoka, MH; Matsuo, AL; Romoff, P; Scutti, JA; Travassos, LR, 2012) |
| "We found that the combined treatment of human melanoma cells with ATRA and polyI:C strongly increased the expression of TLR3 and MDA5 in both WM35 and WM983A cells associated with significantly higher mRNA and secreted levels of interferon β (IFNβ), CXCL1, CXCL8/IL-8, CXCL9, and CXCL10 than cells treated with either ATRA or polyI:C." | ( Agod, Z; Bacskai, I; Gogolak, P; Kumar, BV; Lanyi, A; Osman, RM; Rajnavolgyi, E; Szabo, A, 2012) |
| "Later, TMZ proved its efficacy in the treatment of melanoma." | ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013) |
| "After GSK2118436 treatment, the melanoma cells decreased in size and demonstrated hyperchromatic nuclei and indistinct nucleoli." | ( Curry, JL; Duvic, M; Falchook, GS; Hwu, WJ; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA, 2013) |
| "Furthermore, treating metastatic melanoma cells with the drug, Elesclomol, which induces cancer cell apoptosis through oxidative stress, we document by way of stable isotope labeling with amino acids in cell culture (SILAC) that proteins participating in OXPHOS are downregulated." | ( Barbi de Moura, M; Bateman, NW; Becker, D; Conrads, TP; Duensing, S; Fayewicz, SL; Hood, BL; Kirkwood, JM; Moschos, SJ; Sander, C; Suhan, J; Sun, M; Van Houten, B; Vincent, G; Yin, Y, 2012) |
| "Halofuginone treatment of human melanoma cells inhibited cell proliferation, phosphorylation of SMAD proteins in response to TGF-β, and TGF-β-induced SMAD-driven transcription." | ( Chirgwin, JM; Davis, HW; Fournier, PG; Guise, TA; Javelaud, D; Juárez, P; Mauviel, A; McKenna, RC; Mohammad, KS; Niewolna, M; Peng, XH; Yin, JJ, 2012) |
| "The pretreatment of melanoma cells with the inhibitor of caspase-3 (Ac-DEVD-CHO) was found to block bortezomib-induced apoptosis that subsequently led to the increase of autophagic formation." | ( Ahmad, M; Badura, HE; El-Khattouti, A; Ghanjati, F; Haikel, Y; Hassan, M; Porzig, BB; Santourlidis, S; Selimovic, D, 2013) |
| "The decision to treat a uveal melanoma with radiotherapy requires the ability to manage iatrogenic side effects and complications." | ( Damato, B; Groenewald, C; Konstantinidis, L, 2013) |
| "After DM-1 treatment, SK-MEL-5 melanoma cells showed actin filament disorganization with spicule formation throughout the cytoskeleton and significant reduction of focal adhesion as well as they were present only at cell extremities, conferring a poor connection between the cell and the substrate." | ( Espona-Fiedler, M; Faião-Flores, F; Maria, DA; Pérez-Tomás, R; Soto-Cerrato, V; Suarez, JA, 2013) |
| "Vemurafenib-treated melanoma cells showed increased cytosolic concentration of calcium, a potential trigger for endoplasmic reticulum (ER) stress, which can lead to apoptosis." | ( Bauer, J; Beck, D; Biedermann, T; Busch, C; Drießen, S; Eberle, J; Flaherty, K; Garbe, C; Iovanna, JL; Kulms, D; Lasithiotakis, K; Meier, F; Niessner, H; Paraiso, KH; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Smalley, KS; Stork, B; Vasseur, S; Weide, B; Wesselborg, S, 2013) |
| "Vemurafenib treatment of melanoma patients reduced the frequency of both moMDSCs and grMDSCs." | ( Giebel, B; Görgens, A; Griewank, K; Paschen, A; Schadendorf, D; Schilling, B; Sucker, A; Weide, B; Zhao, F, 2013) |
| "Concretely, we found that treatment of melanoma with methotrexate (MTX) altered melanogenesis and accelerated the exportation of melanosomes; however, the cellular and molecular processes by which MTX is trapped into melanosomes and exported out of cells have not been elucidated." | ( Cabezas-Herrera, J; Fernández-Pérez, MP; Montenegro, MF; Piñero-Madrona, A; Rodríguez-López, JN; Sáez-Ayala, M; Sánchez-del-Campo, L, 2013) |
| "BRAF inhibition therapy, used to treat melanomas with BRAF mutations, is associated with both neoplastic and non-neoplastic cutaneous side effects including squamous cell carcinomas, warty dyskeratomas, verrucous keratoses, photosensitivity and widespread eruptions that present histopathologically as acantholytic dyskeratosis." | ( Brockstein, B; Cibull, T; Clarke, M; Ortel, B; Rojanapremsuk, T; Thomas, A; Victor, T, 2013) |
| "In vivo, LBH589 treatment of melanoma-bearing mice results in a significant increase in survival." | ( Atadja, P; Cheng, F; Lee, C; Lienlaf, M; Perez-Villarroel, P; Seto, E; Sotomayor, EM; Villagra, A; Wang, H; Weber, J; Woan, K; Woods, DM, 2013) |
| "Upon treatment, melanoma cell lines responded by dramatically increasing phosphorylation on proteins containing a canonical DNA damage-response (DDR) motif, as defined by a phosphorylated serine or threonine residue adjacent to glutamine, [s/t]Q." | ( Bakalarski, CE; Belvin, M; Bustos, DJ; Chan, J; Dogan, T; Friedman, LS; Hoeflich, KP; Kirkpatrick, DS; Phu, L; Song, Q; Young, A, 2013) |
| "Indications for treatment of melanoma in-transit metastases (ITMs) confined to the limb with isolated limb perfusion (ILP) are not well defined." | ( Hoekstra, HJ; van Ginkel, RJ; Veerman, K, 2014) |
| "Moreover, treatment of melanoma cells with PKCβ-specific inhibitor enzastaurin reduced melanoma cell growth but had only small effects on benign fibroblasts." | ( Bhattacharya, A; Köberle, M; Koczan, D; Kottek, T; Kunz, M; Magin, TM; Saalbach, A; Schönherr, M; Siebolts, U; Simon, JC; Szymczak, S; Wickenhauser, C, 2014) |
| "After 24 h and up to 72 h, 7-DHC-treated melanoma cells showed a reduction in cell growth and viability." | ( Albano, F; Arcucci, A; Corso, G; De Vendittis, E; Dello Russo, A; Gelzo, M; Granato, G; Ruocco, MR, 2014) |
| "Shortly after BRAF inhibitor treatment in melanoma cell lines, mutant BRAF bound the ER stress gatekeeper GRP78, which rapidly expanded the ER." | ( Amaravadi, RK; Davies, MA; Dey, S; Hart, LS; Herlyn, M; Hu, J; Karakousis, G; Klump, V; Koumenis, C; Lazova, R; Levi, S; Ma, XH; McAfee, Q; Pawelek, JM; Piao, SF; Schuchter, LM; Villanueva, J; Winkler, J; Xu, W; Xu, X; Zhang, G, 2014) |
| "There is currently no curative treatment for melanoma once the disease spreads beyond the original site." | ( Chen, J; Chi, M; Ye, Y; Zhang, XD, 2014) |
| "In addition, treatment of melanoma cell lines A375, Hs294T, and G361 with Tenovin-1, a small molecule SIRT1 inhibitor, resulted in a significant decrease in cell growth and cell viability." | ( Ahmad, N; Nihal, M; Singh, C; Wilking, MJ; Zhong, W, 2014) |
| "Here, we treated two melanoma brain metastasis cell lines, H1_DL2, harboring a BRAFV600E mutation and PTEN loss, and H3, harboring WT (wild-type) BRAF and PTEN loss, with the MAPK (BRAF) inhibitor vemurafenib and the PI3K pathway associated mTOR inhibitor temsirolimus." | ( Bjerkvig, R; Dale, HA; Daphu, I; Horn, S; Skaftnesmo, KO; Spriet, E; Stieber, D; Thorsen, F; Varughese, JK, 2014) |
| "The combinational treatment of melanoma cells with fisetin and melatonin significantly enhanced the inhibitions of cell viability, cell migration and clone formation, and the induction of apoptosis when compared with the treatment of fisetin alone." | ( Deng, W; Guo, W; Qiu, H; Tang, R; Wang, J; Xiao, Y; Yi, C; Yu, W; Yu, Z; Yuan, Y; Zhang, Y, 2014) |
| "Fisetin treated 2-D melanoma cultures displayed autophagic response concomitant with induction of apoptosis." | ( Chamcheu, JC; Haidar, O; Lall, RK; Mukhtar, H; Syed, DN, 2014) |
| "In vemurafenib-treated melanoma patients, brain metastases are frequent and associated with a particularly poor prognosis." | ( Brocard, A; Dréno, B; Khammari, A; Knol, AC; Peuvrel, L; Quéreux, G; Saint-Jean, M, 2014) |
| "His medical history revealed treatment for melanoma in the periumbilical region and micrometastases in the inguinal lymph nodes." | ( Almeida, JD; Alves, MG; Cabral, LA; Carvalho, YR; Chagas, LR; Coletta, RD, 2014) |
| "After many years with no new treatments for melanoma, the U." | ( Bortoluzzi, AJ; Cisilotto, J; Creczynski-Pasa, TB; Ferreira, M; Filippin-Monteiro, FB; Sa, MM, 2015) |
| "We used a VSV-cDNA library to treat recurrent melanoma, identifying immunogenic antigens, allowing us to target recurrences with immunotherapy or chemotherapy." | ( Blanchard, M; Boisgerault, N; Celis, E; Harrington, K; Ilett, E; Kottke, T; Melcher, A; Pandha, H; Parrish, C; Pulido, J; Rajani, K; Selby, P; Shim, K; Thompson, J; Vile, R; Zaidi, S, 2015) |
| "An effective treatment for melanoma is greatly needed." | ( Aziz, F; Liu, JW; Shan, X; Tian, LL; Wang, XQ; Yan, Q, 2015) |
| "We describe a method of treating melanoma with MMS that combines breadloaf frozen sectioning of the central debulking excision with complete peripheral and deep microscopic margin evaluation, allowing detection of upstaging and comprehensive pathologic margin assessment before reconstruction." | ( Elenitsas, R; Etzkorn, JR; Goldbach, H; Miller, CJ; Newman, JG; Shin, TM; Sobanko, JF, 2015) |
| "Despite advances in the treatment of melanoma, patients with metastatic disease still have a poor prognosis and low survival rate." | ( Anderson, CJ; Beaino, W; Nedrow, JR, 2015) |
| "Current treatment for melanoma metastatic to the brain is grouped into those providing symptomatic relief such as corticosteroids and antiepileptic agents, to those that are disease modifying." | ( Chen, S; Wall, BA; Yu, LJ, 2015) |
| "Mechanistically, Bay60-6583-treated melanoma tissues showed increased STAT3 activation." | ( Miele, L; Morello, S; Pinto, A; Porta, A; Sorrentino, C, 2015) |
| "Vemurafenib is a revolutionary treatment for melanoma, but the magnitude of therapeutic response is highly variable, and the rapid acquisition of resistance is frequent." | ( Henderson, CJ; MacLeod, AK; McLaughlin, LA; Wolf, CR, 2015) |
| "Rhododendrol might be effective in treating melanomas." | ( Kawano, M; Matsushita, S; Nakamura, K; Takagi, R; Tsuchida, T, 2016) |
| "Advances in the treatment of melanoma are providing significant palliative benefit for patients with brain metastases." | ( Goldinger, SM; Nathan, P; Panje, C, 2016) |
| "GSK126 treatment of melanoma lines containing EZH2 activation reversed such transcriptional repression in 98 candidate target genes." | ( Filipp, FV; Gallagher, SJ; Hersey, P; Tiffen, J; Wilson, S, 2016) |
| "Of clinical relevance, pretreatment of melanoma cells with a mitogen-activated protein kinase pathway inhibitor, which induced G1 arrest, resulted in resistance to temozolomide or bortezomib." | ( Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W, 2016) |
| "SU11274-treated melanoma cells exhibited higher ATP content and lactate release indicative of increased glycolysis." | ( Bohovic, R; Demkova, L; Kucerova, L; Matuskova, M; Skolekova, S, 2016) |
| "But the treatment of melanoma remains unsatisfactory." | ( Chen, X; Han, J; Hao, W; Ma, J; Sun, S; Wang, C; Yang, M; Zheng, Q, 2016) |
| "We next treated established melanoma cell lines with S-adenosyl methionine (SAM), a universal methyl group donor, in an effort to cause changes in 5-mC levels." | ( Bosenberg, MW; Micevic, G; Rodić, N; Taube, JM; Theodosakis, N, 2017) |
| "Indications to treat invasive melanoma with Mohs micrographic surgery (MMS) or analogous techniques with exhaustive microscopic margin assessment have not been defined." | ( Chu, EY; Elenitsas, R; Etzkorn, JR; Gelfand, JM; Margolis, DJ; Miller, CJ; Shaikh, WR; Shin, TM; Sobanko, JF, 2017) |
| "Curcumin has a potential role in the treatment of melanoma, though further studies are necessary to explore its clinical efficacy." | ( Lelli, D; Pedone, C; Sahebkar, A, 2017) |
| "We found that GH treatment of human melanoma cells upregulates expression of multiple ABC transporters and increases the EC50 of melanoma drug vemurafenib." | ( Basu, R; Baumgaertel, N; Kopchick, JJ; Wu, S, 2017) |
| "The mainstream treatments for non-melanoma skin cancer (NMSC) include photodynamic therapy (PDT), surgery excision (SE), cryotherapy (CT), imiquimod (IM), radiotherapy (RT), 5-fluorouracil (FU), and vehicle (VE)." | ( Lv, R; Sun, Q, 2017) |
| "Although treatment of melanoma with BRAF inhibitors and immune checkpoint inhibitors achieves a high response rate, a subset of melanoma patients with intrinsic and acquired resistance are insensitive to these therapeutics, so to improve melanoma therapy other target molecules need to be found." | ( Aida, S; Fujii, T; Mizuno, T; Sakamoto, H; Sakata, K; Sonobe, Y; Yuhki, M, 2017) |
| "Adrenaline-treated uveal melanoma cells showed an increased migration rate, whereas, in cutaneous melanoma cells, no changes or even lower migration speed were observed." | ( Gołas, A; Janik, ME; Lityńska, A; Przybyło, M; Surman, M; Szlęzak, D, 2017) |
| "One of the most common treatments for melanoma is surgery, followed by various combinations of chemotherapy drugs." | ( Chang, X; Lian, S; Zhang, H; Zhu, W, 2017) |
| "AC inhibition may thus be key to treating malignant melanoma." | ( Arencibia, JM; Armirotti, A; Bauer, I; Bono, L; Borgogno, M; Braccia, C; De Vivo, M; Ganesan, A; Girotto, S; La Sala, G; Ortega, JA, 2017) |
| "With the application of CAP posttreatment, melanoma cell viability significantly decreased (80% were killed) compared to not using a light source (45% were killed) or using a UV light source (65% were killed)." | ( Geilich, BM; Keidar, M; Wang, M; Webster, TJ, 2017) |
| "To accomplish these aims, we treated choroidal melanoma cells with pemetrexed and cisplatin and assessed cell survival with SRB and MTT assays." | ( Kong, F; Wang, L; Zhang, H; Zhao, X, 2017) |
| "Further experiments, treating melanoma cell lines with αMSH in the presence/absence of GW9662, as an inhibitor of PPARγ, confirmed the key role of this transcription factor in decreasing cell proliferation in response to the hormone exposure." | ( Bellei, B; Cardinali, G; Flori, E; Kovacs, D; Maresca, V; Picardo, M; Rosati, E, 2017) |
| "In contrast, upfront treatment of melanoma cells with palbociclib in combination with BRAF and/or MEK inhibitors induced either cell death or senescence and was superior to a BRAF plus MEK inhibitor combination." | ( Abuhammad, S; Brajanovski, N; Cameron, DP; Cullinane, C; Hannan, RD; Hicks, RJ; Kirby, L; Lelliott, EJ; Martin, CA; McArthur, GA; Pearson, RB; Poortinga, G; Sanij, E; Sheppard, KE; Waldeck, K; Walker, R; Young, RJ, 2018) |
| "This novel finding was confirmed in PAR-treated melanoma cells cultured in 3D, where an increase in functional gap junctions and a higher spheroid compactness were observed." | ( Benedusi, M; Calamandrei, D; Cavicchio, C; Cervellati, F; Maellaro, E; Maioli, E; Pambianchi, E; Pecorelli, A; Rispoli, G; Savelli, V; Valacchi, G, 2017) |
| "CDDP treatment induced melanoma A375 cells into senescence through the sequential activation of the DNA damage response and the P53/P21 pathway." | ( Cui, H; Huang, W; Li, X; Liao, X; Liu, X; Min, L; Shi, B; Sun, X; Xu, S; Yang, J; Zhang, M; Zheng, H; Zhu, Z, 2018) |
| "Since 2012, we have treated 16 melanoma patients with cutaneous metastases with topical diphencyprone." | ( Bertolli, E; Duprat Neto, JP; Gibbons, IL; Macedo, MP; Pinto, CAL; Sonagli, M, 2018) |
| "In ICB-treated melanoma patients, low mCTLA4 was further strongly correlated with response to therapy (P = 0." | ( Bootz, F; Dietrich, D; Dietrich, J; Gevensleben, H; Golletz, C; Goltz, D; Kristiansen, G; Landsberg, J; Vogt, TJ, 2018) |
| "The effects of flavonoid treatment on melanoma sensitivity towards T cells were investigated using Jurkat cell killing, cytotoxicity, cell viability, and IL-2 secretion assays." | ( Chen, X; Liu, F; Liu, H; Liu, S; Mu, X; Tian, K; Tu, C; Wang, D; Wang, S; Wang, T; Wu, Y; Xu, L; Zhang, J; Zhang, R; Zhang, Y, 2018) |
| "The ABCB5 mRNA expression in micro-TiO2-treated melanoma cells also decreased significantly after 24 and 48 hours, in a time-dependent manner." | ( Ferk, P; Lunder, M; Prunk Zdravković, T; Zdravković, B, 2019) |
| "Currently, the number of drugs to treat melanoma is low." | ( Jiang, QQ; Liu, WB, 2018) |
| "Temozolomide (TMZ) is widely used to treat melanoma; however, response rates to TMZ are low because of rapid and frequent resistance." | ( Feng, S; Guo, W; Huang, Q; Jiang, A; Jiang, G; Liu, Y; Tang, J; Tao, Y; Xu, X; Yang, C; Yang, M, 2018) |
| "Alternative means to treat melanoma, in particular through the induction of programmed cell death modalities such as apoptosis or necroptosis, therefore still need to be explored." | ( Alexopoulos, LG; Feoktistova, M; Gerlach, E; Guttà, C; Leverkus, M; Panayotova-Dimitrova, D; Podder, B; Rehm, M; Rožanc, J, 2019) |
| "After 6 years of follow-up treating 364 canine melanoma patients, we present here results about the proof-of-concept, safety, and efficacy of a new surgery adjuvant combined gene therapy." | ( Agnetti, L; Finocchiaro, LME; Fondello, C; Glikin, GC, 2019) |
| "Recent advances in the treatment of melanoma that involve immunotherapy and B-Raf inhibition have revolutionised cancer care for this disease." | ( Baillie, GS; Blair, CM; Littman, BH; Marcoux, FW; Walsh, NM, 2019) |
| "Cisplatin treatment of melanoma cells resulted in an induction of apoptosis as demonstrated by flow cytometry (accumulation of cells at the subG1 phase of the cell cycle), whereas dacarbazine caused G1/G0 cell cycle arrest, with the effects being improved by pre‑treatment with vitamin D analogs." | ( Piotrowska, A; Rybarczyk, A; Slominski, AT; Tuckey, RC; Wierzbicka, J; Żmijewski, MA, 2019) |
| "In addition to being refractory to treatment, melanoma cancer stem cells (CSC) are known to suppress host antitumor immunity, the underlying mechanisms of which need further elucidation." | ( Nagarkatti, M; Nagarkatti, P; Shidal, C; Singh, NP, 2019) |
| "In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) checkpoint blockade which has improved survival." | ( Acharya, G; Elahy, M; Khachigian, LM; Li, Y; Xin, H, 2019) |
| "To characterize the use of MMS in the treatment of melanoma at 3 academic and 8 private practices throughout the United States, to recommend excision margins when 100% histologic margin evaluation is not used, and to compare actual costs of tumor removal with MMS vs standard surgical excision." | ( Brodland, DG; Ellison, PM; Zitelli, JA, 2019) |
| "Unfortunately, the treatment of melanoma is difficult because of its aggressive metastasis and resistance to treatment." | ( Ashby, CR; Chauhan, H; Heenatigala Palliyage, G; Singh, S; Tiwari, AK, 2019) |
| "Oral paclitaxel treatment of canine melanoma cells exerted mediated antiproliferative effects and mediated cell cycle arrest in vitro." | ( Jin, B; Kim, SY; Lee, WW; Li, Q; Nam, A; Park, HJ; Ryu, MO; Son, MH; Song, WJ; Yang, JI; Youn, HY, 2020) |
| "Moreover, treatment of melanoma cells with pioglitazone showed that the inhibitory effects of pioglitazone on LPS-induced inflammatory responses were TLR4 dependent." | ( Dana, N; Haghjooy Javanmard, S; Vaseghi, G, 2019) |
| "Therefore, safe and effective treatments for melanoma treatment are required." | ( Seo, KI; Won, YS, 2020) |
| "Isolated limb infusion (ILI) is used to treat in-transit melanoma metastases confined to an extremity." | ( Barbour, A; Beasley, GM; Carr, M; Coventry, BJ; Daou, H; Delman, KA; Farley, CR; Farma, JM; Farrow, NE; Henderson, MA; Kenyon-Smith, T; Kroon, HM; Lowe, MC; Miura, JT; Mosca, PJ; Mullen, D; Potdar, A; Serpell, J; Smithers, BM; Speakman, D; Sun, J; Teras, J; Thompson, JF; Tyler, DS; Zager, JS, 2020) |
| "As a result of treating melanoma cells with sorafenib, pigmentation was promoted in terms of melanin content and tyrosinase activity." | ( Jung, KE; Kim, CD; Kim, KI; Shin, YB; Yoon, TJ, 2022) |
| "In conclusion, Polyphyllin I treatment enhanced melanoma cell autophagy and apoptosis, as well as blocked melanoma cell cycle via suppressing PI3K/Akt/mTOR signal pathway." | ( Long, J; Pi, X, 2020) |
| "ILI is safe and effective to treat melanoma in-transit metastases." | ( Barbour, A; Beasley, GM; Coventry, BJ; Daou, H; Delman, KA; Farley, CR; Farma, JM; Farrow, NE; Henderson, MA; Kenyon-Smith, TJ; Kroon, HM; Lowe, MC; Miura, JT; Mosca, PJ; Mullen, D; Potdar, A; Serpell, J; Smithers, BM; Speakman, D; Sun, J; Teras, J; Thompson, JF; Tyler, DS; Zager, JS, 2020) |
| "Over half of surveyed Mohs surgeons treating melanoma with MMS are treating early invasive melanoma with MMS." | ( Hocker, TLH; Hooton, TA; Neill, BC; Seger, EW; Siscos, SM, 2020) |
| "Combined treatment in melanoma cells distinctly increases G2/M arrest." | ( Distel, LV; Fietkau, R; Hecht, M; Heinzerling, L; Jost, T; Knippertz, I; Weigert, V, 2020) |
| "These findings have implications in the treatment of melanomas with enhanced OXPHOS status due to metabolic reprogramming or drug resistance." | ( Abu Eid, M; Bennett, B; Boyle, KA; Cheng, G; Dwinell, MB; Hardy, M; Kalyanaraman, B; Kresty, LA; McAllister, D; Weh, K; Zielonka, J; Zielonka, M, 2020) |
| "Common treatments for melanoma are limited to poor tissue selectivity, high toxicity and drug resistance." | ( Cai, W; Chen, C; Hu, M; Jiang, F; Li, Z; Lin, L; Liu, J; Mei, E; Pan, Z; Shao, J; Zheng, T, 2021) |
| "Hydroxyurea (HU) is used to treat melanoma, and miRNA expression is altered after HU treatment in B16 melanoma cells." | ( Gao, Y; Han, DX; Huang, YJ; Jiang, H; Wang, CJ; Wang, WH; Yuan, B; Zhang, JB; Zheng, Y, 2021) |
| "Dacarbazine (DTIC) is used in the treatment of melanoma with limited clinical efficacy." | ( He, J; Huang, X; Sun, K; Teng, W; Tian, J; Yang, J; Zhan, X; Zhou, C; Zhou, L, 2021) |
| "Physicians who treat melanoma patients thus face news issues relating to prevention, detection and treatment of these adverse events." | ( Baric, L; Cantagrel, A; Di Palma, M; Ederhy, S; Paques, M; Perlemuter, G; Sibaud, V, 2021) |
| "In hernandezine-treated melanoma cells, G0/G1 cycle arrest occurred accompanied by significantly downregulated levels of phosphorylated JAK2 and STAT3." | ( Jiang, Q; Li, D; Li, X; Liu, L; Wang, D; Wang, X; Xia, Y; Zheng, Q, 2022) |
| "Following the treatment of melanoma cells with 5‑Aza‑2'‑deoxycytidine (5‑Aza‑dC), GAS5 methylation was significantly reversed." | ( Chen, DX; Chen, L; Jiang, J; Niu, HT; Wang, X; Xie, R; Yang, CH; Zhai, L; Zhang, J; Zhang, YJ, 2022) |
| "Despite recent progress in the treatment of melanoma brain metastasis, therapy resistance and relapse of disease remain unsolved challenges." | ( Aasen, SN; Bjørnstad, OV; Haan, C; Herdlevær, CF; Hoang, T; Preis, J; Reigstad, A; Rigg, E; Sundstrøm, T; Thorsen, F, 2022) |
| "Despite new treatment options, melanoma continues to have an unfavorable prognosis." | ( Deloch, L; Distel, LV; Faulhaber, EM; Fietkau, R; Gaipl, US; Hecht, M; Hildebrand, LS; Jost, T; Scheper, J; Symank, J, 2023) |
| "Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades." | ( Asano, Y; Fujimura, T; Muto, Y, 2022) |
| "More important, while treating melanoma tumor-bearing mice, ACEXO-treated group showed the lowest tumor weight without body weight loss." | ( Chen, H; Jiang, Y; Li, X, 2023) |
| "Temozolomide plays a role in treating melanoma refractory to immunomodulatory and mitogen-activated protein kinase-targeted approaches, but its efficacy is limited." | ( Benes, EN; Friedlander, P; Jursic, B; Morgan, LR; Rodgers, AH, 2023) |
| "Surgery is the mainstream treatment for melanoma." | ( Cai, Q; Guo, Z; Li, J; Lin, K; Tang, Y; Yu, Y; Yuan, C; Zhang, D, 2023) |
| "The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins." | ( Carr, M; Correa, L; Culbreth, A; Cunningham, K; DePalo, DK; Harkins, A; Longbottom, B; Patel, N; Puleo, C; Reed, R; Seminario-Vidal, L; Ward, C; Zager, JS, 2023) |
| "We show that XAV-Np treatment of mouse melanoma cells significantly suppresses cell viability, tumor cell migration, and tumor spheroid formation compared to control nanoparticle (Con-Np) or free XAV939-treated groups." | ( Antony, F; Babu, RJ; Chen, P; Kang, X; Mishra, A; Pundkar, C; Suryawanshi, A; Wang, C, 2023) |
| "RNA sequencing data of 4 immunotherapy-treated melanoma datasets and TCGA melanoma was obtained from open access repository." | ( Cao, L; Du, T; Liao, Y; Lin, M; Tang, X; Zhang, Y; Zheng, W; Zhou, J, 2023) |
| "Despite the progress made in treatments, melanoma is one of the cancers for which its incidence and mortality have increased during recent decades." | ( Aires, V; Chekir-Ghedira, L; Cotte, AK; Delmas, D; Fredon, M; Fuselier, C; Martiny, L; Monchaud, D; Sassi, A; Schneider, C, 2023) |
| "Following trametinib treatment of melanoma cells, viability was reduced in both cutaneous (MEL888 26%, P < 0." | ( Andrews-Pfannkoch, CM; Dalvin, LA; Erickson, SA; Fautsch, MP; Marmorstein, AD; Miley, DR; Pulido, JS; Vile, RG, 2023) |
| "The effect of traditional treatment for melanoma is quite limited, especially for its recurrence." | ( Kang, X; Lei, J; Li, Q; Yang, C; Zhang, J; Zhang, P; Zheng, S, 2023) |